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FOREWORD 
 
 Concise International Chemical Assessment 
Documents (CICADs) are published by the International 
Programme on Chemical Safety (IPCS)—a cooperative 
programme of the World Health Organization (WHO), 
the International Labour Organization (ILO), and the 
United Nations Environment Programme (UNEP). 
CICADs have been developed from the Environmental 
Health Criteria documents (EHCs), more than 200 of 
which have been published since 1976 as authoritative 
documents on the risk assessment of chemicals. 
 
 International Chemical Safety Cards on the relevant 
chemical(s) are attached at the end of the CICAD, to 
provide the reader with concise information on the 
protection of human health and on emergency action. 
They are produced in a separate peer-reviewed procedure 
at IPCS. They may be complemented by information 
from IPCS Poison Information Monographs (PIM), 
similarly produced separately from the CICAD process. 
 
 CICADs are concise documents that provide sum-
maries of the relevant scientific information concerning 
the potential effects of chemicals upon human health 
and/or the environment. They are usually based on 
selected national or regional evaluation documents or on 
existing EHCs. Before acceptance for publication as 
CICADs by IPCS, these documents undergo extensive 
peer review by internationally selected experts to ensure 
their completeness, accuracy in the way in which the 
original data are represented, and the validity of the 
conclusions drawn. 
 
 The primary objective of CICADs is characteriza-
tion of hazard and dose–response from exposure to a 
chemical. CICADs are not a summary of all available 
data on a particular chemical; rather, they include only 
that information considered critical for characterization 
of the risk posed by the chemical. The critical studies 
are, however, presented in sufficient detail to support the 
conclusions drawn. For additional information, the 
reader should consult the identified source documents 
upon which the CICAD has been based. 
 
 Risks to human health and the environment will 
vary considerably depending upon the type and extent of 
exposure. Responsible authorities are strongly encour-
aged to characterize risk on the basis of locally measured 
or predicted exposure scenarios. To assist the reader, 
examples of exposure estimation and risk characteriza-
tion are provided in CICADs, whenever possible. These 
examples cannot be considered as representing all 
possible exposure situations, but are provided as 
guidance only. The reader is referred to EHC 170.1
 
 While every effort is made to ensure that CICADs 
represent the current status of knowledge, new informa-
tion is being developed constantly. Unless otherwise 
stated, CICADs are based on a search of the scientific 
literature to the date shown in the executive summary. In 
the event that a reader becomes aware of new informa-
tion that would change the conclusions drawn in a 
CICAD, the reader is requested to contact IPCS to 
inform it of the new information. 
 
Procedures 
 
The flow chart on page 2 shows the procedures 
followed to produce a CICAD. These procedures are 
designed to take advantage of the expertise that exists 
around the world—expertise that is required to produce 
the high-quality evaluations of toxicological, exposure, 
and other data that are necessary for assessing risks to 
human health and/or the environment. The IPCS Risk 
Assessment Steering Group advises the Coordinator, 
IPCS, on the selection of chemicals for an IPCS risk 
assessment based on the following criteria: 
 
• there is the probability of exposure; and/or 
• there is significant toxicity/ecotoxicity. 
 
Thus, it is typical of a priority chemical that: 
 
• it is of transboundary concern; 
• it is of concern to a range of countries (developed, 
developing, and those with economies in transition) 
for possible risk management; 
• there is significant international trade; 
• it has high production volume; 
• it has dispersive use. 
 
The Steering Group will also advise IPCS on the appro-
priate form of the document (i.e. a standard CICAD or a 
de novo CICAD) and which institution bears the respon-
sibility for the document production, as well as on the 
type and extent of the international peer review.  
 
The first draft is usually based on an existing 
national, regional, or international review. When no 
appropriate source document is available, a CICAD may 
be produced de novo. Authors of the first draft are 
usually, but not necessarily, from the institution that 
developed the original review. A standard outline has 
been developed to encourage consistency in form. The 
                                                 
1 International Programme on Chemical Safety (1994) 
Assessing human health risks of chemicals: derivation of 
guidance values for health-based exposure limits. Geneva, 
World Health Organization (Environmental Health Criteria 
170) (also available at http://www.who.int/pcs/). 
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 CICAD PREPARATION FLOW CHART 
 
Selection of priority 
chemical, author 
institution, and 
agreement on CICAD 
format 
↓ 
Preparation of first draft 
↓ 
Primary acceptance 
review by IPCS and 
revisions as necessary 
↓ 
Selection of review 
process 
↓ 
Peer review 
↓ 
Review of the 
comments and revision 
of the document 
↓ 
Final Review Board: 
Verification of revisions 
due to peer review 
comments, revision, 
and approval of the 
document 
↓ 
Editing  
Approval by 
Coordinator, IPCS 
↓ 
Advice from Risk Assessment  
Steering Group 
 
Criteria of priority: 
 
• there is the probability of exposure; 
and/or 
• there is significant toxicity/ecotoxicity.  
 
Thus, it is typical of a priority chemical that: 
 
• it is of transboundary concern;  
• it is of concern to a range of countries 
(developed, developing, and those with 
economies in transition) for possible risk 
management;  
• there is significant international trade;  
• the production volume is high;  
• the use is dispersive.   
  
Special emphasis is placed on avoiding  
duplication of effort by WHO and other  
international organizations.  
  
A usual prerequisite of the production of a  
CICAD is the availability of a recent high- 
quality national/regional risk assessment  
document = source document. The source 
document and the CICAD may be produced 
in parallel. If the source document does not 
contain an environmental section, this may 
be produced de novo, provided it is not 
controversial. If no source document is 
available, IPCS may produce a de novo risk 
assessment document if the cost is 
justified. 
 
Depending on the complexity and extent of 
controversy of the issues involved, the 
steering group may advise on different 
levels of peer review: 
 
• standard IPCS Contact Points; Publication of CICAD 
on web and as printed 
text 
• above + specialized experts; 
• above + consultative group. 
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first draft undergoes primary review by IPCS to ensure 
that it meets the specified criteria for CICADs. 
 
 The second stage involves international peer review 
by scientists known for their particular expertise and by 
scientists selected from an international roster compiled 
by IPCS through recommendations from IPCS national 
Contact Points and from IPCS Participating Institutions. 
Adequate time is allowed for the selected experts to 
undertake a thorough review. Authors are required to 
take reviewers’ comments into account and revise their 
draft, if necessary. The resulting second draft is 
submitted to a Final Review Board together with the 
reviewers’ comments. At any stage in the international 
review process, a consultative group may be necessary 
to address specific areas of the science. When a CICAD 
is prepared de novo, a consultative group is normally 
convened. 
 
 The CICAD Final Review Board has several 
important functions: 
 
• to ensure that each CICAD has been subjected to an 
appropriate and thorough peer review; 
• to verify that the peer reviewers’ comments have 
been addressed appropriately; 
• to provide guidance to those responsible for the 
preparation of CICADs on how to resolve any 
remaining issues if, in the opinion of the Board, the 
author has not adequately addressed all comments 
of the reviewers; and 
• to approve CICADs as international assessments. 
 
Board members serve in their personal capacity, not as 
representatives of any organization, government, or 
industry. They are selected because of their expertise in 
human and environmental toxicology or because of their 
experience in the regulation of chemicals. Boards are 
chosen according to the range of expertise required for a 
meeting and the need for balanced geographic repre-
sentation. 
 
 Board members, authors, reviewers, consultants, 
and advisers who participate in the preparation of a 
CICAD are required to declare any real or potential 
conflict of interest in relation to the subjects under 
discussion at any stage of the process. Representatives 
of nongovernmental organizations may be invited to 
observe the proceedings of the Final Review Board. 
Observers may participate in Board discussions only at 
the invitation of the Chairperson, and they may not 
participate in the final decision-making process.
3 
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genic sources, but also by every combustion process, 
including forest fires. Chromium is present in the atmos-
phere primarily in particulate form. 
1. EXECUTIVE SUMMARY 
 
  
  This Concise International Chemical Assessment 
Document (CICAD)  Industrial effluents containing chromium, some of 
which is in the hexavalent form, are emitted into surface 
waters. Whether the chromium remains hexavalent until 
it reaches the ocean depends on the amount of organic 
matter present in the water. If organic matter is present 
in large quantities, the chromium(VI) may be reduced 
by, and chromium(III) adsorbed on, the particulate mat-
ter. If it is not adsorbed, the chromium(III) will form 
large, polynucleate complexes that are no longer soluble. 
The reduction of chromium(VI) to chromium(III) occurs 
rapidly under anaerobic conditions, and reducing condi-
tions generally exist in deeper groundwaters. Most of the 
chromium released into water will ultimately be depos-
ited in the sediment. The major dissolved species of 
chromium(III) are Cr
1 on inorganic chromium(III) 
compounds was prepared jointly by the Finnish Institute 
of Occupational Health, Helsinki, Finland (human health 
sections), and the Centre for Ecology and Hydrology, 
Monks Wood, United Kingdom (environmental 
sections), based on the Health Risk Assessment Report 
for Metallic Chromium and Trivalent Chromium, 
prepared by the Finnish Institute of Occupational Health 
(Riihimäki & Luotamo, 2006), and the Agency for Toxic 
Substances and Disease Registry’s Toxicological Profile 
for Chromium (ATSDR, 2000). The date for the last 
literature search was December 2004 for the health 
effects part and December 2005 for the environmental 
part of the CICAD. Information on the source docu-
ments is presented in Appendix 2. Information on the 
peer review of this CICAD is presented in Appendix 3. 
This CICAD on inorganic chromium compounds was 
approved as an international assessment at a meeting of 
the Final Review Board, held in Helsinki, Finland, on 
26–29 March 2007. Participants at the Final Review 
Board meeting are listed in Appendix 4. International 
Chemical Safety Cards on the most common inorganic 
trivalent chromium compounds, produced by the 
International Programme on Chemical Safety (IPCS), 
have also been reproduced in this document (IPCS, 
2002b, 2004a,b,c,d, 2006). This CICAD is restricted to 
inorganic trivalent chromium compounds, but when 
additional value can be given, data on organic chromium 
compounds are also presented. CICAD No. 78 concern-
ing hexavalent chromium is currently in preparation. 
3+
 
 Trivalent chromium is thermodynamically the most 
stable state of chromium. In the environment, almost all 
naturally occurring chromium is in the trivalent form. 
There are a wide variety of commercially available 
trivalent chromium compounds, the most important ones 
being chromium(III) oxide and basic chromium sulfate. 
 
 The general population is exposed to trivalent 
chromium mainly from the daily diet. Other sources 
include food supplements containing chromium, ambient 
air, chrome-tanned leather articles, chromium pigment–
based cosmetics, stainless steel articles, prosthetic 
implants, and orthodontic appliances. Occupational 
exposure to trivalent chromium may occur in a wide 
range of industrial activities related to the production, 
formulation, and use of chromium.  
 
 There is a complete chromium cycle, from rocks or 
soil to plants, animals, and humans, and back to soil. 
Chromium is emitted into the air, not only by anthropo-
 
1 For a complete list of acronyms and abbreviations used in 
this report, the reader should refer to Appendix 1. 
, CrOH2+, Cr(OH)30, and 
Cr(OH)4−. 
 
 Chromium in soil is present mainly as insoluble 
oxide and is not very mobile. Chromium(III) is expected 
to be rapidly and strongly adsorbed onto soil, particu-
larly by iron and manganese oxides, clay minerals, and 
sand. The mobility of soluble chromium in soil will 
depend on the sorption characteristics of the soil. Living 
plants and animals absorb the hexavalent form in prefer-
ence to the trivalent form; once absorbed, however, the 
hexavalent form is reduced to the more stable, trivalent 
state.  
 
 Bioconcentration factors for chromium(VI) in fish 
are low, at around 1; however, once in the organism, 
chromium(VI) appears to be reduced to chromium(III), 
resulting in the accumulation of total chromium in the 
organisms to a factor of approximately 100 times the 
water concentration.  
 
 The concentrations of atmospheric total chromium 
in remote areas range from 0.005 to 2.6 ng/m3, with 
typically <10 ng/m3 in rural areas and 10–30 ng/m3 in 
urban areas. Higher concentrations (>500 ng/m3) have 
been reported near anthropogenic sources. Total chro-
mium concentrations in river water in the United States 
of America (USA) usually range from <1 to 30 µg/l, 
with a median value of 10 µg/l. In Europe, a median 
total chromium concentration of 0.38 µg/l (<0.01–
43.3 µg/l) has been reported for surface waters. Total 
chromium concentrations in lake water generally do not 
exceed 5 µg/l. Mean chromium(III) concentrations of up 
to 2 µg/l have been reported for surface waters. Higher 
levels of chromium can be related to sources of anthro-
pogenic pollution, with the highest levels of up to 40 mg 
chromium(III)/l near tannery discharges. 
 
 In general, the concentration of chromium in ocean 
water is much lower than that in lakes and rivers. The 
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mean total chromium concentration in ocean water is 
0.3 µg/l, with a range of 0.2–50 µg/l. Mean chro-
mium(III) concentrations of 2–3 µg/l have been reported 
for coastal waters. In the suspended materials and sedi-
ments of water bodies, total chromium levels ranged 
from 1 to 500 mg/kg. Total chromium levels in soil vary 
greatly and depend on the composition of the parent rock 
from which the soils were formed. The concentration 
range of total chromium in soils and other surficial 
materials in Canada and the USA was 1–2000 mg/kg, 
with a geometric mean of around 40 mg/kg. In Europe, 
median chromium concentrations for topsoil were 60 
mg/kg (<3–6230 mg/kg) after hydrofluoric acid extrac-
tion and 22 mg/kg (<1–2340 mg/kg) after nitric acid 
extraction. Higher levels have been reported at contam-
inated sites. 
 
 Trivalent chromium is considered to be an essential 
trace element in mammals, being involved in lipid and 
glucose metabolism. Limited amounts (<0.5–2%) of 
chromium(III) are absorbed from the normal diet—more 
if the content of chromium in diet is abnormally low, 
and less when intake is increased. Absorption of water-
soluble chromium(III) aerosols of respirable size is more 
efficient from the respiratory system than from the 
gastrointestinal tract: approximately 5% may be taken up 
rapidly within hours, followed by a further slow release 
into circulation over weeks and months. For insoluble 
chromium(III) oxide, uptake of deposited and retained 
particles is a very slow process. Water-soluble trivalent 
chromium salts are able to penetrate into the skin, but 
they have not been shown to reach the systemic circula-
tion. 
 
 In the blood plasma, 95% of chromium(III) is bound 
to large molecular mass proteins (e.g. transferrin), but it 
also associates with an oligopeptide called low-molecu-
lar-weight chromium-binding substance (LMWCr). 
Chromium is distributed predominantly into the liver, 
kidneys, spleen, and bone. Some administered chromium 
may reach the interstitium of the testis, and it may accu-
mulate in placenta, but only low amounts cross the pla-
centa. Absorbed chromium(III) is excreted mainly in the 
urine and to a lesser extent in the faeces.  
 
 In rats, the oral acute toxicity of chromium(III) 
oxide is very low, with median lethal doses (LD50 
values) above 5 g/kg body weight (bw). The oral LD50 
for basic chromium sulfate is reported to be 3530 mg/kg 
bw in rats. Values given for chromium nitrate range 
from 1540 to 3250 mg/kg bw.  
 
 Based on animal studies, chromium(III) oxide and 
basic chromium sulfate are not skin or eye irritants.  
 
 Insoluble chromium(III) oxide does not cause skin 
sensitization. Trivalent chromium may act as an ultimate 
haptenic determinant for chromium sensitization in the 
skin, but the poor skin penetration limits the sensitizing 
ability of trivalent chromium salts. The sensitizing 
effects of water-soluble trivalent chromium salts, 
chromium chloride, and hydrated chromium sulfate have 
been demonstrated in non-standard tests employing 
intradermal or subcutaneous injections. Two studies on 
chromium chloride also showed positive reactions after 
an epicutaneous challenge. Clinical evidence on skin 
sensitization relates mainly to the wearing of leather 
articles. The relationship between trivalent chromium 
and sensitization induced by leather articles is clouded 
by the fact that low levels of hexavalent chromium may 
be present in tanned leather and that the reported cases 
of foot dermatitis may actually concern elicitation 
reactions in previously chromium-sensitized people. 
Skin sensitization among workers handling trivalent 
chromium salts appears to be a rare event. There is at 
present no unequivocal evidence to show that exposure 
to trivalent chromium compounds has induced occupa-
tional asthma.  
 
 Inhalation of mean chromium concentrations of 3, 
10, and 30 mg/m3 as chromium(III) oxide resulted in 
very mild inflammatory changes in the lungs of exposed 
rats at all air levels, whereas dusts of basic chromium 
sulfate at the same Cr3+ air concentrations resulted in 
more severe and more widespread inflammatory effects 
and signs of systemic toxicity in middle and high dose 
groups. Small inflammatory changes seen after chromi-
um(III) oxide inhalation may reflect a nonspecific lung 
response to accumulated insoluble particles (overload) 
rather than intrinsic toxicity of chromium(III). The no-
observed-adverse-effect concentration (NOAEC) of 
3 mg Cr3+/m3 was identified for basic chromium sulfate 
for systemic effects; however, since inflammatory 
changes in the lungs and the respiratory tract were seen 
even at the lowest level, it was a lowest-observed-
adverse-effect concentration (LOAEC) for local effects. 
The minimal severity of findings at the lowest exposure 
level suggests that the LOAEC of 3 mg Cr3+/m3 is near a 
NOAEC for chromium(III) oxide in rats. 
 
 Feeding rats with chromium(III) oxide even at very 
high doses did not result in any adverse effects. This 
lack of effects can be explained by the poor oral bio-
availability of chromium(III) oxide. In a 20-week oral 
feeding study with water-soluble chromium chloride, no 
adverse treatment-related effects were seen in Sprague-
Dawley rats even at the highest dose level, correspond-
ing to a chromium intake of 7 mg/kg bw per day. 
 
 Although chromium(III) may interact with deoxy-
ribonucleic acid (DNA), the data on in vitro and in vivo 
genotoxicity studies are conflicting and give no clear 
evidence on the mutagenicity of trivalent chromium.  
 
 Animal studies regarded relevant for the carcino-
genicity assessment of chromium(III) did not show an 
5 
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increased incidence of cancer with trivalent chromium 
compounds. For some occupations involving trivalent 
chromium exposure, increased risks for some cancers 
have been suggested, but the epidemiological data do not 
permit the discrimination between the simultaneous 
exposure to trivalent chromium and hexavalent chro-
mium or other carcinogenic agents.  
 
 Available data suggest a lack of effects of trivalent 
chromium on fertility. Based on poor bioavailability and 
a limited oral developmental toxicity study at high 
doses, chromium(III) oxide is not a developmental 
toxicant. No appropriate developmental toxicity studies 
were available for soluble trivalent chromium salts.  
 
 The key end-point considered to be relevant for 
human exposure to chromium(III) oxide is sustained 
local irritation and inflammation associated with accu-
mulation of respirable particles in the lungs to the extent 
that the clearance mechanisms are overloaded. The key 
end-points relevant for human exposure to basic chromi-
um sulfate, presumed to represent soluble chromium(III) 
salts as a group, are local respiratory toxicity and sensiti-
zation of the skin. Tolerable concentrations (27 µg 
Cr3+/m3 for insoluble chromium(III) and 6 µg Cr3+/m3 
for soluble chromium(III) compounds) based on these 
effects and applicable assessment factors are usually 
well above the air levels of chromium(III); even in the 
vicinity of point sources, air levels fall below the toler-
able concentrations. Concerning skin sensitization, it is 
rather unlikely that soluble trivalent chromium salts 
induce skin sensitization in people using shoes, gloves, 
or other articles made of chrome-tanned leather, whereas 
elicitation of chromium allergy in a previously sensitized 
person is possible owing to small amounts of chromium 
leached from leather articles. 
 
 Chromium(III) is required by some microorganisms 
for specific metabolic processes, such as glucose metab-
olism and enzyme stimulation. Chromium(III), in trace 
amounts, has been reported to be an essential component 
of animal nutrition and is most notably associated with 
glucose and fat metabolism. However, whereas chro-
mium has been shown to be essential for glucose metab-
olism in some laboratory mammals, studies on other 
animals are equivocal.  
 
 The available toxicity data for chromium(III) have 
been mainly derived using the water-soluble forms 
(chromium(III) chloride, chromium(III) nitrate, and 
chromium potassium sulfate). In the environment, 
chromium(III) is likely to be present in much less 
soluble forms and hence less bioavailable to aquatic 
organisms. 
 
 Ninety-six-hour median effective concentrations 
(EC50s) for one freshwater alga, based on growth, ranged 
from 0.3 to 0.4 mg chromium(III)/l. A 96-h EC50, based 
on growth, was reported for a marine diatom at 2 mg 
chromium(III)/l. Median lethal concentrations (LC50s) in 
freshwater invertebrates ranged from 0.1 mg/l (Daphnia 
pulex) to 442 mg/l (Asellus aquaticus), with a life cycle 
no-observed-effect concentration (NOEC) of 0.047 mg/l 
for Daphnia magna. LC50s ranging from 10 to 100 mg/l 
have been reported for marine invertebrates. Ninety-six-
hour LC50s for freshwater fish ranged from 3.3 mg/l for 
the guppy (Poecilia reticulata) to 151 mg/l for the 
bighead (Aristichthys nobilis), whereas 96-h LC50s of 
31.5 and 53 mg/l were reported for marine fish. A 72-
day NOEC (survival) of 0.05 mg/l was reported for 
rainbow trout (Oncorhynchus mykiss). 
 
 A guidance value for trivalent chromium toxicity in 
the freshwater environment can be derived using a prob-
abilistic approach, since the data set is sufficiently large 
to warrant it. A moderate-reliability guidance value of 
10 µg chromium(III)/l was derived for the protection of 
99% of freshwater species with 50% confidence. There 
were insufficient toxicity data on marine organisms to 
allow a guidance value to be calculated using a prob-
abilistic method. A very limited data set was available 
based on a diatom, aquatic invertebrates, and fish. 
Therefore, a factor of 1000 was applied to the lowest 
reliable toxicity value (2 mg/l) to give a low-reliability 
guidance value of 2 µg chromium(III)/l. 
 
 The moderate-reliability guidance value of 10 µg 
chromium(III)/l for the freshwater environment suggests 
a low risk for surface waters in general. However, there 
is a potential risk to organisms when the guidance value 
is compared with the highest chromium(III) level of 
around 100 µg/l for surface waters in industrial areas. 
The higher levels of trivalent chromium in effluent, 
especially from tanneries, suggest that there is a risk to 
freshwater organisms in the vicinity of such effluent 
releases. Comparing the low-reliability guidance value 
of 2 µg chromium(III)/l for the marine environment with 
trivalent chromium concentrations in seawater suggests a 
low risk of toxicity to marine organisms.  
 
 The main feature of chromium intoxication in plants 
is chlorosis. Hexavalent chromium appears to be more 
toxic to terrestrial plants than is trivalent chromium.  
 
 In the absence of more data on the bioavailability of 
chromium in soils, it is difficult to assess the risk of 
chromium(III) to soil organisms. 
 
 
 
2. IDENTITY AND PHYSICAL/CHEMICAL 
PROPERTIES 
 
 
 The oxidation states of chromium range from –2 to 
+6; the important valences are 0, +3, and +6. The 
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trivalent state is the thermodynamically most stable. In 
the environment, almost all chromium exists in trivalent 
compounds, other forms being mainly of anthropogenic 
origin. 
 
 Identification data for some trivalent chromium 
compounds of technological importance are given in 
Table 1, and their physical and chemical properties are 
given in Table 2. 
 
 Commercially, the most important trivalent com-
pounds are chromium(III) oxide and basic chromium 
sulfate. 
 
 
 
3. ANALYTICAL METHODS 
 
 
 Analysis of chromium in air, water, soil, or 
biological media is performed mainly by atomic 
absorption spectrometry (AAS) or by inductively 
coupled plasma atomic emission spectrometry (ICP-
AES) or inductively coupled plasma mass spectrometry 
(ICP-MS), although several chromatographic methods 
often coupled with AAS, ICP-AES, or ICP-MS have 
been devised to separate anionic chromium(VI) from 
cationic chromium(III) species (Urasa & Nam, 1989; 
Sperling et al., 1992; Gjerde et al., 1993; Byrdy et al., 
1995; Inoue et al., 1995; Girard & Hubert, 1996; 
Goodarzi & Huggins, 2001). The spectrophotometric 
determination of chromium(VI) as a coloured complex 
with 1,5-diphenylcarbazide is still widely used for 
speciation. Trivalent chromium can be similarly 
measured as the diphenylcarbazide complex after 
oxidation to the hexavalent state.  
 
 In most cases, speciation is based on the deter-
mination of hexavalent chromium and total chromium, 
the difference being trivalent chromium. A major 
analytical problem in speciation is the instability of 
hexavalent chromium during sample storage. Although 
the phenomenon is of fundamental importance, little 
attention has been given to its quantitative assessment. 
 
3.1 Samples from the general and work 
environment  
 
 The National Institute for Occupational Safety and 
Health (NIOSH) in the United States of America (USA) 
has developed a field analytical method to measure 
hexavalent chromium (chromate) in air (NIOSH Method 
7703) (NIOSH, 1994c). The procedure includes ultra-
sonic extraction from sampling filters, solid-phase 
extraction of chromate from the previous solution, and 
the determination of chromium(VI) by spectrophotom-
etry. The method is relatively easy to use, has a low  
detection limit, and allows analysis before hexavalent 
chromium can significantly reduce to the trivalent state. 
For total chromium measurements, it is possible to use 
atomic absorption with a nitrous oxide–acetylene 
reducing flame (NIOSH Method 7024) (NIOSH, 1994a) 
or ICP-AES according to NIOSH Method 7300 (NIOSH, 
1994b), which has a detection limit of 20 ng/filter.  
 
 A wide variety of methods have been developed for 
the determination of chromium in water. Analyses of 
chromium(VI) from groundwater, surface water, raw or 
potable water, or wastewater, according to International 
Organization for Standardization (ISO) Standard 
18412:2005 (ISO, 2005) or ISO Standard 11083:1994 
(ISO, 1994), are based on the spectrophotometric 
method with 1,5-diphenylcarbazide as a complexing 
agent. The determination of total chromium can be 
carried out using AAS with graphite furnace (GAAS) 
and magnesium nitrate as a recommended modifier (ISO 
Standard 15586:2003) (ISO, 2003), using ICP-AES (ISO 
Standard 11885:1996) (ISO, 1996), or using ICP-MS 
(ISO Standard 17294-2:2004) (ISO, 2004).  
 
3.2   Biological monitoring 
 
 Most methods use AAS to measure total chromium 
in urine, serum, blood, and other human tissues. Chro-
mium in biological samples may also be determined 
using ICP-MS and neutron activation analysis (NAA) 
(Nicolaou et al., 1987; Lavi & Alfassi, 1990; Tomlinson 
et al., 1994; Apostoli et al., 1997). The detection limit in 
urine measured by AAS is between 0.03 and 0.1 µg/l 
(Riihimäki & Luotamo, 2006); when measured by NAA, 
the detection limit in urine is 10 ng chromium per 
sample (Lavi & Alfassi, 1990). The detection limit in 
serum measured by GAAS with a background correction 
lamp is 0.05 µg/l (Randall & Gibson, 1987; Kornhauser 
et al., 2002); with Zeeman background correction, it 
varies between 0.02 and 0.2 µg/l (Riihimäki & Luotamo, 
2006). 
 
 Knowledge of uncertainty has improved the quality 
of measurements, especially near the detection limit 
(Ellison et al., 2000; CITAC/Eurachem, 2002), with the 
paradoxical outcome that detection limits reported in 
recent publications have become higher. International 
quality assurance programmes (Interlaboratory Compar-
ison Program for Metals in Biological Matrices, Canada, 
http://www.inspq.qc.ca/ctq/; German External Quality 
Assessment Scheme for Analyses in Biological Materi-
als, Germany, http://www.g-equas.de/) provide the 
opportunity for participants to compare their own results 
with those from other laboratories.  
 
 Determination of chromium in urine is the preferred 
approach for the biological monitoring of exposure to 
trivalent chromium. The urine sample is usually diluted 
  
Table 1: Identification data for trivalent chromium compounds (IARC, 1990; Kirk-Othmer, 2003; Ullmann’s, 2004; industry information). 
 
Substance name CAS No. Synonyms Chemical formula 
Relative 
molecular 
mass 
Chromite (pure) 1308-31-2 Chromium ore; chromite (mineral); chromite mineral; chromite ore; iron chromite FeOCr2O3 223.84 
Chromium(III) oxide 1308-38-9 CI 77288; CI pigment green 17; Casalis green; chrome green; chrome ocher; chrome ochre; 
chrome oxide; chromium acid green; chromium oxide; chromium oxide green; chromium 
oxide pigment; chromium oxide X1134; chromium oxide greens; chromium sesquioxide; 
chromium trioxide; Cosmetic hydrophobic green 9409; Cosmetic micro blend chrome oxide 
9229; dichromium trioxide; green chrome oxide; green oxide of chromium; green chromium 
oxide; green cinnabar; green oxide of chromium OC-31; green rouge; leaf green; oil green; 
oxide of chromium  
Cr2O3 151.99 
Chromium(III) oxide, hydrated 12001-99-9 Chromium hydrate Cr2O3·2H2O 188.05 
Chromium(III) sulfate 10101-53-8 Dichromium tris(sulfate) Cr2(SO4)3 392.17 
Chromium(III) hydroxide sulfate 12336-95-7 Basic chrome sulfate; basic chromium sulfate; chromedol; monobasic chromium sulfate  Cr(OH)SO4 165.06 
Chromium(III) potassium sulfate 10141-00-1 KCr(SO4)2 283.23 
Chromium(III) potassium sulfate, 
dodecahydrate 
7788-99-0
Chrome alum; chrome potash alum; chromium potassium sulfate; crystal chrome alum; 
potassium chromium sulfate; potassium chromium alum; potassium chromium disulfate; 
potassium chromium(III) sulfate; potassium disulfatochromate(III) KCr(SO4)2·12H2O 499.39 
Chromium(III) hydroxide, trihydrate 1308-14-1 Chromium(III) hydroxide; chromium hydroxide; chromium oxide gel; chromium oxide, 
hydrous; chromium trihydroxide  
Cr(OH)3·3H2O 163.02 
Chromium(III) chloride 10025-73-7 CrCl3 158.36 
Chromium(III) chloride, hexahydrate 10060-12-5
Chromium chloride; chromium trichloride; chromium(III) chloride, anhydrous; puratronic 
chromium chloride; trichlorochromium CrCl3·6H2O 266.45 
Chromium(III) nitrate 13548-38-4 Cr(NO3)3 238.03 
Chromium(III) nitrate, 7.5 hydrate Cr(NO3)3·7.5H2O 373.13 
Chromium(III) nitrate, nonahydrate 
Chromium nitrate; chromium trinitrate; nitric acid, chromium (3+) salt 
Cr(NO3)3·9H2O 400.15 
Chromium acetate 1066-30-4 Cr(OCOCH3)3 229.14 
Chromium acetate, hydrate 
Chromium acetate; chromium(III) acetate; chromium triacetate  
Cr(OCOCH3)3·H2O 247.15 
Chromium(III) fluoride, tetrahydrate 7788-97-8 Chromium trifluoride CrF3·4H2O 181.05 
Chromium(III) formate 27115-36-2 Chromium formate; chromium triformate Cr(HCOOH)3 190.08 
Chromium(III) phosphate 7789-04-0 CrPO4 146.97 
Chromium(III) phosphate, monohydrate 27096-04-4 CrPO4·H2O 164.98 
Chromium(III) phosphate, dihydrate 
Arnaudon’s green; chromium phosphate; chromium monophosphate; chromium 
orthophosphate; phosphoric acid chromium(III) salt; phosphoric acid, chromium (3+) salt 
(1:1) 
CrPO4·2H2O 183.00 
CAS, Chemical Abstracts Service 
 
 
 
Table 2: Physical and chemical properties of chromium and chromium(III) compounds (IARC, 1990; Kirk-Othmer, 2003; Ullmann's, 2004; industry information). 
 
Substance name Physical form Melting point (°C) Boiling point (°C) Solubility in water  
Solubility in other 
solvents 
Chromite Brown-black solid Depends on composition Insoluble Insoluble in organic solvents 
Chromium(III) oxide Light to dark green, fine crystals 2435 4000 Insoluble Insoluble 
Chromium(III) oxide, hydrated Blue-green powder – – Insoluble Insoluble 
Chromium(III) sulfate, hydrated Green or violet crystals  90  Decomposes 84–120 g/l00 ml  Insoluble 
Chromium(III) potassium 
sulfate, dodecahydrate 
Violet ruby-red to black crystals 89 400 Soluble in water (243.9 g/l) at 
25 °C; 500 g/l in hot water 
Slightly soluble in dilute 
acids, insoluble in ethanol 
Chromium(III) hydroxide sulfate Green powder – – Soluble (700 g/l at 30 °C) – 
Chromium(III) hydroxide Red-brown hexagonal crystals Insoluble Soluble in alcohol 
Chromium(III) hydroxide, 
trihydrate 
Blue-green powder 
 
Composition varies Insoluble Soluble in acids 
Chromium(III) chloride Violet crystalline scales 1152 Sublimes at 1300 Insoluble in cold water, slightly 
soluble in hot water 
Insoluble in ethanol, 
acetone, methanol, and 
diethyl ether 
Chromium(III) chloride, 
hexahydrate 
Green to violet crystalline powder 83–95 – Soluble in water (585 g/l) Soluble in ethanol, slightly 
soluble in acetone, and 
insoluble in diethyl ether 
Chromium(III) nitrate Pale green powder – – Soluble – 
Chromium(III) nitrate, 7.5 
hydrate 
Brown crystals 100 Decomposes Soluble – 
Chromium(III) nitrate, 
nonahydrate 
Deep-violet crystals 60 Decomposes at 100 Soluble Soluble in acids, alkali, 
ethanol, and acetone 
Chromium(III) acetate Grey-green powder – – Soluble – 
Chromium(III) acetate, 
dihydrate 
Red crystals – – Slightly soluble Slightly soluble in ethanol, 
soluble in acids 
Chromium(III) phosphate Violet crystalline solid >1800 – Insoluble Soluble in most acids and 
alkali but not in acetic acid 
Chromium(III) phosphate, 
dihydrate 
Violet crystalline solid – – Slightly soluble in cold water – 
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with water, nitric acid, Triton X-100, or a combination 
of these. To normalize for the degree of dilution of the 
urine sample, the measured chromium concentration can 
be adjusted for relative density or for creatinine excre-
tion. The control values must be similarly adjusted. 
 
 
 
4. SOURCES OF HUMAN AND 
ENVIRONMENTAL EXPOSURE 
 
 
4.1  Natural sources  
 
 Chromium is a relatively common element, 
naturally occurring in rocks, soil, plants, animals, 
volcanic dust, and gases. Oil and coal contain traces of 
chromium(III). Chromium is chiefly found as the 
chromium(III) form in nature (ATSDR, 2000). 
 
 Continental dust flux is the main natural source of 
chromium in the atmosphere; volcanic dust and gas flux 
are minor natural sources of chromium in the atmos-
phere (Fishbein, 1981). 
 
4.2  Anthropogenic sources 
 
 Approximately 12 million tonnes of chromite ore 
are mined globally per year. Of this amount, approxi-
mately 90% is used for metallurgy, 7% for the manu-
facture of chemicals, 3% for foundry sands, and 1% for 
refractories (Keegan, 2001). Chromium(III) is the most 
stable oxidation state of chromium. This property and 
the ability of chromium(III) to form coordination 
complexes with a wide variety of ligands have given 
chromium(III) compounds diverse industrial applica-
tions. The most extensively produced compounds are 
basic chromium sulfate (global production capacity 
about 500 000 tonnes per year) and chromium(III) oxide 
(global production capacity about 88 500 tonnes per 
year) (Keegan, 2001). 
 
 Tanning of leather is by far the most widespread end 
use of trivalent chromium. The tanning is based on a 
covalent reaction between the hide proteins, notably 
collagen, and trivalent chromium salts. Usually the 
tanning agent is basic chromium sulfate; previously, 
chromium(III) potassium sulfate was also used. 
 
 Chromium(III) oxide pigments are used in paints, 
plastics, concrete building products, artistic colours, 
ceramics, and glass. Hydrated chromium oxide pigment 
is used in cosmetic and personal care products such as 
eye shadows and soaps. The chromium oxide pigments 
are used because of their colour, light fastness, stability, 
and durability. Different grades of chromium oxide–
based pigments are used in varying quantities depending 
on the shade of green required. For example, the concen-
tration of chromium oxide in paint can vary from 8% to 
50%. 
 
 Some chromium(III) salts (basic chromium(III) 
sulfate, chromium(III) chloride, chromium(III) sulfate) 
have found increasing use in decorative chromium 
plating substituting for hexavalent chromic acid. 
Decorative plating is common in, for example, faucets, 
door handles, and furniture.  
 
 Chromium(III) oxide, hydroxide, and some salts can 
be used to make catalysts for the chemical industry. 
Chromium–iron catalysts are usually made from chro-
mium and iron salts. Iron–chromium catalysts are used 
in high-temperature shift reactions in the petroleum 
industry and in the production of hydrogen from 
methane. Chromium(III) oxide is also used as a raw 
material in the manufacture of pure chromium metal by 
the aluminothermic process. 
 
 Trivalent chromium compounds (e.g. chromium(III) 
hydroxide, sulfate, nitrate, acetate) have been used as 
mordants in textile dyeing to fix dyes to fibres. Chromi-
um(III) complexes are used especially in wool dyes. 
 
 Chromite is used as a refractory material because of 
its high melting point, moderate thermal expansion, 
inertness, and corrosion resistance. In refractory prod-
ucts, chromium is usually in the form of chromium(III) 
oxide or chromite. Chromite is used as foundry sand. 
 
 Chromium(III) chloride and chromium(III) sulfate 
have been used as dietary supplements (approved for the 
manufacture of foods for particular nutritional uses and 
in food supplements in the European Union), whereas 
the organic chromium(III) complexes chromium picoli-
nate and nicotinate are not approved in the European 
Union but find widespread uses (e.g. in the USA) in 
multivitamin, multimineral products (Riihimäki & 
Luotamo, 2006). They are also marketed for weight loss 
purposes and athletic supplements. 
 
 
 
5. ENVIRONMENTAL TRANSPORT, 
DISTRIBUTION, AND TRANSFORMATION 
 
 
 There is a complete chromium cycle, from rocks or 
soil to plants, animals, and humans, and back to soil. 
Only part of the chromium is diverted to a second path-
way leading to the repository, the ocean floor. This part 
consists of chromium from rocks and soil carried by 
water (concentrations of a few micrograms per litre) and 
animal and human excreta, a small part of which may 
find their way into water (e.g. runoff from sewage 
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sludge). Another cycle consists of airborne chromium 
from natural sources, such as fires, and from the chro-
mate industry. This cycle also contains some hexavalent 
chromium, with by-products going into the water and 
air. Part of the air chromium completes the cycle by 
settling on the land, but a very significant portion goes 
into the repository, the ocean, where it ends up as 
sediment on the ocean floor (IPCS, 1988). 
 A maximum of 47% of the total chromium in 
ferrochrome smelter dust may be bioavailable, as 
indicated by acid/base extraction. About 40% of the 
bioavailable chromium may exist as chromium(VI), 
mostly in the form of Cr
 
5.1  Environmental transport and 
distribution  
 
5.1.1  Air 
 
 Chromium is emitted into the air, not only by 
anthropogenic sources, but also by every combustion 
process, including forest fires. The oxidation state of 
chromium emissions is not well defined quantitatively, 
but it can be assumed that the heat of combustion may 
oxidize an unknown proportion of the element to the 
hexavalent state. While suspended in the air, chromium 
in this state is probably stable, until it settles down and 
comes into contact with organic matter, which will 
eventually reduce it to the trivalent form (IPCS, 1988). 
 
 Chromium is present in the atmosphere primarily in 
particulate form. Naturally occurring gaseous forms of 
chromium are rare (Cary, 1982). The transport and 
partitioning of particulate matter in the atmosphere 
depend largely on particle size and density. Atmospheric 
particulate matter is deposited on land and water by wet 
and dry deposition. In the case of chromium, the mass 
median diameter of the ambient atmospheric particle is 
0.1 µm (Milford & Davidson, 1985; Ondov et al., 1989), 
and the dry deposition velocity is 0.5 cm/s (Schroeder et 
al., 1987). This size and deposition velocity favour dry 
deposition by inertial impaction (Schroeder et al., 1987). 
Wet removal of particulate chromium also occurs by 
rainout within a cloud and washout below a cloud, and 
acid rain may facilitate the removal of acid-soluble 
chromium compounds from the atmosphere. The wet 
scavenging ratio (i.e. the ratio of the concentration of 
contaminant in precipitation to the concentration in 
unscavenged air) ranges from 150 to 290 for chromium 
(Schroeder et al., 1987; Dasch & Wolff, 1989). The wet 
deposition ratio increases with particle size and 
decreases with precipitation intensity (Schroeder et al., 
1987). Chromium particles of aerodynamic diameter 
below 20 µm may remain airborne for longer periods of 
time and be transported for greater distances compared 
with larger particles. The monthly dry deposition flux 
rate of chromium measured in Bologna, Italy, over the 
course of 1 year ranged from about 40 to 270 µg/m2 per 
month, with the largest values occurring during the 
winter months (Morselli et al., 1999). Golomb et al. 
(1997) reported a deposition rate (wet plus dry) of 
2700 µg chromium/m2 per year for Massachusetts Bay, 
USA, during 1992 and 1993.  
2O72− or CrO42− (Cox et al., 
1985).  
 
 There are no data in the reviewed literature indi-
cating that chromium particles are transported from the 
troposphere to the stratosphere (Pacyna & Ottar, 1985). 
By analogy with the residence time of general particles 
with mass median diameters similar to that of chromium, 
the residence time of atmospheric chromium is expected 
to be less than 10 days (Nriagu, 1979). Based on a 
troposphere to stratosphere turnover time of 30 years 
(USEPA, 1979), atmospheric particles with a residence 
time of less than 10 days are not expected to transport 
from the troposphere to the stratosphere. 
 
5.1.2  Water 
 
 Industrial effluents containing chromium, some of 
which is in the hexavalent form, are emitted into surface 
waters. Whether the chromium remains hexavalent until 
it reaches the ocean depends on the amount of organic 
matter present in the water. If organic matter is present 
in large quantities, the chromium(VI) may be reduced 
by, and chromium(III) adsorbed on, the particulate 
matter. If it is not adsorbed, the chromium(III) will form 
large, polynucleate complexes that are no longer soluble. 
These may remain in colloidal suspension and be trans-
ported to the ocean as such, or they may precipitate and 
become part of the stream sediment (IPCS, 1988). 
Whalley et al. (1999) found that a proportion of the 
chromium(III) may subsequently be remobilized in the 
form of soluble chromium(III)–organic complexes. 
Similar processes occur in the oceans, where chromi-
um(VI) is reduced and settles on the ocean bed (IPCS, 
1988). In seawater, the proportion of chromium(III) 
increases with increasing depth (Fukai, 1967). 
 
 Since chromium compounds cannot volatilize from 
water, transport of chromium from water to the atmos-
phere is not likely, except by transport in windblown sea 
sprays. Most of the chromium released into water will 
ultimately be deposited in the sediment. A very small 
percentage of chromium can be present in water in both 
soluble and insoluble forms. Soluble chromium gener-
ally accounts for a very small percentage of the total 
chromium. Most of the soluble chromium is present as 
chromium(VI) and soluble chromium(III) complexes. 
The major dissolved species of chromium(III) are Cr3+, 
CrOH2+, Cr(OH)30, and Cr(OH)4−. Of these species, Cr3+ 
exists in significant amounts only at pH below about 
3.6–3.8; similarly, Cr(OH)4− is prevalent only at high pH 
(pH above about 10–11.5). Between these pH values, 
CrOH2+ is thought to be the dominant species up to 
around pH 6.3–6.5, and Cr(OH)30 is the dominant 
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species in solution at pHs between 6.3–7 and 10–11.5. 
Polymeric species such as Cr2(OH)24+, Cr3(OH)45+, and 
Cr4(OH)66+, although they exist, are never significant in 
the environment. Overall, chromium(III) species show a 
minimum solubility between pH 7 and pH 10 (Rai et al., 
1987; Richard & Bourg, 1991). At pHs from about 5–6 
up to about 12, the solubility of chromium(III) in aque-
ous systems is limited by the formation of chromium(III) 
hydroxide. If iron, particularly iron(III), is also present, 
the chromium(III) can also form insoluble iron com-
plexes. The free energy of formation is lower for the 
mixed chromium/iron hydroxides than for chromium(III) 
hydroxide, and so the mixed hydroxides are expected to 
form preferentially (Rai & Dubey, 1989). The chromi-
um(III) ion readily forms complexes with ligands such 
as hydroxyl, sulfate, ammonium, cyanide, sulfocyanide, 
fluoride, and chloride, as well as natural and synthetic 
organic ligands. In the aquatic phase, chromium(III) 
occurs mostly as suspended solids adsorbed onto clayish 
materials, organics, or iron oxide present in water. 
Approximately 10% of chromium in the aquatic phase of 
the Amazon and Yukon rivers was in solution, the rest 
being present in the suspended solid phase (Cary, 1982). 
The ratio of suspended to dissolved chromium in an 
organic-rich river in Brazil was 2:1 (Malm et al., 1988).  
 
 Sediment–water partition coefficients of approxi-
mately 30 000 l/kg have been reported for chromium(III) 
in both fresh water and seawater at pH 8 and 2–3% 
organic matter (Young et al., 1992; Wang et al., 1997). 
Soluble forms and suspended chromium can undergo 
intramedia transport. Chromium(VI) in water will 
eventually be reduced to chromium(III) by organic 
matter in the water. It has been estimated that the 
residence time of total chromium in Lake Michigan 
ranges from 4.6 to 18 years (Fishbein, 1981; Schmidt & 
Andren, 1984). 
 
5.1.3  Soil 
 
 Chromium in soil is present mainly as insoluble 
oxide (Cr2O3·nH2O) (USEPA, 1984) and is not very 
mobile. A leachability study was conducted to study the 
mobility of chromium in soil. Owing to different pH 
values, a complicated adsorption process was observed, 
and chromium moved only slightly in soil. Chromium 
was not found in the leachate from soil, possibly because 
it formed complexes with organic matter (Lin et al., 
1996). These results are supported by a leachability 
investigation in which chromium mobility was studied 
for a period of 4 years in a sandy loam (Sheppard & 
Thibault, 1991). The vertical migration pattern of 
chromium indicated that after an initial period of 
mobility, chromium forms insoluble complexes, and 
little leaching is observed. Flooding of soils and the 
subsequent anaerobic decomposition of plant detritus 
matters may increase the mobilization of chromium(III) 
in soils owing to the formation of soluble complexes 
(Stackhouse & Benson, 1989). This complexation may 
be facilitated by a lower soil pH. A smaller percentage 
of total chromium in soil exists as soluble chromium(VI) 
and chromium(III), which are more mobile in soil.  
 
 The mobility of soluble chromium in soil will 
depend on the sorption characteristics of the soil. The 
relative retention of metals by soil is in the order of lead 
> antimony > copper > chromium > zinc > nickel > 
cobalt > cadmium (King, 1988). The sorption of chro-
mium to soil depends primarily on the clay content of 
the soil and, to a lesser extent, on iron oxide and the 
organic content of soil. Chromium that is irreversibly 
sorbed onto soil—for example, in the interstitial lattice 
of geothite (FeOOH)—will not be bioavailable to plants 
or animals under any conditions (Calder, 1988; Hassan 
& Garrison, 1996). Chromium(III) appears to be much 
more strongly adsorbed to soils than is chromium(VI) 
(Hassan & Garrison, 1996).  
 
 Organic matter in soil is expected to convert soluble 
chromate, chromium(VI), to insoluble chromium(III) 
oxide (Calder, 1988). Chromium in soil may be trans-
ported to the atmosphere as an aerosol. Surface runoff 
from soil can transport both soluble and bulk precipitate 
of chromium to surface water. Soluble and unadsorbed 
chromium(VI) and chromium(III) complexes in soil may 
leach into groundwater. The leachability of chromi-
um(VI) in the soil increases as the pH of the soil 
increases. On the other hand, lower pH present in acid 
rain may facilitate the leaching of acid-soluble chromi-
um(III) and chromium(VI) compounds in soil. 
 
5.1.4  Biota 
 
 Living plants and animals absorb the hexavalent 
form in preference to the trivalent form; once absorbed, 
however, the hexavalent form is reduced to the more 
stable, trivalent state (IPCS, 1988). Chromium has a low 
mobility for translocation from roots to aboveground 
parts of plants (Cary, 1982).  
 
5.2  Environmental transformation 
 
5.2.1  Air 
 
 In the atmosphere, chromium(VI) may be reduced 
to chromium(III) by vanadium (V2+, V3+, and VO2+), 
Fe2+, HSO3−, and As3+. Conversely, chromium(III), if 
present as a salt other than chromium(III) oxide, may be 
oxidized to chromium(VI) in the atmosphere in the 
presence of at least 1% manganese oxide (ATSDR, 
2000). However, this reaction is unlikely under most 
environmental conditions. The estimated atmospheric 
half-life for chromium(VI) reduction to chromium(III) 
was reported to be in the range of 16 h to about 5 days 
(Kimbrough et al., 1999). 
 
 12
Inorganic chromium(III) compounds 
 
 
5.2.2  Water 5.2.3  Soil 
  
 The reduction of chromium(VI) to chromium (III) 
by S
 The fate of chromium in soil is greatly dependent 
upon the speciation of chromium, which is a function of 
redox potential and the pH of the soil. In most soils, 
chromium will be present predominantly in the chro-
mium(III) state (Barnhart, 1997). Under oxidizing 
conditions, chromium(VI) may be present in soil as 
CrO
2− or Fe2+ ions under anaerobic conditions is fast, 
and reduction half-lives range from instantaneous to a 
few days. However, the reduction of chromium(VI) by 
organic sediments and soils was much slower and 
depended on the type and amount of organic material 
and on the redox condition of the water. The reaction 
was generally more rapid under anaerobic than under 
aerobic conditions. The reduction half-life of chromi-
um(VI) in water with soil and sediment ranged from 4 to 
140 days (Saleh et al., 1989). Dissolved oxygen by itself 
in natural waters did not cause any measurable oxidation 
of chromium(III) to chromium(VI) in 128 days (Saleh et 
al., 1989). When chromium(III) was added to lake water, 
a slow oxidation of chromium(III) to chromium(VI) 
occurred, corresponding to an oxidation half-life of 
9 years. Addition of manganese oxide at 50 mg/l accel-
erated the process, decreasing the oxidation half-life to 
around 2 years (Saleh et al., 1989). Therefore, this oxi-
dation process would not be important in most natural 
waters except in the presence of naturally occurring 
manganese oxides (Rai & Dubey, 1989; Richard & 
Bourg, 1991). The oxidation of chromium(III) to chro-
mium(VI) during chlorination of water was highest in 
the pH range of 5.5–6.0 (Saleh et al., 1989). However, 
the process would rarely occur during chlorination of 
drinking-water because of the low concentrations of 
chromium(III) in these waters and the presence of 
naturally occurring organics that may protect chromi-
um(III) from oxidation, either by forming strong com-
plexes with chromium(III) or by acting as a reducing 
agent to free available chlorine (USEPA, 1988). In 
chromium(III)-contaminated wastewaters with pHs 
ranging from 5 to 7, chlorination may convert chro-
mium(III) to chromium(VI) in the absence of chromi-
um(III) complexing and free chlorine reducing agents 
(ATSDR, 2000). 
 
 Chromium speciation in groundwater depends on 
the redox potential and pH conditions in the aquifer. 
Chromium(VI) predominates under highly oxidizing 
conditions, whereas chromium(III) predominates under 
reducing conditions. Oxidizing conditions are generally 
found in shallow aquifers, and reducing conditions 
generally exist in deeper groundwaters. In natural 
groundwater, the pH is typically 6–8, and CrO42− is the 
predominant species of chromium in the hexavalent 
oxidation state, whereas Cr(OH)2+ will be the dominant 
species in the trivalent oxidation state. This species and 
other chromium(III) species will predominate at more 
acidic pHs, whereas Cr(OH)3 and Cr(OH)4− predominate 
in more alkaline waters (Calder, 1988). In seawater, 
chromium(VI) is generally stable (Fukai, 1967). 
 
4
2− and HCrO4− (James et al., 1997). In deeper soil, 
where anaerobic conditions exist, chromium(VI) will be 
reduced to chromium(III) by S2− and Fe2+ present in soil. 
The reduction of chromium(VI) to chromium(III) is 
possible in aerobic soils that contain appropriate organic 
energy sources to carry out the redox reaction. The 
reduction of chromium(VI) to chromium(III) is facil-
itated by low pH (Cary, 1982; Saleh et al., 1989; 
ATSDR, 2000). From thermodynamic considerations, 
chromium(VI) may exist in the aerobic zone of some 
natural soil. The oxidation of chromium(III) to chromi-
um(VI) in soil is facilitated by the presence of low 
oxidizable organic substances, oxygen, manganese 
dioxide, and moisture. Oxidation is also enhanced at 
elevated temperatures in surface soil that result from 
brush fires (Cary, 1982; Calder, 1988). Organic forms of 
chromium(III) (e.g. humic acid complexes) are more 
easily oxidized than insoluble oxides. However, oxida-
tion of chromium(III) to chromium(VI) was not 
observed in soil under conditions of maximum aeration 
and a maximum pH of 7.3 (Bartlett & Kimble, 1976). It 
was later reported that soluble chromium(III) in soil can 
be partly oxidized to chromium(VI) by manganese diox-
ide in soil, and the process is enhanced by pH values 
higher than 6 (Bartlett, 1991). Because most chromi-
um(III) in soil is immobilized as a result of adsorption 
and complexation with soil materials, the barrier to this 
oxidation process is the lack of availability of mobile 
chromium(III) to immobile manganese dioxide in soil 
surfaces. Owing to this lack of availability of mobile 
chromium(III) to manganese dioxide surfaces, a large 
portion of chromium in soil will not be oxidized to 
chromium(VI), even in the presence of manganese 
dioxide and favourable pH conditions (Barth et al., 1965; 
James et al., 1997). 
 
 The microbial reduction of chromium(VI) to chro-
mium(III) has been discussed as a possible remediation 
technique in heavily contaminated environmental media 
or wastes (Chen & Hao, 1998). Factors affecting the 
microbial reduction of chromium(VI) to chromium(III) 
include biomass concentration, initial chromium(VI) 
concentration, temperature, pH, carbon source, oxida-
tion–reduction potential, and the presence of both 
oxyanions and metal cations. Although high levels of 
chromium(VI) are toxic to most microbes, several 
resistant bacterial species have been identified that could 
ultimately be employed in remediation strategies (Chen 
& Hao, 1998). Elemental iron, sodium sulfite, sodium 
hydrosulfite, sodium bisulfite, sodium metabisulfite, 
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sulfur dioxide, and certain organic compounds, such as 
hydroquinone, have also been shown to reduce chro-
mium(VI) to chromium(III) and have been discussed as 
possible remediation strategies in heavily contaminated 
soils (Higgins et al., 1997; James et al., 1997). The 
limitations and efficacy of these and all remediation 
techniques are dependent upon the ease with which the 
reducing agents are incorporated into the contaminated 
soils.  
 
5.3  Bioaccumulation 
 
 Bioconcentration factors for chromium(VI) in fish 
are low, at around 1; however, once in the organism, 
chromium(VI) appears to be reduced to chromium(III), 
resulting in the accumulation of total chromium in the 
organisms to a factor of approximately 100 times the 
water concentration. Uptake of chromium(III) directly 
from water is likely to be very low owing to the limited 
water solubility of trivalent chromium compounds found 
in the environment and strong adsorption to sediment 
under most conditions in the environment. 
 
 The uptake of chromium(III) potassium sulfate, 
chromium(III)–ethylenediaminetetraacetic acid (EDTA) 
complex and chromium(III)–glycine complex by the 
freshwater alga Chlorella pyrenoidosa was studied by 
Meisch & Schmitt-Beckmann (1979). Bioconcentration 
factors ranged from 558 to 580, from 11 to 12, and from 
224 to 254 for the three compounds, respectively, 
following 5 days of exposure to chromium concentra-
tions of 0.5 and 1 mg/l. 
 
 In bottom-feeding bivalves, such as the oyster 
(Crassostrea virginica), blue mussel (Mytilus edulis), 
and soft shell clam (Mya arenaria), the bioconcentration 
factors for chromium(III) were found to range from 86 
to 192 (USEPA, 1980, 1984; Fishbein, 1981; Schmidt & 
Andren, 1984). The bioavailability of chromium(III) to 
freshwater invertebrates (Daphnia pulex) decreased with 
the addition of humic acid. This decrease in bioavail-
ability was attributed to lower availability of the free 
form of the metal due to its complexation with humic 
acid. Stackhouse & Benson (1989) reported that the 
accumulation of chromium was significantly reduced by 
the presence of humic acid. The bioconcentration factor 
for chromium(III) in 96-h exposures (10 mg/l) of 
Daphnia magna was reduced from 10 000 to 3000 by the 
presence of 50 mg humic acid/l. 
 
 Chromium is not expected to biomagnify in the 
aquatic food-chain.  
 
 Although higher concentrations of chromium have 
been reported in plants growing in high chromium-
containing soils (e.g. soil near ore deposits or chromium-
emitting industries and soil fertilized by sewage sludge) 
compared with plants growing in normal soils, most of 
the increased uptake in plants is retained in roots, and 
only a small fraction is translocated to the aboveground 
part of edible plants (Cary, 1982; IPCS, 1988). There-
fore, bioaccumulation of chromium from soil to above-
ground parts of plants is unlikely (Petruzzelli et al., 
1987).  
 
 Van Gestel et al. (1993) reported low bioconcentra-
tion factors for chromium(III) in earthworms (Eisenia 
andrei). Chromium nitrate was added to artificial soil; 
after 3 weeks, bioconcentration factors of 0.03–0.05 
were determined at exposure concentrations ranging 
from 10 to 100 mg chromium(III)/kg dry soil. The 
elimination half-life for total chromium was estimated to 
be 51–109 days. 
 
 There is no indication of biomagnification of chro-
mium along the terrestrial food-chain (Cary, 1982). 
 
 
 
6. ENVIRONMENTAL LEVELS AND HUMAN 
EXPOSURE 
 
 
6.1  Environmental levels 
 
 Chromium occurs naturally in the Earth’s crust. 
Continental dust is the main source of exposure to 
natural chromium present in the environment (Fishbein, 
1981). As a result of human activities, however, chro-
mium is released into the environment in larger amounts. 
Many of the data in section 6 are reported as total chro-
mium because no speciation has been carried out, 
although chromium(III) is likely to be the dominant 
species in most environmental samples. 
 
6.1.1  Air 
 
 The atmospheric total chromium concentration in 
the USA is typically <10 ng/m3 in rural areas and 10–
30 ng/m3 in urban areas (Fishbein, 1984). Levels of total 
chromium in the ambient air in urban and non-urban 
areas in the USA during 1977–1984 are reported in the 
United States Environmental Protection Agency’s 
(USEPA) National Aerometric Data Bank (USEPA, 
1984; ATSDR, 2000). The arithmetic mean total chro-
mium concentrations from a total of 2106 monitoring 
stations ranged from 5 to 525 ng/m3. The two locations 
that showed the highest total arithmetic mean chromium 
concentrations were in Steubenville, Ohio, in 1977 
(525 ng/m3) and in Baltimore, Maryland, in 1980 
(226 ng/m3) (ATSDR, 2000). Arithmetic mean total 
chromium concentrations were above 100 ng/m3 in only 
8 of 173 sites monitored in 1984 (ATSDR, 2000). 
During the period 1978–1982, the maximum level of 
total chromium in ambient air samples in Corpus Christi, 
Texas, a site of chromate manufacture, was 5500 ng/m3. 
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The annual average concentration of chromium in 
Corpus Christi ambient air was 400 ng/m3 during the 
same period (Wiersema et al., 1984). The USEPA 
monitored two locations in Corpus Christi in 1981 and 
reported an arithmetic mean chromium concentration of 
100 ng/m3 (ATSDR, 2000).  
 
 The concentrations of atmospheric chromium in 
remote areas range from 0.005 to 2.6 ng/m3 (Cary, 1982; 
Barrie & Hoff, 1985; Schroeder et al., 1987; Sheridan & 
Zoller, 1989). Saltzman et al. (1985) compared the levels 
of atmospheric chromium at 59 sites in cities in the USA 
during 1968–1971 with data from the USEPA’s National 
Aerometric Data Bank file for 1975–1983. They con-
cluded that atmospheric chromium levels may have 
declined in the early 1980s from the levels detected in 
the 1960s and 1970s. 
 
 Chromium concentrations in air vary with location. 
Background levels determined at the South Pole ranged 
from 2.5 to 10 pg/m3 and are believed to be due to the 
weathering of crustal material (IPCS, 1988). Data 
collected by the National Air Sampling Network in the 
USA in 1964 gave the national average concentration for 
chromium in the ambient air as 15 ng/m3, varying from 
non-measurable levels to a maximum of 350 ng/m3. 
Chromium concentrations in most non-urban areas and 
even in many urban areas were below detection levels. 
Yearly average concentrations for cities in the USA 
varied from 9 to 102 ng/m3. Concentrations ranging 
from 17 to 87 ng/m3 have been reported for Osaka, 
Japan (IPCS, 1988). The chromium content of the air in 
the vicinity of industrial plants may be higher. In 1973, 
the reported chromium concentrations ranged from 1 to 
100 mg/m3 for coal-fired power plants, from 100 to 
1000 mg/m3 for cement plants, from 10 to 100 mg/m3 
for iron and steel industries, and from 100 to 1000 
mg/m3 for municipal incinerators (IPCS, 1988). Ferro-
chromium plants have the highest emission rates (IPCS, 
1988). However, modern chromium chemical plants 
contribute very little to pollution today, because of the 
installation of collecting equipment that returns the 
material for reuse. Drift from cooling towers contributes 
to atmospheric pollution, when chromium is used as a 
corrosion inhibitor.  
 
 Kieber et al. (2002) reported a volume-weighted 
annual average dissolved chromium(III) concentration of 
0.04 µg/l for rainwater collected at Wilmington, North 
Carolina, USA (1999–2001). 
 
6.1.2  Surface water 
 
 Total chromium concentrations in river water in the 
USA usually range from <1 to 30 µg/l (USEPA, 1984; 
Malm et al., 1988), with a median value of 10 µg/l 
(Smith et al., 1987; Eckel & Jacob, 1988). In Europe, a 
median concentration of 0.38 µg total chromium/l 
(<0.01–43.3 µg/l) has been reported for surface waters 
(Salminen et al., 2005). Total chromium concentrations 
in lake water generally do not exceed 5 µg/l (Cary, 1982; 
Borg, 1987). The higher levels of chromium can be 
related to sources of anthropogenic pollution. Except for 
regions with substantial chromium deposits, the natural 
content of chromium in surface waters is very low, most 
of the samples containing between 1 and 10 µg/l (IPCS, 
1988). Chromium concentrations ranging from 1.2 to 
94.4 µg/l for unfiltered surface water and from 0.1 to 
0.5 µg/l for filtered (<0.45 µm) water were reported for 
the source area of the Yangtze River, China (Zhang & 
Zhou, 1992). Mean dissolved chromium concentrations 
ranging from 0.3 to 6.8 µg/l were found for 14 rivers in 
the United Kingdom, with particulate chromium concen-
trations of 0.1–4 µg/l (Neal et al., 2000). Cranston & 
Murray (1980) reported that <2% of the total dissolved 
chromium in the Columbia River, USA, was present as 
trivalent chromium. Dissolved chromium concentrations 
of 0.6–1.3 µg/l were reported in the Delaware River near 
Marcus Hook and Fieldsboro, Pennsylvania, USA, in 
January 1992, with chromium(III) composing 67% of 
the total (Riedel & Sanders, 1998). In March 1992, these 
concentrations decreased to 0.03–0.2 µg/l. Sumida et al. 
(2005) reported a mean total chromium concentration of 
0.22 µg/l for the Kokubu and Kagami rivers in Japan and 
a mean concentration of 1.57 µg chromium/l for post-
treatment wastewater from a metal recycling plant. The 
river water samples contained about 60% chromium(III), 
and the wastewater contained about 70% chromium(III). 
Motomizu et al. (2003) found mean total dissolved 
chromium concentrations ranging from 0.41 to 0.48 µg/l 
for the Asahi and Zasu rivers in Japan, with chromi-
um(III) comprising 75% of the total chromium concen-
tration. Tang et al. (2004) reported mean concentrations 
of 2 µg chromium(III)/l and 3 µg chromium(VI)/l for 
river water in China. The mean total chromium concen-
tration 80 m from a disused tannery in Sweden was 
found to be 225 µg/l, with 1.1 µg/l as free chromium(III) 
species and 63 µg/l as free chromium(VI) species; 
chromium concentrations were below the detection limit 
(<0.05 µg/l) at a distance of 300 m (Djane et al., 1999). 
Chromium(III) and chromium(VI) concentrations 
ranging up to 85.2 and 3.5 µg/l, respectively, were 
reported downstream of a tannery in the Upper Dunajec 
River in Poland; mean concentrations of 0.52 µg 
chromium(III)/l and 0.1 µg chromium(VI)/l were found 
in the unpolluted Bialka River (Bobrowski et al., 2004). 
Giusti & Barakat (2005) found that chromium(III) 
concentrations ranged from 0.5 to 97.5 µg/l for the Fratta 
River, Italy, with the highest concentrations close to 
tannery effluent discharges. Similarly, Dominguez 
Renedo et al. (2004) reported a mean chromium(III) 
concentration of 104 µg/l for an industrial area in Spain. 
Water samples from Lake Ontario revealed that 75–85% 
of dissolved chromium was chromium(VI), whereas 
chromium(III) levels were consistently below detection 
limits (<21 ng/l) (Beaubien et al., 1994). Liang et al. 
 15
Concise International Chemical Assessment Document 76 
 
 
(2003) reported mean chromium(III) concentrations of 
0.57 µg/l for East Lake, Wuhan, China, around 50% of 
chromium(VI) concentrations.  
6.1.3  Sediment 
 
 In the suspended materials and sediments of water 
bodies, total chromium levels ranged from 1 to 
500 mg/kg (USEPA, 1984; Byrne & DeLeon, 1986; 
Ramelow et al., 1987; Mudroch et al., 1988; Heiny & 
Tate, 1997). In Europe, median stream sediment chro-
mium concentrations were 64 mg/kg (<3–3324 mg/kg) 
after hydrofluoric acid extraction and 22 mg/kg (2–
1750 mg/kg) after nitric acid extraction; for floodplain 
sediment, chromium concentrations were 59 mg/kg (5–
2731 mg/kg) and 23 mg/kg (3–1596 mg/kg) after the 
two extractions, respectively (Salminen et al., 2005). 
Chromium was detected in sediment obtained from the 
coastal waters of the eastern USA at concentrations of 
3.8–130.9 mg/kg in 1994 and 0.8–98.1 mg/kg in 1995 
(Hyland et al., 1998). A total mean concentration of 
93 mg chromium/kg was reported for sediment from the 
Po River delta in Italy (Fabbri et al., 2001). A mean 
chromium concentration of 20.3 mg/kg (<2 mm fraction) 
was reported for Terra Nova Bay sediment, Antarctica, 
in 1993–1994 (Giordano et al., 1999). 
 
 
 Higher levels of chromium(III) have been found in 
industrial effluents. Ding et al. (2005) reported a concen-
tration of 1 mg chromium(III)/l in industrial effluents, 
whereas wastewater from an electroplating plant 
contained around 4 mg/l (Kiptoo et al., 2004). Mean 
chromium(III) and chromium(VI) concentrations in 
wastewater ranging from 60 to 126 µg/l and from 185 to 
648 µg/l, respectively, were reported by Tang et al. 
(2004), and mean wastewater concentrations of 410 µg 
chromium(III)/l and 296 µg chromium(VI)/l were found 
at a dye plant (Hashemi et al., 2004). Chromium(III) and 
chromium(VI) concentrations in plating industry efflu-
ents ranged from 5 to 50 µg/l and from 25 to 100 µg/l, 
respectively (Prasada Rao et al., 1998). The highest 
chromium(III) concentrations have been reported in 
tannery effluents, with mean concentrations ranging 
from 1 to 44 mg/l (Prasada Rao et al., 1998; Dominguez 
& Arcos, 2002; Dominguez Renedo et al., 2004). 
 
6.1.4  Soil  In general, the concentration of chromium in ocean 
water is much lower than that in lakes and rivers. The 
mean total chromium concentration in ocean water is 
0.3 µg/l, with a range of 0.2–50 µg/l (Cary, 1982). 
Florence & Batley (1980) reported that in seawater, 
typical chromium(III) concentrations lie in the range 
0.002–0.05 µg/l, and typical chromium(VI) concentra-
tions range from 0.1 to 1.3 µg/l. In nearshore and river 
waters, there is a general lowering of chromium(VI)/ 
chromium(III) ratios; for example, Batley & Matousek 
(1980) found labile chromium(III) and chromium(VI) 
concentrations ranging from 0.03 to 0.22 µg/l and from 
0.13 to 0.68 µg/l, respectively, in nearshore and saline 
river water samples from Australia. Seawater samples 
from the south-western coast of India contained chro-
mium(III) at concentrations ranging from 0.08 to 
0.26 µg/l (Prasada Rao et al., 1998). They noted that 
chromium(VI) is not detected in seawater samples that 
have been preserved for more than 4 h. In samples 
analysed immediately after collection, chromium(III) 
and chromium(VI) concentrations were found to be 
0.04 and 0.05 µg/l, respectively. Yalçin & Apak (2004) 
reported a chromium(III) concentration of 2 µg/l for 
coastal waters in Avcilar, Turkey (Marmara Sea). 
Likewise, mean chromium(III) concentrations of 2–
3 µg/l have been reported for coastal seawater in China 
(Yu et al., 2001; Tang et al., 2004). 
 
 Total chromium levels in soil vary greatly and 
depend on the composition of the parent rock from 
which the soils were formed. Basalt and serpentine soils, 
ultramafic rocks, and phosphorites may contain chro-
mium concentrations as high as a few thousand milli-
grams per kilogram (Merian, 1984), whereas soils 
derived from granite or sandstone will have lower 
concentrations of chromium (Swaine & Mitchell, 1960). 
The concentration range of total chromium in 1319 
samples of soils and other surficial materials collected in 
the conterminous USA was 1–2000 mg/kg, with a geo-
metric mean of 37 mg/kg (USGS, 1984). Chromium 
concentrations in Canadian soils ranged from 5 to 
1500 mg/kg, with a mean of 43 mg/kg (Cary, 1982). In 
Europe, median chromium concentrations for topsoil 
were 60 mg/kg (<3–6230 mg/kg) after hydrofluoric acid 
extraction and 22 mg/kg (<1–2340 mg/kg) after nitric 
acid extraction (Salminen et al., 2005). In a study with 
soils from 20 diverse sites, including old chromite 
mining sites in Maryland, Pennsylvania, and Virginia, 
USA, the chromium concentrations ranged from 4.9 to 
71 mg/kg (Beyer & Cromartie, 1987). Soil beneath 
decks treated with copper chrome arsenate wood 
preservative contained a mean chromium concentration 
of 43 mg/kg (Stilwell & Gorny, 1997). Chromium has 
been detected at a high concentration (43 000 mg/kg) in 
soil at the Butterworth Landfill site in Grand Rapid City, 
Michigan, which was a site listed on the National 
Priorities List in the USA (ATSDR, 2000). Hu & 
Deming (2005) found the mean “bioavailable” (EDTA 
extractable) total chromium concentration in soil sam-
ples to be 0.053 mg/kg dry weight (dw), with 57% as 
chromium(III) (0.03 mg/kg). 
 
 The concentration of chromium in the particulate 
portion of melted snow collected from two urban areas 
(Toronto and Montreal) of Canada ranged from 100 to 
3500 mg/kg (Landsberger et al., 1983). 
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 The chromium concentration in incinerated sewage 
sludge ash may be as high as 5280 mg/kg (USEPA, 
1984).  
 
6.1.5  Biota 
 
 Mean chromium levels in periphyton and zoo-
plankton sampled from the Calcasieu River/Lake 
Complex, Louisiana, USA, were 79 and 34 mg/kg dw, 
respectively (Ramelow et al., 1987). 
 
 Chromium levels in shellfish vary from <0.1 to 
6.8 mg/kg dw (Byrne & DeLeon, 1986; Ramelow et al., 
1989). The chromium concentration in fish sampled 
from 167 lakes in the north-eastern USA ranged from 
0.03 to 1.46 mg/kg, with a mean concentration of 
0.19 mg/kg (Yeardley et al., 1998). Ramelow et al. 
(1989) reported mean chromium concentrations in 
freshwater fish species ranging from 0.15 to 5.5 mg/kg 
dw. Mean chromium concentrations ranging from 5 to 
7.6 mg chromium/kg were reported for fish liver 
samples from the South Platte River basin, USA (Heiny 
& Tate, 1997). Fish and shellfish collected from ocean 
dump sites off New York City, Delaware Bay, and New 
Haven, Connecticut, contained <0.3–2.7 mg chromi-
um/kg wet weight (ww) (Greig & Jones, 1976). 
 
 Pine snakes (Pituophis melanoleucus) contained 
whole-body mean chromium concentrations ranging 
from 1.6 to 6.7 mg/kg dw (Burger & Gochfeld, 1992). 
 
 Mean chromium concentrations in birds’ eggs from 
a variety of geographical areas range from <0.2 to 
1 mg/kg dw (Hothem et al., 1995; Hui et al., 1998; 
Burger et al., 1999), and mean liver concentrations range 
from 0.1 to 4.4 mg/kg dw (Hui et al., 1998; Burger & 
Gochfeld, 1999, 2000). Mean concentrations of chro-
mium in bird feathers collected between 1988 and 1997 
from the USA, China, and the Pacific basin ranged from 
0.5 to 49.1 mg/kg dw. The lowest mean concentrations 
were reported for sooty terns (Sterna fuscata) on 
Midway Island, Pacific Ocean, and the highest for 
Chinese pond herons (Ardeola bacchus) in Szechuan, 
China (Burger & Gochfeld, 1992, 1993, 1995a; Burger 
et al., 1994, 2000).  
 
 Mean chromium concentrations in European otter 
(Lutra lutra) livers ranged from 0.02 to 0.3 mg/kg dw 
(Mason & Stephenson, 2001).  
 
6.2   Human exposure 
 
6.2.1 General population exposure 
 
 The general population is exposed to trivalent 
chromium mainly orally from the daily diet. Use of 
chromium supplements can multiply the oral intake. 
Orthodontic appliances made of stainless steel may leach 
minimal amounts of chromium into the oral cavity. 
Small amounts of chromium enter the respiratory system 
in inhaled ambient air. Dermal exposure will result from 
the use of chrome-tanned leather in shoes and gloves, 
from cosmetic products containing chromium pigments, 
and from stainless steel articles lying on the skin, such as 
watches. Prosthetic implants made of chromium-
containing alloys may degrade and release chromium 
internally. 
 
6.2.1.1 Diet  
 
 The chromium content in most Finnish foods was 
below 100 µg/kg. In staple foods, particularly cereals 
and milk, concentrations were very low, 10 µg/kg or 
less. Processing may increase the concentration in food 
significantly. For example, meat grinding using stainless 
steel equipment almost doubled the chromium content in 
the meat (Kumpulainen, 1992). In basic Spanish foods, 
the ranges of chromium concentrations were 4–79 µg/kg 
in seafood, 7–456 µg/kg in cereals and vegetables, not 
detectable to 625 µg/kg in dairy products, and not 
detectable to 40 µg/kg in olive oil (Lendinez et al., 
2001). In Austria, high levels were found in spices (59–
4530 µg/kg) and cocoa and cocoa products (152–1840 
µg/kg) (Wilplinger et al., 1995). Whole meal products 
contained 20–171 µg/kg, and fruits, vegetables, and 
meat, <15–44 µg/kg. High levels of chromium in some 
spices and aromatic herbs were confirmed in Spain 
(Garcia et al., 2000). In that country, chromium concen-
trations varied between non-detectable and 17.6 µg/l in 
fruit juices and between 3.6 and 60.5 µg/l in soft drinks 
(Garcia et al., 1999). The highest levels were analysed in 
orange soft drinks, possibly as a result of releases from 
stainless steel during production. Beer samples con-
tained chromium at concentrations ranging from 0.5 to 
56 µg/l (Anderson et al., 1992). The higher levels were 
attributed to external sources (e.g. during processing, 
preparation, or storage). 
 
 The concentration of chromium in uncontaminated 
water is low. Garcia et al. (1999) found that the chro-
mium level in 15 samples of tap water in Spain was 
below the detection limit (i.e. <0.1 µg/l), whereas in 15 
samples of commercial bottled water, the concentration 
varied between 4.2 and 11.8 µg/l. Total concentrations in 
drinking-water in the USA were reported to range from 
0.4 to 8 µg/l, with a mean of 1.8 µg/l (ATSDR, 2000). 
 
 To estimate the dietary intake in the USA, Anderson 
et al. (1992) analysed the chromium content of 22 pre-
pared daily diets designed by nutritionists. As all indi-
vidual food items were analysed as eaten, the potential 
release of chromium from kitchenware and utensils was 
included. The intake ranged from 2.0 to 5.6 µg/MJ, with 
a mean of 3.2 ± 0.3 µg/MJ. Based on the mean caloric 
intake by adult men and women of 9.0 and 7.7 MJ/day, 
respectively (Anderson et al., 1993), the corresponding 
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dietary intakes were 18–51 and 15–43 µg/day. Similar 
assessments of the daily dietary intake gave a mean of 
34.4 µg/day (range 28.5–44.7 µg/day) in Austria 
(Wilplinger et al., 1996), a mean ± standard deviation of 
58 ± 31 µg/day in Belgium (Van Cauwenbergh et al., 
1996), and a range from 16 to 117 µg/day in Spain 
(Garcia et al., 2001). Kumpulainen (1992) concluded 
that the dietary intake of chromium in Finland, Sweden, 
and Switzerland was 50 µg/day or lower, whereas in 
many developing countries, such as Brazil, Sudan, and 
Iran, the corresponding intakes were 2 times higher. 
 
 In the USA and Finland, the average chromium 
content of human milk was reported to be below 
0.5 µg/l, which would result in a low average intake of 
0.3 µg chromium/day by breastfed infants (Kumpu-
lainen, 1992). However, ICP-MS analysis of chromium 
in milk samples collected from 27 healthy mothers in 
Austria gave higher concentrations, ranging from <0.8 to 
163 µg/l (mean 24.3 µg/l) (Krachler et al., 2000). 
 
6.2.1.2 Food supplements 
 
 Under legislation in the European Union, chromi-
um(III) chloride and chromium(III) sulfate can be used 
in the manufacture of food for particular nutritional uses 
and in food supplements. Apart from these salts, more 
bioavailable organic chromium complexes (chromium 
picolinate, nicotinate) are widely used as supplements 
and as weight loss agents (e.g. in the USA). Recom-
mended daily regimens of chromium supplements 
available on the market contain 200–600 µg trivalent 
chromium, and multivitamin supplements contain up to 
100 µg chromium in a daily serving unit (EVM, 2003). 
 
6.2.1.3 Orthodontic appliances 
 
 Orthodontic bands, brackets, and wires made of 
stainless steel contain 17–22% chromium (Kocadereli et 
al., 2000). Studies investigating the release of chromium 
from orthodontic appliances into saliva have provided 
conflicting results (Kerosuo et al., 1997; Kocadereli et 
al., 2000; Agaoglu et al., 2001). A large variation was 
observed in chromium concentrations in saliva in two 
studies, and there was no increase in chromium concen-
trations in samples taken before and after insertion of the 
appliances. The amount of chromium potentially 
ingested as a result of release from orthodontic appli-
ances is probably negligible compared with the dietary 
intake. 
 
6.2.1.4 Ambient air 
 
 Levels of chromium in air are summarized in sec-
tion 6.1.1. Generally, chromium concentrations in air 
vary with location, being very low in unpolluted regions. 
A typical range of <0.01–0.03 µg chromium/m3 in ambi-
ent air was used by the United States Department of 
Health and Human Services (ATSDR, 2000) to estimate 
the exposure to chromium via inhalation (i.e. <0.2–
0.6 µg/day). 
 
6.2.1.5 Consumer goods 
 
 About 80% of leather products are currently tanned 
with chromium(III) salts, notably basic chromium sul-
fate (Graf, 2001). Tanned leather contains about 3% 
chromium (Nygren & Wahlberg, 1998). It has been 
reported that chrome-tanned leather products may also 
contain low concentrations of chromium(VI) (Nygren & 
Wahlberg, 1998; Hansen et al., 2002), but its true occur-
rence is still debated because of analytical complica-
tions. Human sweat may extract soluble, unbound 
chromium from chrome-tanned leather. Higher levels of 
unbound chromium(III) may occur in the leather if 
washing has not been done properly after tanning. In an 
old study, specimens of shoe leather immersed in human 
sweat were reported to release 20–300 µg total chromi-
um/ml sweat (Samitz & Gross, 1960). Fregert & 
Gruvberger (1979) measured both total chromium and 
chromium released from seven samples of industrial 
leather gloves into synthetic sweat at pH 6.5 during 
1 week. Total chromium ranged from 11 000 to 36 000 
µg/g, and the chromium released ranged from 100 to 
1300 µg/g. A more recent study measured the amount of 
free chromium(III) capable of migrating from the upper 
of baby shoes to an aqueous solution of hydrochloric 
acid with a pH of 1–1.5 during 2 h at 37 °C and found 
370 and 560 µg/g leather for two shoes, respectively 
(Hansen et al., 2002). Unfortunately, no accurate data 
are available regarding the actual chromium(III) concen-
trations at the surface of the skin derived from wearing 
leather shoes or gloves. 
 
 Insoluble green chromium pigments (chromium 
hydrates) are used in soaps and cosmetics (e.g. eye shad-
ows). Chemical analysis of some eye shadow colours on 
the market revealed a total chromium concentration 
above 2000 mg/kg (Sainio et al., 2000). A typical 
amount of “eye make-up powder” per application is 
0.01 g (European Commission, 2003), and the typical 
frequency of use is once daily. Thus, the daily topical 
dose of (insoluble) chromium could be up to 20 µg.  
 
 There are no data available on the release of chro-
mium from stainless steel articles such as watches, 
jewellery, and fasteners of clothing that lie in direct 
contact with skin.  
 
6.2.1.6 Orthopaedic implants 
 
 Total hip and knee replacements made of cobalt–
chromium alloy or stainless steel can corrode and release 
metal debris from wear (Case et al., 1994; Merritt & 
Brown, 1996). Loosening of the implant and local 
inflammation are expected to aggravate the release of 
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metals (Hennig et al., 1992). Black et al. (1983) esti-
mated that dissolution of metals from a total hip replace-
ment could be 0.15–0.30 µg/cm
6.2.2.2 Inorganic chromium(III) salts 
 
 The most common trivalent chromium salt is basic 
chromium sulfate, which is used for leather tanning. 
Other chromium(III) compounds (e.g. chlorides, 
fluorides, phosphates, nitrates, and hydroxides) are 
found in miscellaneous applications, such as catalysts, 
hardeners, mordants, and crosslinking and binding 
agents (Kirk-Othmer, 2003). For most of these com-
pounds, information on the processes and use conditions 
is scarcely available. In addition to leather tanning, basic 
chromium sulfate is used for electroplating. Chromium 
chloride is also used for trivalent electroplating. 
2 per day, or 30 µg/day 
and 11 mg/year. There are reports of increased tissue 
chromium in patients carrying especially metal on metal 
total hip replacements. More recent advancements in 
implant design and composition and surgical techniques 
reduce the likelihood and magnitude of internal exposure 
to chromium in patients. 
 
6.2.2 Occupational exposure 
 
 A wide variety of exposures to trivalent chromium 
compounds may occur in activities related to production, 
formulation, and uses (Kirk-Othmer, 2003; Riihimäki & 
Luotamo, 2006). Some of the processes or applications 
involve intentional or unintentional transformation of 
trivalent chromium to hexavalent chromium. The former 
applies to the manufacture of chromium chemicals from 
chromite ore, whereby sodium dichromate is produced 
as a chemical intermediate. Hexavalent chromium is 
inadvertently generated from trivalent chromium under 
oxidizing and alkaline conditions, such as in the use of 
refractories. 
 
 Inhalation exposure to basic chromium sulfate in the 
tanning process was low (about 0.03 mg chromium/m3) 
(Riihimäki & Luotamo, 2006). According to one report, 
some tannery workers had remarkably increased chro-
mium levels in urine, which the authors attributed to 
probable entrance of airborne droplets of the tanning 
liquor into the mouth and ingestion (Aitio et al., 1984). 
Polishing (buffing) of tanned leather is dusty, and 
airborne levels up to 0.3 mg chromium/m3, mainly in 
non-respirable large particles, have been measured 
(Stupar et al., 1999). Airborne chromium levels in 
trivalent electroplating are presumed to be very low 
(Riihimäki & Luotamo, 2006). 
 
 The following text deals with meaningful exposures 
to trivalent chromium, where the more toxic hexavalent 
compounds are excluded because of their likely over-
riding health significance.  
 
6.3  Levels in humans 
 
6.2.2.1 Chromium(III) oxide 
 
6.3.1 General population 
  
 Trivalent chromium is considered to be an essential 
trace element in mammals (see section 9.1), which 
implies that endogenous chromium is homeostatically 
maintained.  
 Exposure to chromium oxide occurs in chromite 
mining and processing, ferrochrome production, and the 
production of chromium oxide, chromium carbide, and 
chromium refractories. Other sources of occupational 
exposure derive from the uses of chromite sand, ferro-
chrome slag, and chromium oxide pigments and cata-
lysts. Metallic chromium exposed to air is immediately 
oxidized and covered with chromium(III) oxide. 
Therefore, processes and applications dealing with 
chromium metal or its alloys also involve exposures to 
oxide. The smaller the airborne particles generated, the 
greater the mass fraction of chromium oxide. An impor-
tant area of potential exposure is the manufacture and 
tooling of products made of chromium alloys, especially 
stainless steel. 
 
 Chromium occurs at very low levels in the human 
body. Concentrations less than 0.2 µg/l in serum and 
plasma and slightly higher levels in whole blood and 
urine (<0.5 µg/l) are currently considered as normal 
(Brune et al., 1993; Kumpulainen, 1995; Fagliano et al., 
1997). However, since urinary excretion depends on the 
daily intake, which may vary considerably (processed 
meats, whole grain products, pulses, spices, and bever-
ages such as beer contain higher amounts), urinary chro-
mium in successive spot samples may vary considerably 
(Gargas et al., 1994). Intake of chromium supplements 
caused a still more marked (at least 10-fold) but transient 
increase in urinary concentrations (Gargas et al., 1994).  
 
 Workers are exposed to airborne dusts of chromi-
um(III) oxide. The highest measured or estimated levels 
were found in chromite ore mining (1 mg chromi-
um/m
 
3), bagging of refractory materials (3.5 mg chro-
mium/m
 Lung chromium concentrations measured in 
accidental or violent cases of death in Germany were 
133–277 ng/g ww (Raithel et al., 1993), whereas corres-
ponding concentrations measured in Belgium were 32–
181 ng/g (Vanoeteren et al., 1986). Chromium levels in 
the lungs were higher in subjects living in polluted areas 
(250–7070 ng/g dw) than in those living in an unpolluted 
3), use of chromite sand (1.5 mg chromium/m3), 
handling of chromium oxide pigments or catalysts (0.6–
0.7 mg chromium/m3), and polishing of stainless steel 
(1.2 mg chromium/m3) (Riihimäki & Luotamo, 2006).  
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area of Germany (60–150 ng/g dw) (Kollmeier et al., 
1990), and the concentrations were usually higher in 
older people (Vanoeteren et al., 1986). (Note that dry 
weight concentrations are approximately 3.5 times 
higher than wet weight concentrations.) 
6.3.2 Occupationally exposed populations 
 
 Urinary chromium among ferrochromium produc-
tion workers exposed to trivalent chromium oxide and 
among unexposed clerks was studied (Foa et al., 1988). 
Urinary chromium concentrations were stable among 
unexposed clerks (0.60–0.58 µg/g creatinine) during the 
work day and over the work week. Production workers 
had significantly increased urinary concentrations, 
ranging from 0.94 to 1.21 µg/g creatinine during the 
work shift and to 1.25 µg/g creatinine at the end of the 
working week. Subcontractors also showed an increase 
in urinary chromium concentrations from 0.77 to 0.96 
µg/g creatinine over the shift and to 1.05 µg/g creatinine 
over the work week (Foa et al., 1988). 
 
 In Finnish infants and children under the age of 9, 
chromium concentrations in the liver ranged from 4 to 
15 ng/g dw and in the spleen from 7 to 29 ng/g dw 
(Vuori & Kumpulainen, 1987). In four elderly persons 
who died of non-diabetic causes in Germany, concen-
trations in the liver, spleen, and kidney were <14 ng/g 
dw, 134 ± 117 ng/g dw, and <39 ng/g dw, respectively 
(Michels et al., 1991). 
 
  Orthopaedic patients carrying (especially total hip 
or knee) implants made of chromium alloys have some-
times had markedly increased chromium concentrations 
in serum, urine, and tissues due to corrosion or wear of 
the implant. In some cases, chromium concentrations in 
serum and urine were found to be increased by 10-fold 
or more compared with the normal levels (Jacobs et al., 
1996; Schaffer et al., 1999), and corresponding findings 
have been made in tissues surrounding the implant 
(Hennig et al., 1992) as well as in distant organs 
(Michels et al., 1991; Case et al., 1994). With recent 
developments in the composition and design of implants, 
such internal exposures to released chromium are 
expected to have become less frequent. 
 In Finland, production of ferrochromium covers the 
whole chain from chromite mining to stainless steel 
manufacture. The mean urinary chromium concentra-
tions varied from 0.5 µg/l in miners to 2.1 µg/l in steel 
smelters. In the mine, no hexavalent chromium was 
found in personal air samples; in the steel melting shop, 
the highest concentration of hexavalent chromium was 
6.6 µg/m3 (Huvinen et al., 1993).  
 
 Tannery workers exposed to basic chromium sulfate 
or chromium(III) in leather dust exhibited 4 µg chromi-
um/g in hair, 1.7 µg chromium/g creatinine in urine, and 
25 µg chromium/l in sweat; these concentrations were 
significantly higher than those in the control group 
(0.16 µg/g in hair, 0.13 µg/g creatinine in urine, and 
0.7 µg/l in sweat) (Stupar et al., 1999). In the buffing 
department, the mean chromium level in the urine of 
workers, 2.35 µg/g creatinine, was clearly higher than 
that measured in the chrome tanning process, 1.11 µg/g.  
 
 Thermally induced sweat was found to contain 
about 0.7 µg chromium/l (Stupar et al., 1999). The mean 
chromium concentration in human milk samples from 
Finland and the USA was reported to be <0.5 µg/l 
(Kumpulainen, 1992), whereas the corresponding levels 
in 27 samples in Austria varied from <0.8 to 163 µg/l 
(mean 24.3 µg/l) (Krachler et al., 2000).  
 
 In a tannery, Kornhauser et al. (2002) measured the 
chromium body burden in workers from the tanning and 
retanning departments, in workers from the dyeing, 
drying, and finishing departments, and in control 
subjects. Both serum and urine samples were collected, 
and the highest concentrations were in workers from the 
tanning and retanning departments: 0.43 µg/l in serum 
and 1.78 µg/l in urine. The mean values in controls were 
0.13 µg/l in serum and 1.35 µg/l in urine.  
 
 Conflicting evidence has been provided on the 
relationship between serum or urinary chromium and 
age. Recent observations from over 40 000 ambulatory 
patients indicated a steady decline of chromium levels in 
serum, sweat, and hair from childhood into old age, and 
concentrations in the three tissues correlated with each 
other (Davies et al., 1997). At old age, the concentration 
in serum had decreased by 42%.   
 A week’s follow-up of tannery workers who were 
exposed to chromium(III) from basic chromium sulfate 
in four different tanneries was performed by Randall & 
Gibson (1987). The Monday morning urinary chromium 
concentration, 0.51–1.16 µg/l, was clearly lower than 
that of Friday afternoon, 0.56–2.57 µg/l. Also, the 
median serum (0.49 µg/l) and urinary concentrations 
(0.96 µg/l) were significantly higher in tannery workers 
than in the control population (serum, 0.15 µg/l; urine, 
0.24 µg/l). 
 
 
 
 The total body reservoir of chromium was estimated 
as 0.4–6 mg and, relative to body size, may be higher in 
neonates than in adults (Dubois & Belleville, 1991). The 
upper-range value was, however, based on old measure-
ments, and the true body burden in normal adults may be 
an order of magnitude lower (Lim et al., 1983). It has 
been noted that chromium levels in serum, urine, or hair 
are not reliable indicators of body stores of chromium 
(Offenbacher & Pi-Sunyer, 1988; Mertz, 1993; 
Jeejeebhoy, 1999; Gunton et al., 2001). 
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7. COMPARATIVE KINETICS AND 
METABOLISM IN LABORATORY ANIMALS 
AND HUMANS 
 
 
 The toxicokinetics of trivalent chromium species 
strongly depend on physical-chemical properties, 
particle characteristics (mainly size), and the route of 
administration (Visek et al., 1953; Sayato et al., 1980; 
Anderson et al., 1996; O’Flaherty et al., 2001). 
 
7.1  Absorption, distribution, and excretion 
 
7.1.1 Chromium(III) oxide 
 
 The toxicokinetics of chromium oxide have been 
investigated primarily after administration into the 
respiratory system. 
 
 Chromium oxide particles are insoluble in water and 
organic solvents. Consequently, absorption is strongly 
limited during passage through the gastrointestinal tract 
or from the skin. Particle size–dependent deposition and 
clearance processes with mucociliary clearance and 
phagocytosis are the main toxicokinetic features in the 
respiratory system. Little is known of pure chromium 
oxide, but studies with fine chromite particles and fumes 
from welding of stainless steel with the metal inert gas 
method may provide helpful information.  
 
 A suspension of chromium oxide particles with a 
mean geometric mean diameter of 0.45 µm was instilled 
into the tracheal lobe of sheep (Perrault et al., 1995). 
Bronchoalveolar lavage samples taken over 30 days 
showed the half-time of elimination to be about 11 days. 
According to transmission electron microscopy analysis 
and the surface composition and valency analyses, the 
size of chromium oxide particles remained unchanged 
over the 30 days, and the state of oxidation did not show 
any measurable change. 
 
 Swensson (1977) injected 40 mg of chromite 
particles ground to less than 5 µm in diameter in saline 
into the trachea of rats. Rats were killed at intervals over 
8 months, and the mass of the remaining particles in the 
lungs was determined with emission spectrophotometry. 
From the decay curve, the half-time of elimination was 
calculated to be about 6 months.  
 
 Nose-only exposure of rats to metal inert gas/stain-
less steel welding fumes characterized as long chains 
and agglomerates of submicrometre particles containing 
4–15% chromium mainly in trivalent or metallic form 
and iron, manganese, nickel, and silicon for 1 h/day, 
5 days/week, over up to 4 weeks resulted in a gradual 
increase in lung chromium content with exposure 
duration (Kalliomäki et al., 1983). Clearance of 
chromium was slow, with an estimated half-time of 
approximately 240 days. However, in a further study, 
when metal inert gas/stainless steel welding fumes 
collected on filters were neutron activated, suspended in 
saline, and instilled into the trachea of anaesthetized rats, 
practically no decrease in the pulmonary content of 
chromium, iron, nickel, or cobalt was noted over the first 
2 months after exposure (Kalliomäki et al., 1986). In the 
first study, clearance functions varied for the different 
elements, suggesting that the particles were gradually 
dissolved, whereas in the second study, all the metal 
components of the suspended welding fume had a 
similar slow clearance from the respiratory system, 
indicating different toxicokinetic behaviour of de novo 
metal inert gas/stainless steel welding fumes from the 
“aged” particles. 
 
 Plasma cutting of stainless steel generates fumes 
containing the alloyed metals, including chromium, 
which is mainly in trivalent and metallic form. A plasma 
cutter exposed to these fumes for 7 years had elevated 
concentrations of chromium in serum (10.3 µg/l) and 
urine (10 µg/g creatinine), with a very slow decrease, 
with half-times of 40 months in serum and 129 months 
in urine (Petersen et al., 2000).  
 
7.1.2 Inorganic chromium(III) salts and complexes 
 
 The main body of available data concerns water-
soluble chromium(III) salts: hydrated forms of chro-
mium chloride and chromium potassium sulfate (chrome 
alum), basic chromium sulfate, and chromium nitrate. It 
is generally considered that trivalent chromium is poorly 
absorbed and taken up by cells when not in organic 
complexes, such as in the glucose tolerance factor, 
which is a material isolated from porcine kidney 
(Schwarz & Mertz, 1957, 1959). During and after 
absorption, chromium(III) is expected to form various, 
so far poorly characterized, coordination complexes with 
low molecular weight ligands, which may enhance 
absorption and enable the element to enter tissues and 
traverse cell membranes. There is no evidence of a 
change in valency during the metabolism of trivalent 
chromium. 
 
7.1.2.1 Oral exposure 
 
 Sayato et al. (1980) administered 51CrCl3 (0.1 mg 
chromium/kg bw) by a stomach tube to rats and mea-
sured the radioactivity in the whole body, urine, and 
faeces daily for 30 days. Retention of 51Cr after 2 days 
was less than 1% of the dose, and on day 30, it was 
0.3%. After the first 6 days, the elimination of radio-
active chromium in the body had a half-time of about 
92 days. Over 20 post-administration days, 99% of the 
oral dose was excreted in faeces and 0.8% in the urine. 
Similar findings were made with rats given 1 ng of 
51CrCl3 in saline by a stomach tube: the excretion of the 
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radiolabel over 7 days in faeces and urine was 98% and 
1.4%, respectively (Donaldson & Barreras, 1965).  
 
 Similar oral bioavailability levels have been 
observed in humans. Donaldson & Barreras (1965) gave 
51CrCl3 at a dose of 20 ng orally to six fasting subjects; 
for two patients, the dose was administered through a 
tube placed in the duodenum. Urine was collected for 
24 h and faeces for 6 days, and both were assayed for 
radioactive chromium. After oral administration, the 
mean recovery of faecal radioactivity was 99.6%, and 
the recovery in urine was 0.5%. After duodenal admin-
istration, the corresponding figures were 93.7% and 
0.6%. Anderson & Kozlowsky (1985) demonstrated the 
dependence of the degree of absorption on intake. They 
noted that when the intake was low (10–15 µg/day), 
absorption was about 2%, gradually decreasing with 
increasing intake. At intake levels of about 40 µg/day or 
higher, absorption was only 0.4%. The finding is in 
support of a regulatory mechanism in the human intes-
tine to ensure relatively constant amounts of absorbed 
chromium. 
 
 Other factors also modify gastrointestinal absorption 
of chromium(III). In rats, co-administration of 51CrCl3 
with phytate and with oxalate significantly decreased 
and markedly increased, respectively, chromium absorp-
tion (Nelson et al., 1973). Experiments with rats given 
51CrCl3 showed that ascorbic acid and a prostaglandin 
inhibitor, aspirin, enhanced intestinal absorption of 
chromium, whereas an antacid containing aluminium 
and magnesium hydroxide reduced it (Davis et al., 
1995). Sullivan et al. (1984) demonstrated that 51Cr as 
chromium chloride was absorbed 10 times more effi-
ciently from the gastrointestinal tract of 2-day-old rats 
than from the intestine of the adult rat.  
 
 In humans, ascorbic acid enhanced chromium 
chloride absorption (Offenbacher, 1994). Offenbacher 
(1994) proposed that ascorbate chelated chromium and 
made it more soluble and more readily absorbed. In a 
study by Kerger et al. (1996), the toxicokinetics of a 
chromium(III) complex that was derived from prior 
reduction of potassium dichromate with orange juice 
(chromium(III)–OJ) were investigated with volunteers, 
with chromium chloride as a reference. The estimated 
bioavailability of chromium chloride was lower than that 
of chromium(III)–OJ, 0.13% and 0.6%, respectively, and 
the elimination half-time of chromium chloride in urine 
was shorter than that of chromium(III)–OJ, ~10 h and 
~17 h, respectively. Although chromium(III)–OJ 
exhibited 4-fold higher bioavailability than chromium 
chloride, it showed clearly lower plasma concentrations, 
suggesting a more rapid clearance from plasma to tis-
sues, which is also in keeping with slower elimination 
via the urine. The authors proposed that ingested ionic 
chromium(III) may not be able to form bioavailable 
chromium(III) complexes as readily because of lower 
solubility and tissue permeability. 
 
 Oral bioavailability and tissue distribution studies 
on chromium chloride and organic chromium complexes 
with rats employing single gavage or dietary adminis-
tration for 3 weeks showed that whereas bioavailability 
did not vary significantly among the different chromium 
species, incorporation into tissues, especially the kidney, 
was highly dependent on the species (Olin et al., 1994; 
Anderson et al., 1996). Among inorganic chromium 
compounds, incorporation in the kidney after 3 weeks of 
dietary exposure was high for chromium potassium 
sulfate (407 ng/g) and chromium acetate (397 ng/g) 
compared with chromium chloride (74 ng/g). Control 
rats had chromium levels of 23 ng/g in kidney. Liver 
chromium content was significantly increased from 
control levels with chromium acetate, but not with 
chromium chloride or chromium potassium sulfate 
(Anderson et al., 1996). 
 
 Mertz et al. (1969) administered radiolabelled chro-
mium chloride hexahydrate (51CrCl3·6H2O) orally to 
pregnant rats 5 days/week and counted the radioactivity 
of the litter after the birth. According to the results, the 
radioactivity of the whole litter accounted only for 0.45–
1.57% of that of the mother. However, administration of 
chromium in a complex with glucose tolerance factor 
resulted in high accumulation of chromium in the litters 
(Mertz et al., 1969).  
 
 In in vitro studies on gastrointestinal absorption, it 
has been shown that the absorption of trivalent chro-
mium occurs by passive diffusion (Dowling et al., 1989). 
However, dietary amino acids may enhance chromium 
absorption and reduce the retention in the intestinal wall. 
It has been hypothesized that amino acids act as chro-
mium ligands, resulting in rapidly diffusing chromium 
complexes of low molecular weight (Dowling et al., 
1990). An organic complex, chromium picolinate, has 
demonstrated higher permeability through rat jejunum 
compared with inorganic chromium compounds. 
Measurements by the rat everted gut sac technique 
indicated that the permeability of picolinate across the 
rat jejunum was more than 10 times greater than that of 
chromium chloride or nitrate, whereas there was no 
difference between the latter two (Gammelgaard et al., 
1999). 
 
7.1.2.2 Inhalation exposure 
 
 Rats were exposed to aerosols (particle size 1.5–
1.8 µm) of aqueous solutions of chromium chloride at 
10.7 mg/m3 for 2 h or at 8 mg/m3 for 6 h (Suzuki et al., 
1984). Chromium was analysed in the blood compo-
nents, kidney, liver, heart, spleen, and testis at intervals 
over 7 days after the 2-h exposure using AAS. Retention 
and elimination of chromium in the lung were estimated 
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from chromium measurements in the context of both 2- 
and 6-h exposures. The lung concentrations immediately 
after exposure were nearly proportional to the product of 
exposure concentration and time, and the concentrations 
declined linearly, with an elimination half-time of 164 h 
(6.8 days). In the 2-h exposure group, the chromium 
concentration in the blood cells was about half of the 
concentration in plasma immediately after exposure and 
about the same as the concentration in plasma in later 
samples. The tissue concentrations relative to the lung at 
later time points were slightly above 1% for the kidney 
and slightly below 1% for the spleen (in both cases with 
an increasing tendency over time), about 0.5% for the 
liver and heart, slightly less than 0.5% for the testis, and 
about 0.25% for the whole blood.  
 
 Syrian hamsters were exposed to nebulized liquid 
aerosols (median particle diameter 1.2 µm) of chromium 
chloride labelled with 51Cr at 2.8 or 77 mg/m3 for 30 min 
(Henderson et al., 1979). At 2 h, the labelled chromium 
lung burdens were 0.71 µg and 20.4 µg at the low and 
high exposure levels, respectively (i.e. directly propor-
tional to the exposure concentrations). Labelled chro-
mium in the liver and kidney at 2 h was 4% of the lung 
burden; lower levels were found at day 1. The lung bur-
den decreased by 60% during the subsequent 3 weeks. 
The corresponding elimination rate of 51Cr in the liver 
was similar to that in the lung and somewhat faster than 
that in the kidney. 
 
 Intratracheal instillation has been used as a surro-
gate of inhalation exposure. An early study by Visek et 
al. (1953) with 51Cr-labelled chromium chloride in rats 
showed that 55% of the intratracheally administered 
chromium was excreted in the faeces and 7% in the urine 
in 7 days. Apparently, most of the dose had been cleared 
from the respiratory tract to the oral cavity. The authors 
estimated that probably less than 5% was absorbed from 
the lungs. 
 
  In a study by Baetjer et al. (1959), after the intra-
tracheal injection of 200 µg of chromium chloride hexa-
hydrate to guinea-pigs, 69% of the dose was recovered 
from the lungs and 4% in the blood (mainly in plasma) 
and other tissues immediately after injection. At 24 h, 
45% was retained in the lungs, 6% was excreted in urine, 
and small amounts were found in the liver and spleen. At 
day 30 post-injection, 30% of the dose was still present 
in the lung; at day 60, 12% of the dose remained in the 
lung. 
 
 Edel & Sabbioni (1985) injected four male Sprague-
Dawley rats intratracheally with either 0.1 µg or 10 µg 
of 51Cr-labelled chromium(III) as chromium chloride. In 
the former case, the animals were killed after 24 h, in the 
latter case, after 7 days. At the termination of the 24-h 
study, about 5% of the dose was recovered in lung 
lavage; the lungs and trachea still contained 23% of the 
radiotracer dose per gram of tissue (lungs and trachea 
constitute about 0.5% of body weight, or about 1 g), 
whereas other tissues contained trace amounts, and none 
was detected in the pancreas, brain, heart, thymus, skin, 
fat, or muscle. In the blood, 85% of the label was in 
plasma, and 15% was in the cells. Analysis of the 
subcellular distribution of 51Cr in the lung homogenate 
indicated that 42% was in the nuclear fraction, 24% in 
the mitochondria, 21% in lysosomes, and 10% in 
cytosol, of which 33% was dialysable. In the 7-day 
study, 3.6% of the administered chromium was excreted 
via urine, whereas more than 36% was eliminated via 
faeces, mainly during the first 2 days. 
 
 Similar results on absorption and distribution 
pattern have also been obtained with rabbits treated 
intratracheally with 51CrCl3 (Wiegand et al., 1984). A 
study with chromium acetate hydroxide in male rats 
(Gao et al., 1993) also demonstrated higher concen-
trations of chromium in plasma compared with whole 
blood. No chromium was found in lymphocytes. Peak 
concentrations in all specimens were obtained at 6 h, and 
the levels did not return to control values within 72 h. 
Urine contained remarkably high concentrations, with a 
peak at 6 h after exposure. From the urinary excretion 
curve, it was estimated that about 7% of the dose was 
excreted in urine during the first 24 h. After a rapid drop 
in blood and urinary chromium during the first 24 h, the 
rate of decrease of concentration in plasma and urine had 
slowed down to approximately 20% over the 3rd day of 
follow-up. 
 
 Compared with intratracheal instillation, the pre-
viously described inhalation experiments (Henderson et 
al., 1979; Suzuki et al., 1984) likely resulted in more 
effective chromium deposition in the lung, which 
enhanced pulmonary absorption and decreased the 
likelihood of mucociliary clearance. Nevertheless, both 
types of administration indicated that a fraction of the 
deposited chromium(III) was absorbed rapidly, followed 
by slow elimination, consistent with extensive binding in 
the lung and airway mucosa. 
 
 In a tannery, two workers fed soaking wet hides into 
a press, and four workers received the hides on the other 
side of the press (Aitio et al., 1984). The tanning liquid 
was reported to contain 7 g chromium(III)/l. The 
absence of chromates was verified by the diphenylcar-
bazide reaction. Airborne chromium levels (inhalable 
fraction) were always below 30 µg/m3. However, 
feeding the hides to the press generated a visible cloud 
of large droplets, and splashes to the face were not 
uncommon. The operators of the press had high levels of 
chromium in blood and urine, whereas the receivers 
generally showed concentrations at the limit of detec-
tion. Among two press operators, whole blood chro-
mium reached 6.8 and 11 µg/l, and plasma chromium, 
13 and 22 µg/l, respectively. Thus, chromium was 
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confined to the plasma. One of the operators showed 
occasional, transient high peaks (up to 62 µg/l) in 
urinary chromium, whereas the basal levels in both 
operators towards the end of the week and during the 
exposure-free weekend ranged from 10 to 15 µg/l. After 
an interval of 10 days without exposure, the two 
operators both had 10 µg chromium/l in urine; after a 
vacation of 40 days, the concentrations were 4.8 and 
6.2 µg/l, respectively. Assuming that the basal level at 
the end of work had been 10–15 µg/l, the half-time of 
chromium in urine was about 30 days. The investigators 
assumed that absorption of basic chromium sulfate 
among the press operators actually took place in the 
gastrointestinal tract. 
 
 In another study of tannery workers (Randall & 
Gibson, 1987), chromium in urine significantly 
increased from the first to the last day of the work week. 
Concentrations in serum and urine correlated with each 
other, but neither of them correlated with the length of 
employment in the tanning industry. Thus, long-term 
accumulation did not seem to occur, which was also 
demonstrated in a subsequent study in the same labora-
tory among five men whose employment in a tannery 
had ceased 9 months earlier and among two men who 
had retired 15 or 33 months earlier (Simpson & Gibson, 
1992). Similar results were also obtained in a study by 
Stupar et al. (1999), who measured chromium in hair 
samples obtained from six ex-workers of a tannery who 
had been on retirement for 2–5 years. The retired 
workers exhibited chromium levels in hair similar to 
those of the controls.  
  
7.1.2.3 Dermal exposure 
 
 No relevant animal studies on skin absorption of 
chromium(III) compounds were located. 
 
 Mali et al. (1963) performed skin penetration 
experiments on chromium chloride and chromium 
sulfate (1.2% chromium labelled with 51Cr) with skin 
chambers glued to the skin of normal volunteers. 
Chambers were removed at 6, 12, or 24 h, and radio-
active chromium was analysed in the stratum corneum of 
the chamber site as well as in the underlying epidermis 
and dermis cut out with a punch biopsy. As no label was 
found in the dermis, the authors concluded that chromi-
um(III) salts did not permeate through the intact epider-
mis. Some blood samples and 24-h urine were also 
examined, and no radioactive chromium was detected. 
 
 An experiment was performed in which one male 
volunteer held his hand in a tanning solution containing 
7 g chromium/l as basic chromium sulfate for 1 h (Aitio 
et al., 1984). The concentrations of chromium in blood 
and urine were monitored for 24 h. No increases in 
chromium levels were detected in the samples, and no 
difference in chromium concentration was found in the 
cubital venous blood drawn from the exposed side com-
pared with the contralateral sample. The sensitivity of 
the method, however, was not sufficient to detect slight 
deviations from endogenous baseline levels of 
chromium. 
 
 Wahlberg & Skog (1965) explored the percutaneous 
penetration of chromium chloride in guinea-pigs using a 
disappearance technique and 51Cr-labelled compound. 
The maximum penetration rate was 330 µmol chromi-
um/cm per hour, and the mean relative absorption in 5 h 
was 2% from 0.239–0.261 mol/l solutions. Sodium chro-
mate exhibited 2 times higher penetration. The method 
provides information on substance transfer and binding 
in the skin, but it is not informative on the amounts that 
are ultimately absorbed into the systemic circulation. 
 
 An in vitro skin penetration study on chromium 
chloride hexahydrate (0.034 or 0.17 mol chromium/l, pH 
buffered to 3.0), chromium nitrate nonahydrate (0.034 
mol chromium/l, pH buffered to 2.8), and potassium 
dichromate (0.034 mol chromium/l) was conducted 
employing a modern gas diffusion cell and full-thickness 
human abdominal skin (Gammelgaard et al., 1992). 
After the test duration of 190 h (when the skin barrier 
was still found intact), no chromium was detected in the 
recipient phase after exposure to chromium chloride or 
chromium nitrate. Moreover, the chromium concentra-
tions in the skin layers were about 10 times lower after 
chromium chloride application and about 15–30 times 
lower after nitrate application than the corresponding 
concentrations after application of potassium dichro-
mate. A 5-fold increase in the applied chromium chlor-
ide concentration did not increase chromium levels in 
the skin. 
 
7.1.2.4 Intravenous studies 
 
 Several studies employing intravenous administra-
tion have been conducted. The intravenous route is 
unnatural and can lead to artefacts due to the formation 
of colloids or complexes of trivalent chromium, which 
are trapped by the reticuloendothelial system (Visek et 
al., 1953). However, these studies of intravenously 
administered chromium(III) support findings from oral 
and inhalation studies on chromium distribution in 
various organs, the most prominent organs of chromium 
distribution being liver, kidneys, spleen, and bone 
(Hopkins, 1965; Onkelinx, 1977; Sayato et al., 1980). 
Growing bone in particular takes up chromium 
(Hopkins, 1965).  
 
 Regarding chromium transfer to reproductive 
organs, an increase in chromium(III) levels has been 
seen in testicular tissue after intravenous, intraperitoneal, 
or subcutaneous administration of chromium(III) 
chloride (Hopkins, 1965; Sipowicz et al., 1997). An 
autoradiographic study on testis showed that after an 
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intravenous injection of radiolabelled chromium chlor-
ide, the label is taken up in the interstitial compartment 
of the testis (Danielsson et al., 1984). Danielsson et al. 
(1982) studied chromium distribution in fetuses 1 h after 
the intravenous injection of radioactive chromium 
chloride on gestational day 11, 13, or 16. An accumula-
tion of chromium was seen in the visceral yolk sac 
placenta. No detectable levels of chromium were found 
in embryonal tissues on day 11; even on gestational day 
16, only low levels were detected in the calcified areas 
of the fetal skeleton. When pregnant rats were treated 
with an intravenous injection of radioactive trivalent 
chromium on gestational day 17 and sacrificed 3 days 
after the treatment, chromium was found to accumulate 
in the placenta. On average, 11.4% of the total dose was 
found in the pregnant rat uteri containing 10–16 
placento-fetal units (Wallach & Verch, 1984).  
 
 Studies dealing with toxicokinetic models are 
presented in section 7.3. 
 
7.2 Association of chromium(III) with blood 
components 
 
 Chromium(III) binds in plasma to transferrin 
(Hopkins, 1965; Sayato et al., 1980) and albumin. The 
distribution of 51Cr(III) in the plasma from a healthy 
individual was characterized with fast protein liquid 
chromatography (Cornelis et al., 1992). The major part 
(85%) was associated with transferrin and 8% with 
albumin, and about 6% was spread over other proteins. 
Harris (1977) isolated transferrin from pooled human 
serum and showed with electron paramagnetic spectra 
that trivalent chromium binds under in vitro conditions 
to both sites A and B, but iron added to dichromium 
transferrin selectively displaces chromium from site A. 
Chromium was found to bind competitively with iron or 
aluminium to human apotransferrin in the presence, but 
not in the absence, of bicarbonate, citric acid, or oxalic 
acid (Moshtaghie et al., 1992). A study with a haemo-
chromatosis patient showed that excessive iron burden 
displaces chromium from transferrin, and a larger share 
of chromium is unbound (Lim et al., 1983). Chromium 
could thus interfere with iron metabolism, and vice 
versa.  
 
 Trivalent chromium binds to an oligopeptide called 
low-molecular-weight chromium-binding substance 
(LMWCr), with a molecular mass of about 1500 daltons, 
which has been found in the liver and many other organs 
(Wada et al., 1983; Yamamoto et al., 1989; Vincent, 
1999). LMWCr is believed to be central in the endoge-
nous metabolism of chromium (see section 9.1). Wada et 
al. (1983) studied urinary excretion and renal clearance 
of LMWCr and chromium chloride in Japanese White 
rabbits following an intravenous injection of 500 µg 
chromium/kg bw as each of the two compounds. The 
chromium dose in LMWCr was excreted more rapidly 
than chromium chloride: 66% versus 25% in 6 h. 
LMWCr may play an important role in chromium 
excretion in mammals. 
 
 The distribution of chromium chloride in blood 
components in vitro was studied by Lewalter et al. 
(1985). Blood was spiked to 50 or 500 µg chromium/l 
and incubated for 10 min; after centrifugation, chromium 
in plasma and erythrocytes was measured with GAAS. 
At the lower concentration, plasma contained 48 µg 
chromium/l and red blood cells less than 1 µg chromi-
um/l. At the higher concentration, the corresponding 
levels were 455 and 36 µg/l. Addition of ascorbic acid 
had no effect on chromium distribution. Dialysis of the 
erythrocytes from blood spiked to 500 µg chromium/l 
reduced the red blood cell chromium content to a low 
level in four dialysis steps. The authors’ interpretation of 
the results was that at a very high concentration, chro-
mium ion may penetrate the red cell membrane and that 
it then associates reversibly with the biomolecules. 
 
7.3  Toxicokinetic models 
 
7.3.1 Rats 
 
 Metabolism of 51CrCl3·6H2O after a single intra-
venous injection (0.76 µg chromium) was assessed from 
measurements of radiochromium in blood, urine, and 
faeces in rats of different ages (Onkelinx, 1977). 
Samples were taken for counting from 1 h to 11 days 
post-injection. A computerized iterative curve fitting of 
the measured plasma 51Cr concentrations suggested three 
elimination components with first-order kinetics (the last 
one with an approximate half-time of 53 h). The authors 
proposed a three-compartment model, where the central 
compartment includes plasma from which elimination 
takes place. The other two were hypothetical pools that 
are connected to the central compartment by processes 
of reversible exchange. The total clearance of 51Cr was 
divided into urinary clearance, faecal clearance (based 
on measured data), and the clearance not accounted for 
by the previous two, which was thought to correspond to 
deposition into very slowly exchangeable body reser-
voirs (body sink). Of the total clearance, more than half 
took place via the urine, and less than 10% in the faeces, 
whereas clearance into the body sink was as high as 30–
40%. The authors noted that their third exponential elim-
ination rate was clearly less than that earlier reported for 
the whole body by Mertz et al. (1965) (half-time of 83 
days) and thus did not correspond to the terminal slope, 
which is related to the body sink. Analysis of data in the 
different age groups indicated that the main feature was 
a decrease by age of the functions of excretory clearance 
and clearance by the body sink. 
 
 A repeated-dose experiment with rats given 100 mg 
chromium(VI)/l as potassium chromate via drinking-
water for 6 weeks provided information on chromium 
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that is likely relevant, because by the oral route, hexa-
valent chromium is efficiently reduced to trivalent 
species before tissue distribution (Thomann et al., 1994). 
Chromium assays at the end of the 20-week study and 
after the 42-day exposure showed that the main part 
(about 87%) of the body burden was in the carcass and 
bone and that it was eliminated slowly, such that the 
half-time for chromium label in bone exceeded 100 
days. Elimination from the liver was biphasic, whereas it 
was monophasic in the spleen, kidney, and bone. A 
three-compartment model was devised, assuming that 
diffusion limited chromium uptake. Compartment 1 was 
blood, from which plasma exchanged chromium with 
compartment 2 (storage in bone and carcass) as well as 
with compartment 3 (liver, kidney, spleen), from which 
chromium was lost by excretion. A set of kinetic 
parameters was found to adequately describe post-
exposure chromium elimination in the whole body (half-
time of about 80 days), bone plus carcass (half-time over 
100 days), and liver, kidney, and spleen (half-time about 
10 days). The observations suggested that chromium is 
sequestered and released by the storage compartment 
over an extended period of time. 
 
7.3.2 Humans 
 
 Lim et al. (1983) injected a single dose of 100–
200 µg chromium(III) as 51CrCl3·6H2O into the ante-
cubital vein of three subjects. The radiochromium was 
monitored for 6 months in the whole body and up to 
60 days in blood plasma. Since the relative radiochro-
mium clearance rates showed only three major clearance 
components, the authors devised a functional kinetic 
model characterized by the fast, medium, and slow 
compartments and the central compartment composed of 
bound and free chromium in plasma. Rate constants 
were calculated for each subject by feeding 13 data 
points each from the whole-body retention and for 
plasma clearance. The fast compartment with half-times 
of 12.1 and 5.2 min for transfer in and out of the pool 
was found to the greatest extent in adipose and muscle 
tissue. The medium compartment showed half-times of 
0.8 and 2.2 days in and out of the pool. In this compart-
ment, the radiochromium was rather evenly distributed 
between adipose and muscle tissue, the spleen, and the 
liver. In the slow compartment, the influx half-time was 
4.2 days, and the efflux half-time was 315 days. This 
storage function was relatively greater in the liver and 
spleen. From the determined transfer rates and normal 
plasma chromium (0.1 µg/l), the authors estimated the 
compartment sizes in normal individuals at steady state: 
in total plasma, 0.3 µg chromium, in the fast compart-
ment, 0.13 µg, in the medium compartment, 0.8 µg, and 
in the slow compartment, 24.4 µg chromium. The limita-
tions of the study were that it utilized a single dose and 
the intravenous route of administration; as well, the 
difficulty measuring some tissues (e.g. bone) must be 
borne in mind when one tries to evaluate the overall 
toxicokinetics of chromium(III) in humans from these 
observations.  
 
 O’Flaherty et al. (2001) reviewed human toxico-
kinetics studies involving oral ingestion of chromi-
um(III) or chromium(VI) compounds and, from the 
blood and urinary chromium data, elaborated a compre-
hensive computer program for a physiologically based 
toxicokinetic model. By the oral route, chromium 
kinetics were shown to be essentially independent of the 
oxidation state of the administered chromium except for 
the fraction absorbed from the intestine. Modelled 
absorption for chromium(III) species among seven 
subjects ranged from 0.7% to 2% (optimized absorption 
rate constant was 0.25/day). The authors noted that the 
body conserved nearly all renally filtered chromium in 
the background plasma concentration range of 0.05–
0.15 µg/l but allowed relatively much greater excretion 
at higher plasma concentrations. For modelling chronic 
oral exposures to chromium at ambient or somewhat 
higher than ambient levels, the authors recommended 
setting urinary clearance to 1–2 l/day. If clearance is 
expressed for the ultrafilterable chromium (about 5% of 
total serum chromium) that is handled by the kidneys 
after glomerular filtration, the clearance is 20 times 
higher (20–40 l/day). 
 
 
 
8. EFFECTS ON LABORATORY MAMMALS 
AND IN VITRO TEST SYSTEMS 
 
 
8.1  Single exposure 
 
8.1.1 Chromium(III) oxide 
 
 Five male and five female Wistar rats were given a 
single intragastric chromium oxide dose of 5000 mg/kg 
bw. Two female rats showed a reduced weight gain 
during the second study week. There was no effect on 
weight gain in the male rats. None of the animals died 
during the 14-day observation period. Postmortem 
pathological examination showed no effects. The median 
lethal dose (LD50) was higher than 5000 mg/kg bw 
(Bayer, 1988). 
 
 Male Wistar II rats (10 animals per group) were 
given by gavage 10 or 15 g/kg bw of a chromium oxide 
preparation in distilled water. None of the animals died 
during the study period of 14 days, and the only symp-
tom reported was ruffled hair. The LD50 was higher than 
15 g/kg bw (Bayer, 1972). 
 
 Low oral toxicity can be expected from chromium 
oxide because the compound is insoluble in water and 
poorly absorbed. There are no acute toxicity studies 
available by other routes of administration. 
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8.1.2 Inorganic chromium(III) salts 
 
 Male Wistar II rats (10 animals per group) were 
given by gavage one dose of basic chromium sulfate at 
1.0, 3.1, 3.5, 4.0, 4.5, or 5.0 g/kg bw. The rats were 
followed up for 14 days. The signs observed were 
weight loss, bleeding eyes and nose, and weakening of 
their general condition. The calculated LD50 was 3.53 
g/kg bw (Bayer, 1978).  
 
 Smyth et al. (1969) presented oral (rat) LD50 values 
for chromium acetate nonahydrate and chromium nitrate 
of 11.26 g/kg bw and 3.25 g/kg bw, respectively. Vernot 
et al. (1977) reported that the oral LD50 of chromium 
nitrate nonahydrate in male rats was 1540 mg/kg bw 
(range 1270–3010 mg/kg bw). 
 
 The acute toxicities of several chromium(III) com-
pounds (nitrate, chloride, sulfate) by the intraperitoneal 
route were studied in male NZC mice by Bryson & 
Goodall (1983). The LD50s obtained were as follows: 
chromium chloride, 17.3 mg chromium/kg bw; chro-
mium nitrate, 17.8 (8.6–36.9) mg chromium/kg bw; and 
hydrated chromium sulfate, 28.1 (19.5–39.2) mg chro-
mium/kg bw.  
 
 Two millilitres of an aqueous solution of 0.239 mol 
chromium chloride/l (dose about 339 mg/kg bw) was 
administered intraperitoneally to guinea-pigs. Within 
7 days, 6 of 10 animals died, compared with none of the 
control animals given only distilled water (Wahlberg, 
1965).  
 
 Male Sprague-Dawley rats (4–6 per dose group) 
were injected intravenously with 10, 15, or 20 mg 
chromium/kg bw as chromium potassium sulfate, and 
0/4, 2/6, and 3/4 rats died, respectively. Lethal doses 
usually caused convulsions and death within a few 
minutes following the injection (Mertz et al., 1965). 
 
 The previous studies indicate that inorganic chro-
mium(III) salts have fairly low toxicity by the oral route, 
whereas by the parenteral routes (intraperitoneal or 
intravenous), they are acutely toxic at dose levels that 
are 2–3 orders of magnitude lower than those for the oral 
route. No acute toxicity data were available for the 
inhalation or dermal routes of administration.  
 
8.2  Irritation and sensitization 
 
8.2.1 Chromium(III) oxide 
 
8.2.1.1 Skin irritation 
 
 Skin irritation and corrosion by chromium oxide 
(500 mg moistened with water) were examined in two 
studies with rabbits, the more recent one employing 
Good Laboratory Practice (GLP) and Organisation for 
Economic Co-operation and Development (OECD) Test 
Guideline 404 (Bayer, 1977, 1988). No irritation was 
observed. 
 
8.2.1.2 Eye irritation 
 
 Eye irritation and corrosion by chromium oxide 
were examined in two studies with rabbits. The more 
recent study was conducted according to GLP and 
OECD Test Guideline 405 (Bayer, 1977, 1988). No 
reactions meeting the criteria for eye irritancy were 
observed.  
 
8.2.1.3 Respiratory irritation 
 
 Swensson (1977) studied the lung reaction to a 
single intratracheal instillation of chromite dust in rats. 
Chromite contains about 50% chromium oxide, with the 
remainder consisting of oxides of iron, aluminium, and 
magnesium. Male Sprague-Dawley rats were adminis-
tered 40 mg of chromite particles (33% Cr3+ and only 
0.7% silicon dioxide, ground to less than 5 µm in 
diameter) in 1 ml of saline, and groups of 7–10 rats were 
killed at 1, 2, 4, or 8 months. Quartz served as a positive 
control. The post-injection follow-up assays included a 
macroscopic examination of the lungs, lung weights 
(absolute and relative), lung collagen content and 
concentration, lung histopathology, macroscopic 
examination of the regional lymph nodes, weight of 
lymph nodes, lymph node histopathology, and lymph 
node collagen content. In comparison with the severe 
tissue reaction caused by quartz, the reaction caused by 
chromite was minimal. The histological picture of the 
lung was characterized by the occurrence of particle-
bearing phagocytic cells without any fibroblast reaction. 
The same applied to the hilar lymph nodes. No indica-
tion of fibrogenesis was detected by 8 months of follow-
up. The author likened chromite particles to other min-
eral particles considered to be “inert”, such as iron 
silicate or titanium dioxide. 
 
8.2.1.4 Sensitization 
 
 No sensitization studies on chromium oxide were 
available. 
 
8.2.2 Inorganic chromium(III) salts 
 
8.2.2.1 Skin irritation 
 
 An industry summary report on skin irritation by a 
preparation of basic chromium sulfate was the only 
available document on skin irritation studies with 
chromium(III) salts. The substance was applied under an 
adhesive patch to the inside of an ear of two rabbits for 
24 h, and the condition of the application site was 
followed up for 7 days (Bayer, 1979). The report 
concludes that the basic chromium sulfate preparation 
was not irritating. 
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 The same authors also studied, by the technique of 
positive or negative in vitro and in vivo selection of 
chromium-specific lymphocytes, whether one common 
determinant or different determinants are formed by 
sensitization with trivalent or hexavalent chromium 
compounds (Siegenthaler et al., 1983). Their observa-
tions and rationale suggested the hypothesis that there is 
a common determinant, which is chromium(III): 1) 
chromium(III)-modified macrophages exerted a better 
stimulatory capacity on lymphocytes than chromi-
um(VI)-modified macrophages, 2) trivalent chromium 
compounds are capable of forming covalent bonds with 
proteins, which is the mechanism by which metals form 
allergens, and 3) hexavalent chromium is transformed to 
trivalent chromium in the skin.  
8.2.2.2 Eye irritation 
 
 An industry summary report concluded that a 
preparation of basic chromium sulfate was not a primary 
irritant in the eye after application of 50 mg of the 
substance in the conjunctival pouch. Symptoms and 
signs were followed up over 7 days (Bayer, 1979). 
 
8.2.2.3 Respiratory irritation 
 
 The respiratory irritancy of chromium chloride was 
studied by exposing Syrian hamsters to nebulized liquid 
aerosols of chromium(III) chloride at 2.8 or 77 mg/m3 
for 0.5 h (Henderson et al., 1979). The median diameter 
of the aerosol particles was 1.2 µm. Enzymatic and 
cytological profiles of lung lavage fluids were examined. 
At the higher exposure concentration, a slight increase in 
lysosomal enzymes was found 1 day after exposure, and 
a slight increase in acid phosphatase was found through-
out the study (i.e. for 21 days). Histopathological exam-
ination at day 1 after exposure showed focal accumula-
tions of macrophages, and the alveolar capillaries were 
diffusely congested. The authors considered these 
responses to be minimal. 
 
 Thirteen guinea-pigs were given chromium chloride 
hexahydrate by three subcutaneous injections in the nape 
1 week apart (Gross et al., 1968). The sensitizing injec-
tions contained 0.5 ml of FCA with 0.5 ml of 3.4 × 10−2 
mol chromium chloride hexahydrate/l. Three weeks 
later, the animals were tested with an intradermal 
injection into clipped or epilated skin. The eliciting dose 
was 0.1 ml of 4.2 × 10−4 mol chromium chloride 
hexahydrate/l. After 48 h, this produced moderate 
positive responses in 10 of the 13 animals, whereas the 
control animals (injected only with FCA) showed no 
reactions. In the same study, sensitization to hexavalent 
chromium was achieved by intradermal injections of 
potassium dichromate with 10-fold lower concentrations 
than required for sensitization to chromium chloride. Of 
26 guinea-pigs sensitized to potassium dichromate, all 
reacted to intradermally applied chromium chloride. Of 
the 10 guinea-pigs sensitized to chromium chloride, 
3 elicited weaker cross-reactions after intradermal 
injection of chromium nitrate (9.6 × 10
 
8.2.2.4 Sensitization 
 
 To investigate the sensitizing potency of a trivalent 
and a hexavalent chromium salt, and cross-reactivity 
between them, Siegenthaler et al. (1983) exposed 
guinea-pigs by five injections of 0.2 ml each of an 
emulsion containing either 2 mg chromium chloride/ml 
or 1 mg potassium dichromate (hexavalent chromi-
um)/ml in Freund’s complete adjuvant (FCA) into the 
footpad and nape of the neck. The animals were 
restimulated once a week by intradermal injections of 
25 µg of either chromium chloride or potassium 
dichromate. Simultaneously, 0.02 ml of either 0.5% 
chromium chloride or potassium dichromate in 1% 
Triton X-100 was applied epicutaneously to the skin of 
the opposite flank. The boosting was continued weekly 
until a positive reaction was observed. Four to six weeks 
after the positive skin reaction had emerged, the animals 
were challenged epicutaneously with both haptens, and 
skin inflammation was evaluated 24 h later. Seven out of 
10 guinea-pigs sensitized and boosted with chromium 
chloride responded to an epicutaneous challenge with 
chromium chloride. In the same group, 3 of the 10 
animals responded to a challenge with potassium 
dichromate. In the three guinea-pigs that responded to 
both haptens, no difference in the intensity of skin 
reactions could be observed. Essentially the same results 
were observed in guinea-pigs sensitized and boosted 
with the potassium dichromate. From the 11 animals that 
responded to the epicutaneous challenge with potassium 
dichromate, 7 responded also to chromium chloride, 
whereas 4 guinea-pigs responded only to potassium 
dichromate (Siegenthaler et al., 1983). 
−4 mol/l) and 
sulfate (2.4 × 10−4 mol/l). Using the same study method, 
the authors also attempted to sensitize guinea-pigs with 
chromium acetate and chromium oxalate, but without 
success (Gross et al., 1968). 
 
 Polak et al. (1973) sensitized 21 guinea-pigs with 
2 mg chromium chloride in FCA by a combined method 
in which chromium chloride was injected intramuscu-
larly into the thighs and the neck, intradermally into the 
clipped skin of the right flank, and epicutaneously with a 
non-ionic surfactant (Triton X-100) to the left flank. 
Subsequently, the animals were epicutaneously (weekly) 
and intradermally (every 2 weeks) challenged with 
chromium chloride. With this treatment protocol, it took 
about 6–8 weeks for the positive reactions to occur. 
Chromium chloride produced positive reactions in the 
epicutaneous test in 38% of the animals and in the 
intradermal test in 74% of the animals. A corresponding 
study with an equivalent amount of hexavalent chro-
mium (potassium dichromate) produced positive reac-
tions in an epicutaneous test in 95% of the animals and 
in an intradermal test in 100% of the animals. The 
 28
Inorganic chromium(III) compounds 
 
 
authors thought that the lower rate of elicitation with 
chromium chloride compared with potassium dichro-
mate was understandable, because the former is a poorer 
skin penetrant than the latter. 
 
 Van Neer (1963) sensitized guinea-pigs with three 
intradermal injections, given every 2nd or 3rd day, of 
0.1 ml of a 0.04% chromium sulfate solution and found 
that the sensitized state was detectable only through 
epicutaneous tests with potassium dichromate (nearly 
60% of the animals showed a positive reaction), not with 
chromium sulfate.  
 
 Jansen & Berrens (1968) indicated in guinea-pigs 
not only that two weekly subcutaneous injections of 
hydrated chromium sulfate and potassium dichromate 
(hexavalent chromium), both with FCA, sensitized 
equally well, but also that the intradermal tests 18 days 
later with both compounds yielded equally intense skin 
reactions.  
 
 The previous animal experiments show that trivalent 
chromium salts can sensitize the guinea-pig skin by 
intradermal or subcutaneous injections. When a positive 
allergic skin reaction was achieved intradermally, 
subsequent elicitation in an epicutaneous test (with 
chromium chloride) was demonstrated in two studies; in 
both cases, not all of the sensitized animals reacted. The 
low potency of trivalent chromium salts compared with 
hexavalent potassium dichromate has been attributed to 
the poor penetration of the compounds into the skin. 
However, in some studies, intradermally injected 
chromium chloride elicited fewer positive reactions in 
sensitized guinea-pigs than an equivalent amount of 
potassium dichromate, suggesting that other factors may 
also play a role. Toxicokinetic differences among the 
trivalent chromium salts may underlie the observed 
variation in cross-reaction sensitivity. 
 
8.3  Short- and medium-term exposure 
 
8.3.1 Chromium(III) oxide 
 
8.3.1.1 Inhalation exposure 
 
 Derelanko et al. (1999) conducted a guideline-based 
13-week inhalation toxicity study with chromium(III) 
oxide by exposing 15 male and 15 female CDF rats 
6 h/day, 5 days/week, to chromium(III) oxide aerosols at 
dose levels of 4.4 ± 0.23, 15 ± 1.2, and 44 ± 3.7 mg/m3. 
This corresponds approximately to 3, 10, and 30 mg 
Cr3+/m3. The mean mass median aerodynamic diameters 
(MMADs) of particles were approximately 1.8–1.9 µm, 
and the particles can be regarded as largely respirable. 
Two thirds of the animals were sacrificed immediately 
after the exposure period, and one third were followed 
up for an additional 13-week recovery period. An 
additional satellite group of 10 rats was exposed to 
chromium(III) oxide for 5 days in order to evaluate the 
changes in bronchoalveolar lavage parameters. 
 
 No chromium(III) oxide–related mortality or 
clinical signs of toxicity occurred at any exposure level. 
Also, the weight gain of the exposed animals was 
comparable to the weight gain of the control group. 
Absolute and relative lung weights were increased in 
males in the high exposure group, and the mean weights 
of mediastinal lymph nodes were increased in high-dose 
animals. In macroscopic examination, green discolora-
tion of the lungs and mediastinal lymph nodes was 
observed in all exposed animals. In microscopic 
examination, an accumulation of randomly distributed 
foci or aggregates of alveolar macrophages filled with 
dense black pigment was observed within the alveolar 
spaces. Black pigment was also present at tracheal 
bifurcation, in the peribronchial lymphoid tissue, and 
within the mediastinal lymph nodes. The black pigment 
correlated with the macroscopic green discoloration of 
lungs and was presumed to represent the test article. 
Trace to mild chronic inflammation and septal hyper-
plasia were observed in alveolar septa surrounding the 
aggregates of pigmented macrophages in mid- and high-
exposure animals, and lymphoid hyperplasia was present 
in all exposure groups. Pigment deposits and slight 
inflammatory changes or septal hyperplasia were also 
observed after the recovery period at a similar or 
increased incidence and severity. Also, some low-dose 
males exhibited slight inflammatory changes in alveolar 
septa. No other treatment-related changes in macro-
scopic or microscopic pathology, sperm evaluation, 
clinical biochemisty, urinalysis, or haematology were 
observed. In a satellite group examined for broncho-
alveolar lavage parameters, no differences in cellular 
composition or biochemical parameters of broncho-
alveolar lavage fluid between the control and exposed 
groups were observed.  
 
 Thus, the effects of repeated inhalation of water-
insoluble chromium(III) oxide in rat are restricted to the 
lungs and include pigment deposition in the lower 
respiratory tract and peribronchial and mediastinal 
lymphoid tissue. The accumulation of the pigment was 
accompanied by mild interstitial inflammation and septal 
hyperplasia, especially in the middle and high exposure 
groups, but some very slight changes were also seen in 
low-dose males sacrificed after the recovery period. The 
clearance of the pigment seemed to be low and was most 
likely to occur via the lymphatic system, which was 
demonstrated by the presence of the pigment in the lungs 
and surrounding lymph nodes, also after the recovery 
period. A lowest-observed-adverse-effect concentration 
(LOAEC) of 4.4 mg/m3 was set for chromium(III) oxide 
in rats.  
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 Mean absolute and relative lung weights were 
significantly and dose-dependently increased in both 
sexes and in all treatment groups sacrificed at the end of 
exposure, as well as after the recovery period. Macro-
scopically, the lungs of the mid- and high-exposure 
group animals exhibited grey discoloration in animals 
sacrificed both at the end of the exposure period and 
after the recovery period. Microscopic evaluation 
revealed chronic inflammation of the lungs at all 
exposure levels, consisting of alveolar spaces filled with 
macrophages, neutrophils, lymphocytes, and cellular 
debris. Chronic interstitial inflammation was usually 
multifocally distributed and consisted of thickened 
alveolar walls caused by inflammatory cell infiltration 
and hyperplasia of type II pneumocytes. Areas of 
granulomatous inflammation characterized by infiltra-
tion of macrophages and multinucleated giant cells were 
observed in the lungs at all exposure levels. Microscopic 
changes correlated with lung weights and grey discolor-
ation of the lungs. In peribronchial and mediastinal 
lymph nodes, histiocytosis (macrophage hyperplasia) 
and lymphoid hyperplasia correlated with lymph node 
enlargement. At the recovery sacrifice, foreign material 
persisted in the lungs of some animals, but with 
decreased incidence. The incidence and severity of 
chronic inflammation of the alveoli and chronic inter-
stitial or granulomatous inflammation were similar in the 
middle and high exposure groups and slightly reduced in 
the low exposure group, when compared with the 
animals sacrificed at the end of exposure. Peribronchial 
histiocytosis continued to be observed in mid- and high-
exposure animals of the recovery groups, with an 
increased incidence among the high-exposure animals. 
8.3.1.2  Oral exposure 
 
 In a study by Ivankovic & Preussman (1975), 
chromium(III) oxide was baked into bread at concen-
tration levels of 2% and 5%, and this bread was fed to 
BD rats of both sexes (n = 12–19) on 5 days/week for a 
period of 90 days. Based on the reported food consump-
tion, these chromium(III) oxide levels corresponded to a 
Cr3+ uptake of 568 mg/kg bw per day for males and 547 
mg/kg bw per day for females in the 2% group and 1368 
mg/kg bw per day for males and 1216 mg/kg bw per day 
for females in the 5% group. Regardless of the high Cr3+ 
doses, chromium(III) oxide did not cause any significant 
treatment-related changes in the general condition of 
animals, body weights, clinical biochemistry, haematol-
ogy, or pathological examination. The lack of toxicity of 
chromium(III) oxide can be explained by the poor bio-
availability of this water-insoluble chromium compound. 
Faeces of treated animals showed an intense green 
discoloration, indicating significant excretion of the 
substance into faeces. 
 
8.3.2 Inorganic chromium(III) salts 
 
8.3.2.1  Inhalation exposure 
 
 A comparable 13-week inhalation toxicity study 
with the same test protocol as described above in section 
8.3.1.1 was also conducted with basic chromium sulfate 
(Derelanko et al., 1999). The mean aerosol concentra-
tions were 17 ± 4.3, 54 ± 4.2, and 168 ± 25.3 mg basic 
chromium sulfate/m3, approximating to 3, 10, and 30 mg 
Cr3+/m3, respectively. The mean MMAD of the particles 
ranged from 4.2 to 4.5 µm.   
  Nasal cavity mucosa of the exposed animals 
exhibited acute inflammation with suppurative or 
mucoid exudate, which had largely disappeared at the 
recovery sacrifice. In the larynx, green refractile material 
in the lamina propria and submucosa associated with an 
infiltration of macrophages and multinucleated giant 
cells (granulomatous inflammation) was seen in the 
animals from all treatment groups. After the recovery 
period, these changes were no longer detected in the low 
dose group and in males in the middle exposure group 
and were markedly reduced in incidence and severity in 
the females in the middle exposure group and in both 
sexes in the high exposure group.  
 No clinical signs of toxicity were observed, except 
for sporadic cases of laboured breathing in females of 
the high exposure group. Mean body weights of males in 
the middle and high exposure groups and of females of 
the high exposure group were statistically significantly 
lower than among controls during the exposure period. 
During the recovery period, males from the middle and 
high exposure groups continued to exhibit significantly 
lower body weights than controls, and males in the low 
exposure group continued to exhibit slightly lower body 
weights than controls, but the body weight gains were 
similar. Among females, mean body weights in all 
exposure groups were not different from those of con-
trols at the recovery sacrifice. The exposures did not 
seem to have an impact on food consumption. In 
haematological assays, total leukocytes and neutrophils 
were increased in both sexes in the middle and high 
exposure groups. In clinical chemistry parameters, high-
exposure females had elevated alkaline phosphatase 
levels, and mid- and high-exposure females had 
decreased cholesterol levels.  
 
 In other organs observed to have small exposure-
related increases in absolute or relative organ weights, 
the histopathological findings were unremarkable. No 
exposure-related effects were noted for sperm motility, 
morphology, or concentration or for testicular and 
ovarian weights or histopathology.  
 
 In the satellite group sacrificed after the 5-day 
exposure period, bronchoalveolar lavage samples 
showed a dose-dependent increase in the number of 
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neutrophiles and mononuclear cells. Total protein and 
lactate dehydrogenase levels were also slightly (but not 
statistically significantly) increased. 
 
 The lowest basic chromium sulfate exposure level 
of 17 mg/m3 (3 mg Cr3+/m3, corresponding to an inhaled 
dose of 0.7 mg chromium/kg bw) was a no-observed-
adverse-effect concentration (NOAEC) for systemic 
effects (decreased body weight, changes in haematol-
ogy). However, in the respiratory system, clear, dose-
dependent inflammatory changes were seen at the lowest 
exposure level. Therefore, no NOAEC for the local 
respiratory effects could be determined. 
 
 Johansson and co-workers (Johansson et al., 
1986a,b, 1987) exposed male rabbits to mean 
concentrations of 0.6 or 2.3 mg chromium/m3 as 
chromium(III) nitrate nonahydrate, 5 days/week, 
6 h/day, for 4–6 weeks or 4 months. Only lung effects 
were evaluated. Main findings included increased 
accumulation of test material–filled macrophages in 
lungs and morphological changes in macrophages, 
including an increased size of lysosomes and an 
accumulation of laminated structures in lysosomes. In 
some areas, intra-alveolar accumulation of enlarged 
macrophages was accompanied by a mild interstitial 
inflammation, mainly at the highest dose level. Increased 
oxidative metabolic activity of macrophages and 
decreased phagocytic activity were also demonstrated. 
Apart from slight inflammatory reactions, many of the 
changes observed in this study can be regarded as a 
physiological response to the foreign material rather than 
as an adverse effect.  
 
8.3.2.2 Oral exposure 
 
 Four-week-old male Harlan Sprague-Dawley rats 
(eight per group) were fed a diet supplemented with 0, 5, 
25, 50, or 100 mg Cr3+/kg as chromium chloride for a 
period of 20 weeks (Anderson et al., 1997). Daily Cr3+ 
intakes can be estimated to correspond to 0.35–7 mg/kg 
bw (estimated on the basis of default reference values 
given in Appendix VI of European Commission [2003]). 
The authors calculated the highest dose to correspond to 
a chromium intake of 15 mg/kg bw. However, in 
calculations, they used a rat body weight of only 100 g, 
which seems exceptionally low, because the normal 
weight of adult Sprague-Dawley rats is between 200 and 
300 g. If 200 g is used as a mean body weight, the 
highest dose corresponds to 7 mg chromium/kg bw. 
Effects on body weights, selected organ weights, and the 
histology of liver and kidneys were evaluated. Histo-
pathological examination was performed on four high-
dose and four control rats. Haematology and biochem-
ical analyses of blood (serum glucose, cholesterol, 
triglycerides, liver enzymes, blood urea nitrogen, total 
protein, and creatinine) were performed on animals at 
11, 17, and 24 weeks of age. No changes in body or 
organ weights, no general signs of toxicity, and no 
changes in liver or kidney histopathology were seen. 
Toxicokinetic evaluation showed a dose-dependent 
increase in liver and kidney chromium concentrations. 
Some sporadic, statistically significant changes were 
seen in some clinical chemistry parameters (lactate 
dehydrogenase, aspartate aminotransferase, serum 
creatinine levels), but because these changes did not 
show any dose or time dependency, they were not 
considered to be treatment related. Based on these 
results, the authors suggested the highest dose level as a 
no-observed-adverse-effect level (NOAEL) for trivalent 
chromium (7 mg/kg bw using 200 g as a mean body 
weight). However, because the study was limited only to 
a small number of animals and to a limited number of 
end-points, this conclusion should be regarded with 
reservation.  
 
 A similar study was also performed with organic 
chromium picolinate. Although the estimated Cr3+ intake 
was similar to that of chromium chloride, the chromium 
picolinate treatment resulted in a significantly more 
pronounced increase in liver and kidney chromium 
levels compared with the chromium chloride treatment 
(Anderson et al., 1997). However, no differences 
attributable to the treatment were observed in clinical 
evaluation, body or organ weights, selected organ 
histopathology, haematological parameters, or clinical 
chemistry.  
 
8.4  Long-term exposure and 
carcinogenicity
 
8.4.1 Chromium(III) oxide 
 
 Several studies from the 1950s, 1960s, and 1970s 
tried to evaluate the carcinogenicity of trivalent chro-
mium compounds, but had different shortcomings in 
study designs. A description of all of these studies can 
be found in IARC (1990) or Riihimäki & Luotamo 
(2006). 
 
 Laskin et al. (1970) developed an intrabronchial 
pellet technique to study bronchial carcinogenicity in 
rats. Pellets prepared from molten cholesterol carrier 
mixed with an equal quantity of chromium oxide were 
put inside a cylindrical box of stainless steel wire mesh 
and placed in the left bronchus. The exposure duration 
was up to 136 weeks. None of the 98 chromium oxide–
treated rats had lung tumours. Among rats similarly 
exposed to calcium chromate, bronchial carcinomas 
were found. 
 
 The study was repeated by Levy & Venitt (1986) 
with the same methodology. A group of 48 male and 
52 female rats received a bronchial pellet containing 
2 mg of chromium(III) oxide mixed with an equal 
amount of cholesterol. The animals were kept for 
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2 years, and a postmortem study was performed on the 
94 remaining rats. None of them exhibited local squa-
mous carcinomas or carcinomas in situ, and the occur-
rence of squamous metaplasia was not increased com-
pared with the stainless steel wire mesh controls. 
 
 Groups of 60 male and 60 female BD rats were fed 
1, 2, or 5% chromium(III) oxide baked in bread on 
5 days/week for 2 years (600 feeding days) (Ivankovic & 
Preussman, 1975). Male and female rats, 60 animals per 
group, served as untreated controls. The total consump-
tion of chromium(III) oxide (in 600 days) in the dosed 
groups ranged from 360 to 1800 g/kg bw. After the 
feeding period, animals were maintained on the control 
diet until they died or became moribund. Body weight 
gains in the dosed groups showed no differences from 
those of the controls, and the median survival times in 
all three dose groups were comparable with that of the 
controls. No macroscopic or histological postmortem 
findings could be related to the treatment. Regarding 
tumours, no gastrointestinal tumours were reported in 
any group. Low rates of mammary fibroadenomas, 
mammary carcinomas, or hypophyseal adenomas were 
found in all groups (including controls), without a dose–
response. The occurrence of these tumours was charac-
teristic of the BD strain of rats. It should be noted that 
owing to the insolubility of the chromium oxide powder 
used in the study, very little is expected to become 
absorbed. 
 
8.4.2 Inorganic chromium(III) salts and complexes 
 
 Levy & Venitt (1986) conducted a study in which 
groups of 48 male and 52 female rats received a bron-
chial pellet containing 2 mg of chromium chloride 
hexahydrate or chrome tan (basic chromium sulfate), 
each mixed with an equal amount of cholesterol. The 
animals were kept for 2 years, and a postmortem study 
was performed on the 83 (chromium chloride) or 95 
(basic chromium sulfate) remaining rats. None of the 
rats in either group exhibited local squamous carcinomas 
or carcinomas in situ, and the occurrence of squamous 
metaplasia was not increased compared with the stain-
less wire mesh controls. 
 
 Trivalent chromium was not found to be carcino-
genic in a study in which 5 mg chromium acetate/l in 
drinking-water was given for life to 54 male and 50 
female white Swiss mice of the Charles River strain. The 
experiment continued until all animals had died; the total 
elapsed time was 36 months, but only 60% of the males 
survived more than 18 months (Schroeder et al., 1964). 
 
 Groups of at least 50 male and 50 female Long-
Evans rats were given 5 mg chromium acetate/l in 
drinking-water from weaning until death. Mortality due 
to an intercurrent pneumonia in chromium-fed animals 
was 26.7% for males and 7.8% for females, compared 
with 27.3% and 25.6% in control groups, respectively. 
The incidences of tumours (in either males or females) 
were not significantly different from those in controls. 
The total numbers of autopsied animals with tumours 
were as follows: 16/39 treated males, 18/35 treated 
females, 9/35 male controls, and 15/35 female controls 
(Schroeder et al., 1965). 
 
 The strain A mouse lung tumour system, once 
proposed to screen carcinogenic potential, was used to 
examine a series of metal compounds, including chro-
mium sulfate. Strain A/Strong mice, 20 animals (10 
males and 10 females) per dose group, received 
intraperitoneal injections of chromium(III) sulfate 
(tricaprylin as vehicle) at three dose levels (480, 1200, or 
2400 mg/kg bw) 3 times per week, for a total of 24 
injections. The animals were killed 30 weeks after the 
first injection. Chromium(III) sulfate did not induce any 
increase in the lung tumour frequency compared with the 
vehicle and untreated controls, whereas urethane 
(20 mg) as a positive control was clearly carcinogenic 
(Stoner et al., 1976).  
 
 Chromium chloride hexahydrate was studied, 
among other metal salts, for a promoting effect on rat 
renal tumorigenesis. Fifteen male F344 rats were given 
500 mg N-ethyl-N-hydroxyethylnitrosamine/l in 
drinking-water for 2 weeks and thereafter chromium 
chloride at 600 mg/l in drinking-water for a subsequent 
25 weeks. Statistically significant increases in the mean 
number of dysplastic foci per square centimetre of renal 
tubules were found in rats treated with the five metal 
compounds, including chromium chloride. The inci-
dence of renal cell tumours was, however, significantly 
higher only in rats treated with nickel chloride (Kuro-
kawa et al., 1985).  
 
 Trivalent chromium has also been suggested to have 
the capability to cause paternally mediated transgenera-
tional carcinogenesis (Anderson et al., 1994; Yu et al., 
1999). This is based on two studies employing single 
high-dose (52 mg Cr3+/kg bw) intraperitoneal treatment 
of male rats with chromium(III) chloride and showing 
increases either in lung tumours (Anderson et al., 1994) 
or in adrenal, thyroid, and Harderian gland tumours, as 
well as in reproductive organ tumours (Yu et al., 1999) 
in offspring.  
 
8.5  Genotoxicity and related end-points 
 
8.5.1  In vitro studies 
 
 There are a huge number of in vitro genotoxicity 
studies available on chromium(III) compounds. Studies 
published before the year 1990 have been reviewed 
comprehensively by De Flora et al. (1990). All geno-
toxicity studies available before December 2004 are 
summarized in Riihimäki & Luotamo (2006). 
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 In acellular systems, water-soluble chromium(III) 
compounds, such as chromium(III) chloride and 
chromium(III) nitrate, have been shown to induce 
genotoxic effects, including deoxyribonucleic acid 
(DNA) adducts, DNA strand breaks, DNA–DNA 
interstrand crosslinks, DNA–protein crosslinks, DNA–
amino acid crosslinks, DNA–glutathione crosslinks, 
gene mutations after transfection of treated DNA into 
cells, and 8-oxodeoxyguanosine in DNA in the presence 
of hydrogen peroxide (De Flora et al., 1990; Singh et al., 
1998). The electropositive chromium(III) ion interacts 
with the negatively charged phosphate groups in the 
DNA backbone and with guanine bases, forming 
phosphate–chromium–phosphate or guanine–chromium–
guanine interstrand crosslinks (Singh et al., 1998). 
Consequently, interstrand crosslinks can result in 
functional disturbances in DNA and ribonucleic acid 
(RNA) polymerases and inhibition of DNA and RNA 
synthesis. Whereas chromium(III)-induced low-level 
DNA damage stimulates DNA synthesis of reduced 
fidelity, at higher concentrations, crosslinks result in 
DNA polymerase arrest and inhibition of DNA 
replication and RNA polymerase arrest and transcrip-
tional inhibition (Snow, 1994). In acellular systems, 
chromium(III) compounds have usually been more 
reactive towards DNA than have chromium(VI) 
compounds (Dayan & Paine, 2001), reflecting the fact 
that chromium(III) can readily interact with DNA, 
whereas chromium(VI) acts by reduction products such 
as reactive oxygen species, chromium(VI) esters, chro-
mium(V), chromium(IV), and chromium(III), which are 
formed in cells but not in acellular systems (Singh et al., 
1998). 
 
 In bacterial tests, inorganic chromium(III) com-
pounds have shown mainly negative results. De Flora et 
al. (1990) summarized the results of 25 bacterial geno-
toxicity studies on chromium chloride, 11 studies on 
chromium(III) nitrate, 11 studies on chromium(III) 
acetate, 7 studies on chromium(III) sulfate, 14 studies on 
chromium(III) potassium sulfate, and 2 studies on basic 
chromium sulfate. The assays included various types of 
tests with Escherichia coli, Salmonella typhimurium, and 
Bacillus subtilis with and without metabolic activation 
systems. With few exceptions, these studies showed 
negative results. Positive doses were generally very 
high. Water-insoluble chromium(III) phosphate, chro-
mium(III) oxide, and chromium(III) hydroxide were 
studied in a single study by Yagi & Nishioka (1977) in 
E. coli, and no DNA damage was seen.  
 
 In older studies in cultured mammalian cells, 
chromium(III) chloride gave negative results when 
tested for DNA damage (measured by alkaline elution) 
or interference with DNA synthesis (De Flora et al., 
1990). However, in one recent study, DNA damage 
(single strand breaks and abasic sites) measured as an 
increase in comet tail moment was demonstrated at 
concentrations of 0.5–1 mmol chromium(III) chloride/l 
(Blasiak & Kowalik, 2000). Gene mutations (6-thio-
guanine-resistant mutants) were not seen in human 
fibroblasts at 0.5–1 mmol/l concentrations of chro-
mium(III) chloride (Biedermann & Landolph, 1990). 
Basic chromium sulfate did not cause any increase in 
DNA mutations in Chinese hamster V79 cells at 0.2–
0.8 mmol/l concentrations (Bianchi et al., 1983). 
 
 Eleven out of 14 studies on the induction of sister 
chromatid exchanges (SCEs) by chromium(III) chloride 
in cultured mammalian cells were negative (De Flora et 
al., 1990). Some of these negative studies were 
performed using very low chromium(III) chloride 
concentrations and may thus have been inconclusive. 
The three positive studies utilized Chinese hamster cell 
lines. The clearest effect was seen in Chinese hamster 
V79 cells, where up to a 3.4-fold increase in SCEs and a 
delay in cell cycle progression were observed (Elias & 
Schneider, 1984), with a clear dose- and time-related 
increase in SCE induction by prolongation of treatment 
time from 24 h to 36 h and 48 h. It was suggested that 
the longer incubation time and higher concentrations 
allowed an increased chromium ion accumulation 
through slow transportation into the cell. Venier et al. 
(1985) observed that chromium(III) chloride induced a 
slight, but statistically significant, increase in SCEs in 
Chinese hamster ovary cells when the incubation time 
was 44–52 h to cover two generation cycles. An increase 
in SCEs by chromium(III) chloride was also observed in 
Chinese hamster Don cells (Ohno & Hanaoka, 1982). 
Chromium(III) nitrate, chromium(III) sulfate, basic 
chromium sulfate, and chromium(III) potassium sulfate 
have shown negative or equivocal results in the SCE 
assay (De Flora et al., 1990). Chromium(III) acetate 
increased SCEs in mouse macrophage cells, human 
lymphocytes, and skin fibroblasts (Nakamuro et al., 
1978; Andersen, 1983), but not in Chinese hamster 
ovary cells (Levis & Majone, 1979). 
 
 There are also several studies on the induction of 
chromosomal aberrations by inorganic chromium(III) 
compounds. Chromium(III) chloride has increased 
chromosomal aberrations in mouse fetal tertiary cells at 
low concentrations, but not in Syrian hamster embryo 
primary cells (Raffetto & Parodi, 1977; Tsuda & Kato, 
1977). Both negative and positive results have been 
observed in Chinese hamster ovary cells (Levis & 
Majone, 1979, 1981; Majone & Rensi, 1979; Bianchi & 
Dal Toso, 1980; Stearns et al., 1995). Although two 
studies with human lymphocytes did not show any 
positive effect (Nakamuro et al., 1978), three other 
studies showed a positive response (Kaneko, 1979; 
Stella et al., 1982; Friedman et al., 1987). Concentra-
tions up to the millimole per litre range were used in two 
of these positive studies (Kaneko, 1979; Stella et al., 
1982), whereas one showed a 1.6- to 4.3-fold increase in 
chromosomal aberrations in six out of seven human 
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donors after in vitro exposure to a very low concentra-
tion of chromium(III) chloride (2.5 µg/ml) for 68–72 h 
(Friedman et al., 1987). Various antioxidants reduced the 
incidence of chromosomal aberrations.  
 
 In human diploid MRC-5 fibroblasts, chromium(III) 
chloride (1–5 µmol/l, 24–26 h treatment) induced an 11-
to 22.5-fold increase in the frequency of micronuclei 
(Seoane & Dulout, 2001). The majority of the induced 
micronuclei were kinetochore positive and thus probably 
contained whole chromosomes, indicating an aneugenic 
effect. However, a significant increase was also seen in 
kinetochore-negative micronuclei, suggesting a clasto-
genic influence as well. In primary cultures of human 
fibroblasts treated for one cell cycle (21 h) with chro-
mium(III) chloride, a 2.2-fold increase in aberrant cell 
division patterns (studied by a differential staining 
technique for chromosomes and spindles) was observed 
at a concentration of 100 µmol/l (Nijs & Kirsch-Volders, 
1986).  
 
 Other soluble chromium(III) compounds have also 
shown variable results in chromosomal aberration tests. 
Chromium(III) acetate induced chromosomal aberrations 
in Chinese hamster ovary cells and human lymphocytes 
(Nakamuro et al., 1978; Levis & Majone, 1979; Bianchi 
& Dal Toso, 1980), whereas chromium(III) sulfate 
induced chromosomal aberrations in Chinese hamster 
ovary and 237-21 cells (Levis & Majone, 1981; Rossner 
et al., 1981), but not in mouse mammary carcinoma cells 
(Umeda & Nishimura, 1979) or Syrian hamster embryo 
cells (Tsuda & Kato, 1977) (the latter study involved 
low concentrations only). Both basic chromium(III) 
sulfate and chromium(III) potassium sulfate induced 
chromosomal aberrations in Chinese hamster ovary cells 
(Levis & Majone, 1979, 1981), but chromium(III) nitrate 
was negative in both Chinese hamster ovary cells and 
human lymphocytes (Nakamuro et al., 1978; Levis & 
Majone, 1979; Bianchi & Dal Toso, 1980).  
 
 Water-insoluble chromium(III) oxide has given 
mainly positive results in the few studies available. It has 
induced 6-thioguanine-resistant mutants in Chinese 
hamster V79 cells and human fibroblasts (Elias et al., 
1986; Biedermann & Landolph, 1990), SCEs and 
chromosomal aberrations in Chinese hamster V79 cells 
(Elias et al., 1983; Elias & Schneider, 1984), morpho-
logical transformation in Syrian hamster embryo cells 
(Elias & Schneider, 1984), and anchorage-independent 
growth in human fibroblasts (Biedermann & Landolph, 
1990). It did not, however, induce SCEs in mouse 
macrophage P388D1 cells (Andersen, 1983) or 
anchorage independence in Syrian hamster BHK cells 
(Hansen & Stern, 1985). In Chinese hamster V79 cells, 
prolongation of the treatment time from 24 h to 36 h and 
48 h resulted in a progressive dose- and time-related 
enhancement in SCE frequencies (Elias et al., 1983). 
Lower concentrations of chromium(III) oxide, which 
had no effect after the 28-h treatment, induced an 
increase of SCEs at the prolonged exposure time. The 
penetration of the crystalline chromium(III) oxide into 
the cells appeared to occur by phagocytosis. Chromi-
um(III) oxide particles were usually observed in the 
cytoplasm, around the nucleus. It was suggested that the 
effect of chromium(III) oxide was due to the slow 
solubilization of the particles to yield chromium(III).  
 
8.5.2 In vivo studies 
 
 There are only a few studies on the genotoxic 
effects of chromium(III) in experimental animals in 
vivo.  
 
 In an internal report of Bayer AG (Herbold, 1992), 
chromium oxide green (in corn oil), consisting of 98.9% 
chromium(III) oxide, did not induce micronuclei in bone 
marrow polychromatic erythrocytes of male and female 
NMRI mice at a very high dose single intraperitoneal 
administration (10 g/kg bw), with sampling 16, 24, and 
48 h after the administration. The chromium(III) oxide 
treatment was associated with toxicity seen as a decrease 
in the ratio of polychromatic to normochromatic erythro-
cytes, which indicates a cytotoxic effect on bone 
marrow. 
 
 Chromium(III) chloride has been negative in the 
wing somatic mutation and recombination test in 
Drosophila melanogaster in several studies (Graf et al., 
1992; Ogawa et al., 1994; Amrani et al., 1999; Katz et 
al., 2001). Results obtained with chromium(III) nitrate in 
the D. melanogaster wing somatic mutation and 
recombination test were inconclusive (Yesilada, 2001).  
 
 No DNA strand breaks, DNA interstrand crosslinks, 
or DNA–protein crosslinks were observed by alkaline 
elution of DNA in kidneys of Sprague-Dawley rats 1 h 
after an intraperitoneal injection of chromium(III) 
chloride at 80 mg/kg bw (Tsapakos et al., 1983).  
 
 After an intraperitoneal injection of Sprague-
Dawley rats with chromium(III) chloride (80 mg/kg bw), 
chromium entered liver and kidney tissues at a slow rate 
and bound to liver and kidney chromatin and DNA 
(Cupo & Wetterhahn, 1985). Chromium binding to liver 
chromatin from chromium(III) chloride was observed to 
increase through 40 h (later sampling times were not 
examined). In the kidney, the level of chromium in 
chromatin after the chromium(III) chloride treatment 
increased with time until 24 h, but decreased thereafter. 
Alkaline elution indicated no increase in DNA–protein 
crosslinks, DNA interstrand crosslinks, and DNA strand 
breaks in liver or kidney 4, 24, or 40 h after the chromi-
um(III) chloride injection. 
 
 In female Sprague-Dawley rats, a single oral dose of 
chromium(III) chloride hexahydrate (895 mg/kg bw) 
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resulted in an increased excretion of the urinary lipid 
metabolites formaldehyde, acetaldehyde, and acetone 48, 
72, and 96 h after the dosing and malonaldehyde 72 h 
after the dosing, indicating oxidative stress (Bagchi et 
al., 2002). No effect on these urinary metabolites was 
evident 24 h after the treatment. An increase was also 
seen in the production of superoxide anion by peritoneal 
macrophages and hepatic mitochondrial and microsomal 
lipid peroxidation 48 h after the treatment.  
 
 Chromium(III) chloride (62.5, 125, or 250 mg/kg 
bw) given intraperitoneally once a day for 2 consecutive 
days did not induce micronuclei in Slc:ddY mouse bone 
marrow polychromatic erythrocytes examined 24 h after 
the last injection (Itoh & Shimada, 1996).  
 
 In a study by Fabry (1980), chromium(III) nitrate 
was not observed to induce micronuclei in bone marrow 
polychromatic erythrocytes of BALB/c mice after 
intraperitoneal injection (250–500 mg/kg bw). Further 
experimental details were not available. 
 
 Although this document does not assess the risks of 
organic chromium(III) complexes, the data from studies 
performed with these compounds may provide some 
additional relevant information. Chromium picolinate 
and chromium picolinate monohydrate were tested by 
the United States National Toxicology Program in the 
in vivo micronucleus test. Chromium picolinate admin-
istered at dose levels of 156, 312, 625, 1250, or 
2500 mg/kg bw by gavage 3 times, 24 h apart, and 
sampled 24 h after the last treatment was negative in the 
bone marrow micronucleus test in male Fischer 344 rats 
(NTP, 2004). Chromium picolinate monohydrate (80–
50 000 mg/kg in feed for 90 days; sampling 24 h after 
exposure cessation) was tested in the peripheral blood 
erythrocyte micronucleus assay in male and female 
B6C3F1 mice. It was considered to be “negative (male)” 
and “equivocal (female)” (NTP, 2004), since in female 
mice, the highest dose of chromium picolinate mono-
hydrate was associated with a 1.6-fold increase in the 
mean number of micronucleated normocytes (P = 
0.0396).  
 
8.6  Reproductive and developmental 
toxicity 
 
8.6.1  Effects on fertility 
 
8.6.1.1  Chromium(III) oxide 
 
 In conjunction with a 13-week rat inhalation toxicity 
study with chromium(III) oxide (Derelanko et al., 1999), 
effects on ovarian and testicular weights, histopathology, 
and sperm parameters were evaluated. Chromium(III) 
oxide did not cause any changes in testicular or ovarian 
weights or histopathology or in any sperm parameters, 
even at the highest dose level of 30 mg/m3 (which 
corresponds to an inhaled dose of 6.6 mg Cr3+/kg bw).  
 
 In the study by Ivankovic & Preussman (1975) 
described in section 8.3.1.2, nine male and nine female 
rats were paired after 60 days of exposure to chromi-
um(III) oxide. All females became pregnant.  
 
8.6.1.2  Inorganic chromium(III) salts  
 
 In a 13-week rat inhalation toxicity study with basic 
chromium sulfate (Derelanko et al., 1999), no statisti-
cally significant changes in absolute testicular weights 
were seen at any basic chromium sulfate dose, but the 
relative testicular weights increased at the highest dose 
level of 30 mg Cr3+/m3, corresponding to an inhaled dose 
of 6.6 mg Cr3+/kg bw. This finding was not associated 
with microscopic pathology and was most probably 
attributed to the decreased body weight of animals. No 
exposure-related effects were noted in sperm parameters. 
In females, no effects on ovarian weights were seen.  
 
 Sexually mature male and female Swiss mice were 
exposed for 12 weeks to chromium chloride hexahydrate 
dissolved in drinking-water at concentrations of 2000 or 
5000 mg/l (Elbetieha & Al Hamood, 1997). Daily chro-
mium(III) doses were estimated to be 82 and 204 mg 
Cr3+/kg bw for males and 85 and 212 mg Cr3+/kg bw for 
females. Effects of chromium chloride hexahydrate on 
fertility were evaluated by mating the treated animals 
with untreated counterparts. Main findings included a 
decrease in the number of pregnant females when 
untreated females were mated with high-dose males and 
a decrease in the number of implantations and viable 
fetuses when treated females were mated with untreated 
males. No mortality or clinical signs of toxicity were 
seen in treated animals. The water consumption of mice 
in the highest exposure group was lower than that in the 
control group. In the group of animals killed after a 12-
week exposure, some changes in the relative weights of 
reproductive organs (decreased relative seminal vesicle 
and preputial gland weights in males; increased relative 
uterine weight and decreased relative ovarian weights in 
females) were seen either at both doses or at the higher 
dose level. In the absence of a clear dose–response and 
any histopathological data, the relevance of these 
changes remains unclear. 
 
 In a subsequent study by the same group, 25 preg-
nant mice were exposed to 1000 mg chromium chloride 
hexahydrate/l in the drinking-water from day 12 of 
pregnancy to the weaning of the pups on postnatal day 
20 (Al Hamood et al., 1998). Estimated doses were 36 
and 31 mg Cr3+/kg bw per day during the gestation and 
lactation periods, respectively. Main findings included 
reduced body weights and the relative weights of testes, 
seminal vesicles, and preputial glands in treated male 
offspring, changes in body weights, relative ovarian 
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weights, and uterine weights in a subgroup of female 
offspring studied (n = 8), and delayed time of vaginal 
opening in another subgroup of female offspring (n = 
10). When prenatally and postnatally exposed F
8.6.2 Developmental toxicity 
 
 According to the study by Ivankovic & Preussman 
(1975), no obvious malformations were seen in the 
offspring of the female rats eating chromium(III) oxide–
containing bread throughout pregnancy. The average 
chromium intake was 547 or 1216 mg/kg bw per day, 
and the number of animals per group was nine. 
1 males 
(n = 9) were mated with untreated females (1:2), no 
statistically significant changes in fertility were seen. 
Mating a group of 16 F1 females with untreated males 
resulted in a statistically significant reduction in the 
number of pregnant females and an increase in the 
number of resorptions, although the number of 
implantations and number of viable fetuses per female 
remained unchanged. 
 
 In high-dose intraperitoneal developmental toxicity 
studies, embryotoxic, fetotoxic, and teratogenic effects 
have been seen (Matsumoto et al., 1976; Iijima et al., 
1983). However, because of the very high doses, 
approaching LD
 
 When a group of 10 male rats was treated with 
1000 mg chromium chloride/l in drinking-water for 
12 weeks and mated with virgin females (1:2), no 
significant changes in the number of pregnant females, 
the number of implantations per female, or the number 
of viable fetuses per female were seen (Bataineh et al., 
1997). The estimated daily intake of Cr
50 levels, and intraperitoneal admin-
istration, these studies cannot be used in the develop-
mental risk assessment of trivalent chromium.  
 
 
 
9. EFFECTS ON HUMANS 3+ was 24 mg/kg 
bw, assuming that chromium chloride was in the form of 
hexahydrate. The body weights of treated males, 
absolute but not relative testes weights, as well as the 
absolute and relative seminal vesicle and preputial gland 
weights were significantly reduced. A significant 
increase in the post-ejaculatory latency, a reduction in 
the number of males ejaculating during the observation 
period, and decreased aggressivity of treated males were 
also observed (Bataineh et al., 1997). None of these 
three studies (Bataineh et al., 1997; Elbetieha & Al 
Hamood, 1997; Al Hamood et al., 1998) included 
histopathology of reproductive organs or any sperm 
analysis.  
 
 
9.1  Essentiality 
 
 The primary biological effect attributed to endog-
enous chromium(III) is potentiation of the action of 
insulin, which has an impact on carbohydrate, lipid, and 
protein metabolism. In humans, glucose intolerance, 
insulin resistance, and impaired lipid profile (increased 
serum free fatty acids, cholesterol, and triglycerides) 
have been related to chromium deficiency (Mertz, 1993; 
Anderson, 1997). However, states of true chromium 
deficiency rarely occur because of the trace amounts 
required, whereas some room remains for speculation 
concerning relative deficiencies due to poor nutrition 
and chromium losses in old age or higher chromium 
needs among specific populations, such as Type II 
diabetics (Mertz, 1993; Anderson, 1997; Jeejeebhoy, 
1999). 
 
 In an oral fertility study in mice, effects of trivalent 
chromium on testicular histology and on the number of 
spermatogenic cells and epididymal sperm were sug-
gested (Zahid et al., 1990). However, owing to apparent 
methodological deficiencies and the uncertainty con-
cerning the compound used in this study, the relevance 
of these findings remains unclear (Riihimäki & 
Luotamo, 2006).  
 
 Homeostatic mechanisms involving regulation of 
absorption, excretion, and tissue retention, which enable 
adaptation to varying nutrient intakes, are typical for 
essential trace elements (IPCS, 2002a). In the case of 
chromium, homeostatic mechanisms were found to 
operate in the gastrointestinal tract, such that absorption 
of chromium(III) from normal diets was inversely 
related to daily dietary intakes (Anderson & Kozlowsky, 
1985). In humans, renal clearance appears to function as 
a regulatory mechanism for the removal of excessive 
chromium in plasma (O’Flaherty et al., 2001). This is 
possibly mediated by LMWCr (Wada et al., 1983), 
which is an oligopeptide found mainly in the liver, 
although appreciable quantities also occur in the kidney, 
spleen, intestine, testis, and the brain, and probably it is 
the major form of chromium(III) in urine (Vincent, 
2000). In the normal state of health, there also seems to 
be a homeostatic metabolic control of chromium in 
 
 No effects on testicular weights were seen when 
chromium chloride or chromium picolinate was given to 
rats for 20 weeks at four concentrations ranging from 5 
to 100 mg Cr3+/kg diet (at the highest concentration, the 
approximate intake of chromium was 7 mg Cr3+/kg bw 
per day) (Anderson et al., 1997). 
 
 In an intraperitoneal study, rats were injected with 
1, 2, or 4 mg chromium chloride/kg bw for 5 consecutive 
days, and no changes in histology or in epididymal 
sperm counts were seen (Ernst, 1990). Hexavalent 
chromium (as sodium chromate) at the same dose levels 
induced atrophy of the seminiferous tubules and a 
decrease in epididymal sperm numbers.  
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insulin-sensitive cells that involves LMWCr. This chro-
mium homeostasis is disturbed in Type I and Type II 
diabetes (Morris et al., 1999). 
 
 It has been shown that LMWCr isolated from rabbit 
liver enhances glucose oxidation and lipogenesis from 
glucose in rat adipocytes, whereas the activity is lost in 
chromium-depleted LMWCr (Yamamoto et al., 1989). 
LMWCr occurs in the apo form in insulin-sensitive cells 
and tightly binds four chromium ions to make 
holoLMWCr, the active form of the oligopeptide 
(Vincent, 1999, 2000; Clodfelder et al., 2001). Using 
isolated rat insulin receptor, LMWCr was shown to bind 
to insulin-activated insulin receptor, resulting in an 
increase of its tyrosine protein kinase activity (Davis & 
Vincent, 1997). LMWCr is believed to be part of an 
insulin signal amplification mechanism. In response to 
increases in the concentration of blood insulin, the 
chromium concentration in blood was found to decrease, 
presumably due to uptake of the element by insulin-
dependent cells, where it binds to generate the active 
LMWCr. LMWCr was proposed to stabilize the active 
conformation of insulin receptor, thus resulting in 
increased insulin signalling and subsequent cellular 
actions. 
 
9.2  Acute effects 
 
 A woman ingested 400 ml of a leather tanning 
solution containing 48 g of basic chromium sulfate and 
died of cardiogenic shock 36 h after admission to the 
hospital, in spite of intensive care, including haemo-
dialysis treatment. At postmortem, haemorrhagic erosive 
gastroenteritis of the entire gut, severe haemorrhagic 
pancreatitis, pulmonary congestion and oedema, 
peritonitis, ascites in the abdominal cavity, and 
widespread petaechial haemorrhages were found (Van 
Heerden et al., 1994). 
 
9.3  Irritation and sensitization 
 
9.3.1 Chromium(III) oxide 
 
 No human studies were located concerning irritation 
(skin and eyes) or sensitization by chromium(III) oxide.  
 
9.3.2 Inorganic chromium(III) salts 
 
9.3.2.1 Irritation 
 
 No studies were found that reported skin or eye 
irritation in humans exposed to inorganic chromium(III) 
salts.  
 
9.3.2.2 Sensitization 
 
 Skin sensitization among workers handling trivalent 
chromium salts appears to be a rare event. Two workers 
handling wet hides tanned with basic chromium sulfate 
developed work-related dermatitis of the hands, arms, 
and legs and were found to be sensitized to chromium 
(positive patch test to chromium chloride and potassium 
dichromate) as well as to a polyfunctional aziridine, 
another recognized contact allergen (Estlander et al., 
2000). It is possible that one of the sensitizers had 
enhanced the sensitization reaction to the other. Overall, 
although skin sensitization by basic chromium sulfate 
may occur in tanneries, the few cases reported in the 
open literature indicate that the risk is low. 
 
 Clinical evidence pointing to the potential of 
allergic skin reactions by soluble trivalent chromium 
salts mainly relates to the wearing of leather articles 
tanned with chromium (Oumeish & Rushaidat, 1980; 
Zachariae et al., 1996; Freeman, 1997). In a typical 
clinical report, the development of foot dermatitis linked 
with a positive skin reaction in a standard epicutaneous 
test performed with potassium dichromate (hexavalent 
chromium) in a patient not known to be previously 
sensitized to chromium suggests the causal inference 
that chromium leached from the leather shoe had caused 
sensitization. The cases reported over the last few 
decades involve a substantial number of persons, many 
of them having worn shoes in direct contact with the 
skin, such as sandals, and less frequently workers using 
wet gloves (Nygren & Wahlberg, 1998). The issue is, 
however, clouded by the fact that in a number of 
instances, low levels of hexavalent chromium may have 
been present in the leather (Hansen et al., 2002), which 
is a more likely cause than trivalent chromium, or that 
the reported cases of dermatitis may actually concern 
elicitation reactions in previously chromium-sensitized 
people. 
 
 Hansen et al. (2003) recently determined the 
minimum elicitation threshold (MET) concentrations for 
trivalent chromium chloride hexahydrate and potassium 
dichromate (hexavalent chromium) in chromium(VI)-
sensitive patients with mainly a leather-related history of 
previous chromium dermatitis but no active eczema. 
Dilution series of chromium(III) and chromium(VI) 
were applied on the skin of 18 patients using the 
standard Finn Chamber patch test method. The patches 
were left for 2 days, and readings were done on days 2, 
3, and 7. The concentration of either chromium(III) or 
chromium(VI) that resulted in 10% or 50% of the 
patients with a positive reaction was calculated from 
dose–response curves. According to the study, for 
chromium chloride, the MET10% was approximately 
0.18 µg/cm2 per 48 h, and the MET50% was approxi-
mately 2.7 µg/cm2 per 48 h. For potassium dichromate, 
the MET10% and the MET  were around 0.03 µg/cm250%  
per 48 h and 0.15 µg/cm2 per 48 h, respectively. The 
study showed that both chromium(III) and chromi-
um(VI) are capable of eliciting dermatitis at low 
concentrations in the same patient. The MET concen-
trations found by Hansen et al. (2003) for chromium(III) 
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were much lower than those found in earlier studies by 
Allenby & Goodwin (1983) and Nethercott et al. (1994). 
This difference might be explained by variation in the 
test methods or, possibly, by a change in the sensitivity 
of patients due to changes in exposure patterns over the 
years. 
 
 Park et al. (1994) reported on four workers with 
asthma caused by chromium. Two patients were exposed 
to chromium in metal plating (chromium compounds not 
specified, but most likely chromium(VI)), one in the 
cement industry (exposure to chromium(VI)), and one in 
construction work (exposure to chromium(VI)). Two of 
the patients (one of the metal plating workers and the 
cement industry worker) showed positive skin prick tests 
to 10 mg chromium sulfate/ml in saline, indicating 
immediate-type immunological reactivity to trivalent 
chromium compounds. The former worker, but not the 
latter, was also found to be an atopic. The remaining two 
patients, both with atopy, showed positive responses to 
0.5% potassium dichromate in a patch test, but none of 
the four patients exhibited contact dermatitis. A bron-
chial provocation test was carried out by administering 
chromium sulfate solutions at increasing concentrations 
of 0.1, 1, and 10 mg/ml in saline, each for 10 min, with a 
nebulizer. Asthmatic responses developed in all cases. 
When the same bronchial provocation tests were per-
formed in two patients with intrinsic asthma as well as in 
two healthy controls without any history of exposure to 
chromium, none of them showed a positive response 
after the inhalation of chromium sulfate up to 10 mg/ml. 
 
 There is at present no unequivocal evidence to show 
that exposure to trivalent chromium compounds has 
induced occupational asthma, whereas exposure to the 
fumes of hexavalent chromium (e.g. in electroplating) 
may induce occupational asthma, possibly by an 
immunoglobulin E (IgE)-mediated reaction (Shirakawa 
& Morimoto, 1996). However, among four persons with 
clinical asthma from occupational exposure to hexa-
valent chromium, a bronchial provocation test with 
nebulized chromium sulfate hydrate solution elicited 
clear asthmatic responses. Thus, trivalent chromium 
compounds cannot be regarded as respiratory sensitizers.  
 
9.4  Chronic toxicity 
 
9.4.1 Mortality and morbidity studies 
 
 Mortality has been investigated in worker cohorts 
from different areas of industrial activity involving 
exposure to chromium alloys, chromium oxide, or 
trivalent chromium salts. Although the investigators 
have primarily been interested in the occurrence of 
cancer (see section 9.6), other causes of death by organ 
system have been reported as well. No increased 
standardized mortality rates for diseases of the circula-
tory system, ischaemic heart disease, or diseases of the 
respiratory system were found in ferrochromium and 
stainless steel production workers (Moulin et al., 1990, 
1993), among workers grinding, brushing, and polishing 
stainless steel articles (Svensson et al., 1989), or among 
tannery workers (Puntoni et al., 1984; Stern et al., 1987; 
Costantini et al., 1989; Mikoczy et al., 1994; Stern, 
2003). 
 
 Korallus et al. (1974a) described the circumstances 
of exposure to chromium compounds and gave a 
retrospective overview (since the late 1940s) on the 
causes of death, and health reasons for shifting to other 
jobs, among workers engaged in chromium oxide 
production (54 workers) and basic chromium sulfate 
production (74 workers) in a German plant. Some 
measured exposure data were provided in a different 
publication (Korallus et al., 1974c). Basic chromium 
sulfate production workers also rotated to work 
occasionally at the chromic acid plant, which thus 
implied exposure to hexavalent chromium. The authors 
reported on the types of tumours and numbers of cases 
found in the workforce and provided crude descriptions 
of the causes of death and the causes of sickness-related 
pensioning or sickness-related shifts to other jobs, with 
the numbers of cases involved. No conclusions about 
risks or etiological factors can be drawn from the 
descriptive data. However, the authors noted that in the 
spectrum of illnesses, there was no emphasis on the 
occurrence of chronic obstructive pulmonary disease and 
that no cases of skin sensitization to chromium(III) 
(“allergic reactions”) were found.  
 
 Another report from the same plant (Korallus et al., 
1974b) analysed the occurrence of unfitness to work 
based on medical (sick leave) documents registered in 
the company health insurance scheme. The data sug-
gested higher representation of the diagnoses of asthma, 
bronchitis, and acute illnesses of the upper airways in the 
sick leaves among basic chromium sulfate workers when 
compared with chromium oxide workers. The paper did 
not make reference to the fact that the basic chromium 
sulfate workers occasionally worked at the chromic acid 
plant. 
 
 The third report involving the same plant concerned 
clinical examinations of 106 workers from the two 
above-mentioned work areas (Korallus et al., 1974c). 
The paper provides summary data on symptoms, 
smoking habits, physical examination, lung function 
(forced vital capacity [FVC], forced expiratory volume 
in 1 s [FEV1.0]), haematological and clinical chemical 
examinations, chromium measurements in blood and 
urine (by AAS), and chest radiography. The authors 
concluded from their investigations that the prevailing 
exposures to chromium oxide or basic chromium sulfate 
in the plant caused no serious health impairment, even 
after exposure for years. In the report, one may note that 
five workers exhibited nasal septum perforation. 
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Inadequate methodologies used in these investigations 
and mixed exposure to chromic acid among basic 
chromium sulfate workers do not, however, allow any 
certain conclusions to be drawn about health risks due to 
chromium(III) compounds. 
 
9.4.2 Respiratory effects 
 
 Cross-sectional worker surveillance studies focused 
on the respiratory system were conducted involving 
exposures to chromium oxide in the mining and con-
centration of chromite ore and in the production of 
ferrochromium and stainless steel (Ballal, 1986; 
Huvinen et al., 1996, 2002a,b). A similarly oriented 
study concerned polishers in a tannery with exposure to 
trivalent chromium salts (Bulikowski & Tyras, 1985).  
 
 Chromite ore is up to 50% chromium oxide. In 
Finnish chromite mine dust, one third was chromite, one 
third talc, and one third chlorite serpentine, part of which 
can be classified as fibres (Huvinen et al., 1996). Chro-
mite miners in Sudan exposed to extremely high dust 
levels (up to 224 mg/m3) exhibited an increased 
prevalence of chronic bronchitis or asthma (Ballal, 
1986), whereas their Finnish counterparts exposed to 
low or moderate dust levels (mean of 1 mg/m3 in the 
mine and up to 4.9 mg/m3 in the crushing plant) showed 
an increased prevalence of some respiratory symptoms 
and decreased values in some lung function parameters 
(Huvinen et al., 1996, 2002b). However, the complex 
exposures involved do not allow any conclusions to be 
drawn about the potential respiratory toxicity of chro-
mium oxide. 
 
 Exposures more focused on chromium oxide–
containing dust are involved in certain parts of 
ferrochromium production. Huvinen et al. (1996) 
explored respiratory health in ferrochromium workers 
exposed to chromium(III)–containing dust in grinding, 
pelletizing, and sintering of concentrated chromite and 
crushing of cooled ferrochromium castings and repeated 
the study after a 5-year follow-up (Huvinen et al., 
2002b). The average duration of the work history was 
21 years (range 9–27 years). A group of 95 workers 
from the stainless steel cold rolling mill served as 
controls. The workers involved were specifically 
exposed to dusts containing chromium(III) (Cr3+ group), 
since their work areas were separated from the smelting 
furnaces where some hexavalent chromium was 
generated. In the sintering and crushing departments, the 
average total dust exposure was 2.4 mg/m3. No data on 
the particle size distribution were given. The dust was 
estimated to contain 10–20% chromium, which would 
give approximately 240–480 µg Cr3+/m3. The frequen-
cies of smokers, ex-smokers, and non-smokers were 
39%, 32%, and 29%, respectively; current smoking was 
somewhat less frequent than among the controls. Com-
pared with the control group, work-related cough or 
dyspnoea, production of phlegm, and shortness of breath 
when hurrying on level ground occurred significantly 
more frequently in the Cr3+ group. The lung function 
variables did not differ from the controls except for 
FVC, which was lower among smokers than in the 
smoking controls. In the radiographs of the chest, the 
frequency of small opacities was not significantly 
different between the Cr3+ group and the control group, 
and their occurrence increased with age in both groups. 
However, there were more individuals with more severe 
findings in the Cr3+ group. 
 
 In the 5-year follow-up study (Huvinen et al., 
2002b), 68 persons of the original Cr3+ group were re-
examined, as well as 81 workers from the original 
control group. There was a slightly lower fraction of 
current smokers in both groups compared with the 
original study groups. The Cr3+ group still exhibited a 
higher frequency of shortness of breath (non-smokers) 
and phlegm (current and ex-smokers) than correspond-
ing groups of controls. Lung functions, smokers plus ex-
smokers and non-smokers separated, did not show any 
differences between workers in the Cr3+ group and the 
controls. Thus, the changes over the preceding 5-year 
period had been parallel. In one Cr3+ worker, the pro-
fusion of small opacities in the chest radiograph had 
progressed. Because the same pattern of symptoms in 
the Cr3+ group occurred consistently in both the original 
and the follow-up study and could not be explained by 
smoking habits, the authors proposed that the reason for 
the symptoms was irritation, although they could not 
identify an obvious causative agent. 
 
 In a separate study, 14 workers of the sintering and 
crushing departments (Cr3+ group) and 39 referents from 
the stainless steel cold rolling mill were examined for 
nasal symptoms, appearance of nasal mucosa, muco-
ciliary clearance (saccharine test), and nasal cytology 
(Huvinen et al., 2002a). There were no remarkable 
findings in nasal cytology and no indication of impaired 
mucociliary clearance. In anterior rhinoscopy, infected 
and atrophic mucous membranes tended to occur more 
frequently in the Cr3+ group than among the referents, 
but without statistical significance. 
 
 A pilot health study in a Polish tannery (Bulikowski 
& Tyras, 1985) concerned 24 polishers (12 men and 12 
women) of chrome-tanned dried leather with 2–20 years 
of employment in this job. The authors used 21 office 
workers as a control group. The average concentration of 
the leather dust was reported as 2 mg/m3, and the geo-
metric mean particle size was 2.2 µm. The leather dust 
contained 5.8% chromium; that is, airborne chromium 
levels were about 0.1 mg/m3 (only trivalent chromium 
was mentioned). Among the polishers, the mean post-
shift urinary chromium concentration at the end of the 
work week, measured with a photocolorimetric method, 
was given as 0.030 mg/l. Epicutaneous tests showed that 
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none of the workers had been sensitized to chromium. In 
a laryngological examination, 14 of the 24 polishers 
were reported to exhibit chronic tonsillitis, 5 had chronic 
hypertrophic rhinitis, and 1 had atopic rhinitis as well as 
chronic bronchitis. No laryngological findings were 
reported for the controls. In haematological examina-
tions of the peripheral blood, eosinophils were found to 
occur in significantly higher concentrations among the 
polishers than in control subjects. In blood samples 
obtained from the nasal turbinate and the fingertip, there 
was a significant difference (direction of change not 
given) in the concentration of monocytes between the 
exposed and the controls. Furthermore, the polishers 
frequently experienced a slight rise in body temperature 
on the 1st day of the work week, which the authors 
attributed to airborne bacteria. The findings suggested 
that chrome-tanned leather dust caused chronic 
inflammation in the upper airways, especially in the 
pharynx. Although the reported airborne chromium 
concentration was rather low (average about 0.1 mg/m3), 
the authors attributed the observed effect to airborne 
trivalent chromium, but failed to show evidence to 
exclude other potential causes (e.g. finishing chemicals 
in the leather, airborne microbes, or microbial toxins). 
 
9.5  Genotoxicity  
 
 Studies of the genotoxicity of trivalent or metallic 
chromium in humans in vivo have concerned workers 
occupationally exposed to chromium in leather tanner-
ies, ferrochromium works, chromite mines, metal 
workshops, and dental laboratories, residents living near 
chromium dumpsites, and patients exposed to chromium 
released from prostheses. In most cases, the exposure 
has been complex (Riihimäki & Luotamo, 2006). 
 
 Iraqi tannery workers (n = 17) handling chrome 
alum (chromium potassium sulfate) did not show an 
increase in (total) chromosomal aberrations in cultured 
peripheral lymphocytes in comparison with unexposed 
control subjects (n = 13) (Hamamy et al., 1987). When 
smoking tannery workers (n = 9) were compared with 
smoking controls (n = 7), a statistically significantly 
higher (2.19-fold) frequency of chromosome-type 
aberrations was noted.  
 
 Italian workers employed in the drum workshop of 
the tanning process (n = 19) and in the finishing depart-
ment (n = 17) of tanneries and two control groups (n = 
19 and n = 17) of unexposed administrative office staff 
were studied for the frequency of chromosomal aberra-
tions and micronuclei in cultured peripheral lymphocytes 
(Sbrana et al., 1990; Migliore et al., 1991). The drum 
workshop workers showed a 3.2-fold statistically 
significant increase in the mean frequency of cells with 
chromosomal aberrations, and the finishing department 
workers showed a statistically non-significant increase in 
chromosomal aberrations. No increase in micronucleated 
cells was observed in the drum workshop workers or the 
finishers. The influence of chromium(III) is, however, 
difficult to assess as a result of the other exposures 
involving genotoxic compounds (Riihimäki & Luotamo, 
2006). 
 
 The same problem with complex exposures also 
applies to studies performed in Turkey and Portugal 
showing an increased incidence of markers of genotoxic 
damage in leather tannery workers when compared with 
controls (González Cid et al., 1991; Medeiros et al., 
2003).  
 
 In ferrochromium production, a slight (statistically 
non-significant) increase in the frequency of chromo-
somal aberrations in cultured peripheral lymphocytes 
was observed in 28 workers of a furnace sector of an 
Italian ferrochromium plant, in comparison with 14 
matched control persons and 7 general controls (Sbrana 
et al., 1990). However, the furnace workers may have 
also been exposed to chromium(VI). Workers from 
crushing and milling departments (n = 7), expected to be 
exposed to trivalent chromium, and workers in a 
machine shop (n = 8) did not differ from the controls in 
frequencies of cells with chromosomal aberrations.  
 
 Finnish workers (all non-smokers) exposed to 
chromium(III) in a chromite ore mine (n = 5) and in 
sintering and crushing departments of a ferrochromium 
works (n = 14) showed no increase in nasal cells with 
micronuclei, in comparison with unexposed referents 
(n = 39) (Huvinen et al., 2002a). The average dust con-
tent in the air of the chromite ore mine was 1 mg/m3, and 
the median personal level of exposure to total chromium 
was 22 µg/m3. Chromium(VI) was not detected in the 
samples. At the sintering and crushing departments, the 
average dust level in the air was 2.4 mg/m3, and the 
average exposure to total chromium was 248 µg/m3. 
Chromium remains in a trivalent state in these steps of 
the process.  
 
 Residents of Hudson County, USA, living near large 
chromium dumpsites of waste from mine slags and 
chromite ore processing residues used as landfill and in 
construction of roads and buildings, with urinary chro-
mium levels ≥0.5 µg/l, were found to have a statistically 
significantly higher mean level of DNA–protein cross-
links (1.3%; n = 33) in their mononuclear leukocytes 
compared with unexposed controls (0.8%; n = 49) 
(Taioli et al., 1995). 
 
 Three studies have suggested that patients with hip 
replacements or fracture fixation devices containing 
metallic chromium, among other components, have an 
increased frequency of various types of chromosomal 
damage (Case et al., 1996; Savarino et al., 2000; 
Doherty et al., 2001). Although these patients often 
show elevated levels of serum chromium, it is unclear if 
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 In a French study (Moulin et al., 1990), among 
workers producing ferrochromium and stainless steel, 
lung cancer mortality was in excess, but the link was 
stronger for polycyclic aromatic hydrocarbons than for 
chromium exposure. A further study (Moulin et al., 
1993) was aimed at assessing the potential risk of lung 
cancer related to occupational exposures when produc-
ing stainless steel. No significant excess of lung cancer 
was found in the manufacture of ferroalloys and in the 
melting and casting of stainless steel, whereas a signif-
icant excess was observed among workers with more 
than 30 years of employment in the foundry area. 
However, Moulin et al. (1993) could not point at a 
specific causal factor because of the many simulta-
neously occurring exposures (chromium, nickel, silica, 
asbestos, and polycyclic aromatic hydrocarbons) in the 
industry.  
the increased incidence of cytogenetic alterations is due 
to chromium, other metals, or other substances released 
as particles or ions from the prostheses, or the inflam-
matory reaction associated with the released particles.  
 
9.6  Carcinogenicity 
 
 Epidemiological carcinogenicity studies that may be 
relevant to trivalent chromium concern occupational 
exposures in ferrochromium production, leather tanning, 
and chromate production. In ferrochromium operations, 
insoluble trivalent chromium as concentrated chromite 
and chromium oxide predominates, but soluble hexa-
valent chromium species also occur at smelting furnaces 
(Huvinen et al., 1996). Leather tanning with chromium 
is currently based on trivalent basic chromium sulfate, 
but hexavalent chromium was used in the two-bath 
process before the Second World War. Moreover, it 
must be noted that tanneries have also used a wide 
variety of biocides, dyes, pigments, and solvents, 
including recognized carcinogens (Stern et al., 1987; 
Costantini et al., 1989; Mikoczy et al., 1994). In 
chromate production, although the starting material is 
trivalent chromium (chromite), further stages of the 
process deal with hexavalent chromium in the form of 
chromate and dichromate, and separation of the effects 
for tri- and hexavalent chromium species will be 
problematic, if not impossible. Chromium electroplating 
is currently performed with both hexavalent chromium 
(the predominant process) and trivalent chromium. The 
latter found use only about 20 years ago and is still not 
widely applied. Therefore, cancer risks observed in past 
research among electroplating workers cannot be 
directly associated with trivalent chromium. 
 
 The previous French study cohort of 4900 workers 
was followed up until 1992 (Moulin et al., 2000), and 
the workers’ exposures were carefully assessed. An 
induction period of 10 years for lung cancer was 
assumed. All potential confounders (i.e. smoking and 
known occupational exposures), which in a univariate 
analysis seemed to have an effect, were adjusted for 
using a conditional logistic regression analysis. In a 
case–referent study nested in the cohort, no excess 
mortality from lung cancer was observed. The authors 
concluded that the study failed to demonstrate any 
relationship between lung cancer and exposure to 
chromium (predominantly chromium(III)) or its 
compounds. 
 
 There are few studies on cancer risk in tannery 
workers available. In a retrospective study involving 
9365 chrome leather tannery workers in two tanneries in 
the USA, mortality from all causes and deaths from 
cancers were lower than expected (Stern et al., 1987). In 
a follow-up of this cohort for an additional 11 years with 
data on vital status and work histories and 1153 new 
deaths, no elevation in any primary cause of death was 
seen, with the exception of lung cancer in one tannery 
when state death rates were used as a standard (Stern, 
2003). However, in an Italian tannery study, no excess of 
cancers of all sites was seen, but slight, statistically non-
significant increases were shown in deaths from cancers 
of the lung, bladder, kidney, and pancreas and leukaemia 
(Costantini et al., 1989). In a Swedish cohort of 2026 
workers, a significantly increased incidence of soft tissue 
sarcomas based on only five cases was found among 
tannery workers. Non-significant excesses were also 
found in multiple myelomas and sinonasal cancer 
(Mikoczy et al., 1994). Because of the exposure to 
multiple carcinogens in tanneries, these studies are 
inconclusive regarding trivalent chromium. In the 
Swedish study (Mikoczy et al., 1994), the researchers 
hypothesized that the increased risk of soft tissue 
 
 A cancer mortality and morbidity study in a popu-
lation of male workers employed for at least 1 year 
between 1930 and 1975 at a Swedish plant producing 
ferrochromium alloys from chromite ore showed no 
increased death rate or an increase in the incidence of 
cancer (Axelsson et al., 1980). Levels of chromium 
exposure were based on estimations; no measured data 
existed.  
 
 A Norwegian study (Langård et al., 1990) that 
included all male workers employed in ferrochromium 
and ferrosilicon production for at least 1 year from 1928 
onwards showed a significant excess of lung cancer risk 
in the ferrochromium subgroup when using all non-
ferrochromium workers as a reference group. However, 
measurements conducted in ferrochromium production 
in 1975 indicated that hexavalent chromium constituted 
11–33% of total chromium in the work atmosphere. 
Hence, the study could not address the question of 
whether exposure to chromium(III) was carcinogenic in 
humans. 
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sarcomas could be related to chlorophenols, which had 
been used in all three plants investigated.  
 
 Mancuso (1997) and Gibb et al. (2000) addressed 
the question of whether chromium(III) exposure, like 
chromium(VI) exposure, is associated with an excess 
lung cancer risk in chromate production workers. 
Mancuso (1997) followed up successive cohorts by year 
of hire (1931–1937) at the same chromate manufacturing 
plant, 332 workers in total, through 1993. There were no 
smoking data available. Based on measured atmospheric 
concentrations in 1949, an exposure index was formed 
as a weighted average of exposure to total insoluble 
(mainly trivalent) and total soluble (essentially hexa-
valent) chromium in the departments where the worker 
was assigned during his work history. Lung cancer death 
rates increased by gradient level of exposure to insoluble 
(trivalent) and soluble (hexavalent) chromium. To inves-
tigate whether the relationship was due to one form of 
chromium compound, either chromium(III) or chro-
mium(VI), the age-adjusted death rates for the two 
compounds were cross-classified by the level of total 
chromium. Mancuso (1997) concluded that all forms of 
chromium were carcinogenic. However, from tabled data 
of the exposure distributions, it is evident that chromi-
um(III) and chromium(VI) are highly correlated. Even 
an appropriate statistical analysis might not be able to 
discriminate the separate effects of these compounds 
when collinearity is high (Nurminen, 2005). 
 
 Gibb et al. (2000) studied the mortality experience 
in a cohort of 2357 workers first employed between 
1950 and 1974 at a chromate production plant. The 
follow-up lasted until the end of 1992. Annual average 
exposure estimates, based on historical exposure 
measurements for each job title in the plant for the years 
1950–1985, were made to construct a job–exposure 
matrix, and cumulative chromium(VI) exposures for 
each member of the study population were calculated. 
Following closure of the plant, settled dust samples were 
collected and analysed for hexavalent and trivalent 
chromium. The trivalent/hexavalent concentration ratios 
in each plant area were combined with historic air 
sampling data to estimate cumulative chromium(III) 
exposure for each individual in the study cohort. 
Smoking status and clinical signs of potential chromium 
irritation were identified from company records. A lag 
period of 5 years was assumed for the illnesses. Using 
Cox models for three different exposure measures, 
cumulative hexavalent chromium exposure, cumulative 
trivalent chromium exposure, and work years were 
found to be roughly equivalent in predictive ability when 
smoking was included in the model, and each of these 
exposure measures was significantly associated with 
increased lung cancer risk. There was a strong correla-
tion between the log of cumulative chromium(VI) expo-
sure and the log of chromium(III) exposure (correlation 
coefficient = 0.95). The authors utilized two proportional 
hazard models, one incorporating the log of cumulative 
hexavalent chromium exposure, the log of cumulative 
trivalent chromium exposure, and smoking, the other 
incorporating the log of cumulative hexavalent chro-
mium exposure, work duration, and smoking. The 
inclusion of the three exposure variates as risk factors in 
the same model resulted in cumulative chromium(VI) 
exposure remaining statistically significant, although at a 
lower significance level, whereas the other measures lost 
statistical significance. Thus, although cumulative 
hexavalent chromium exposure was associated with an 
increased lung cancer risk, cumulative trivalent chro-
mium exposure was not. The authors concluded that 
their study provided no evidence that trivalent chromium 
is carcinogenic, and if it is indeed carcinogenic, it is 
much less so than hexavalent chromium (Gibb et al., 
2000). 
 
9.7   Sensitive subpopulations 
 
 There are no data available on subpopulations being 
at extra risk for health hazards caused by inorganic 
trivalent chromium. 
 
 
 
10. EFFECTS ON OTHER ORGANISMS IN 
THE LABORATORY AND FIELD 
 
 
10.1 Essentiality 
 
 Chromium(III) is required by only some micro-
organisms for specific metabolic processes, such as 
glucose metabolism and enzyme stimulation (Hughes & 
Poole, 1989). Huffman & Allaway (1973) demonstrated 
that chromium was not an essential component of plant 
nutrition.  
 
 Chromium(III), in trace amounts, has been reported 
to be an essential component of animal nutrition and is 
most notably associated with glucose and fat metabolism 
(Mertz, 1969). However, whereas NAS (1997) reported 
that chromium has been shown to be essential for 
glucose metabolism in some laboratory mammals, 
studies on other animals are equivocal. The literature 
does not support a general recommendation for chro-
mium supplementation of commercial ruminant diets. 
However, two situations have been identified in which 
chromium supplementation might be beneficial: follow-
ing the transportation of cattle, and first-lactation dairy 
cattle during the transition period (NAS, 1997). 
Although responses of pigs to supplemental chromium 
are inconsistent, there is an increasing amount of 
evidence indicating that chromium may favourably alter 
metabolism of pigs under some circumstances, with 
resultant improvements in growth rate, carcass traits, and 
reproductive performance (NAS, 1997). Chromium 
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deficiency in rabbits has not been demonstrated, but 
positive effects of chromium on cholesterol metabolism 
and sucrose utilization have been reported (NAS, 1997). 
Investigations concerning the influences of dietary 
chromium on fish are limited. Some studies reported no 
effect on growth or tissue chromium distribution, 
whereas others showed that chromium supplementation 
of diets, especially those containing glucose, caused 
significant increases in weight gain, energy deposition, 
and liver glycogen and altered postprandial plasma 
glucose concentrations (NAS, 1997). Research with 
poultry has shown that supplemental dietary chromium 
can be used to alleviate some of the toxic effects of 
vanadium in growing chicks and laying hens. Evidence 
has also been obtained that supplemental chromium at 
20 mg/kg diet as chromium(III) chloride increases the 
rate of glucose utilization by livers of chicks and poults 
in vivo and in vitro. However, the results from experi-
ments to determine the effect of added dietary chromium 
on growth rate and feed efficiency of growing poultry 
are inconsistent (NAS, 1997).  
 
10.2 Aquatic organisms 
 
 The available toxicity data for chromium(III) have 
been mainly derived using the water-soluble forms 
(chromium(III) chloride, chromium(III) nitrate, and 
chromium potassium sulfate). In the environment, 
chromium(III) is likely to be present in much less 
soluble forms and hence less bioavailable to aquatic 
organisms. 
 
 The toxicity of trivalent chromium to aquatic 
organisms is summarized in Table 3. Ninety-six-hour 
median effective concentrations (EC50s) for one 
freshwater alga, based on growth, ranged from 0.3 to 
0.4 mg chromium(III)/l. A 96-h EC50, based on growth, 
was reported for a marine diatom at 2 mg chromi-
um(III)/l. Median lethal concentrations (LC50s) in 
freshwater invertebrates ranged from 0.1 mg/l (Daphnia 
pulex) to 442 mg/l (Asellus aquaticus), with a 21-day no-
observed-effect concentration (NOEC) (reproduction) of 
0.7 mg/l and a life cycle NOEC of 0.047 mg/l for 
Daphnia magna. LC50s ranging from 10 to 100 mg/l 
have been reported for marine invertebrates. Ninety-six-
hour LC50s for freshwater fish range from 3.3 mg/l for 
the guppy (Poecilia reticulata) to 151 mg/l for the 
bighead (Aristichthys nobilis), whereas 96-h LC50s of 
31.5 and 53 mg/l were reported for marine fish. A 72-
day NOEC (survival) of 0.05 mg/l was reported for 
rainbow trout (Oncorhynchus mykiss). 
 
 Trivalent chromium is generally less toxic than 
hexavalent chromium in algae and aquatic invertebrates. 
In both aquatic invertebrates and fish, chromium(III) is 
more toxic in soft waters than in hard waters (Pickering 
& Henderson, 1966; US EPA, 1985). Stackhouse & 
Benson (1989) found a decrease in chromium(III) 
toxicity with increasing humic acid levels. The main 
features of trivalent chromium toxicity to algae are 
inhibition of growth (Nollendorf et al., 1972) and 
inhibition of various metabolic processes, such as 
photosynthesis and protein synthesis (USEPA, 1978). 
The high deposition of chromium(III) in fish gills leads 
to tissue damage, including hyperplasia, clubbing of 
lamellae and necrosis, and the impairment of the ability 
to osmoregulate and respire (Moore, 1991).  
 
 Walsh et al. (1994) studied the effect of chromi-
um(III) effluent from a tannery on marine grey mullet 
(Chelon labrosus). Fish exposed for 2 months to con-
taminated sediment (46 mg chromium/kg dw) and food 
(Enteromorpha intestinalis [9.4 mg/kg] and Mytilus 
edulis [6 mg/kg]) showed no adverse effects on growth, 
mortality, or gross tissue damage. Significant bioaccu-
mulation was measured in livers of exposed fish; how-
ever, chromium levels in liver samples from fish at the 
contaminated site were not significantly higher than 
those of controls. 
 
10.3 Terrestrial organisms 
 
 The toxicity of chromium to soil bacterial isolates 
was studied by measuring the turbidity of liquid cultures 
supplemented with trivalent chromium. Gram-negative 
bacteria were more affected by hexavalent chromium 
(1–12 mg/kg) than were Gram-positive bacteria. 
Toxicity due to trivalent chromium was not observed at 
similar levels (Ross et al., 1981).  
 
 The results of short-term tests indicate that a variety 
of effects are induced in soil microbes at concentrations 
ranging from 25 to 100 mg chromium(III)/kg dw, such 
as changes in species abundance, respiration, nitrogen 
transformation, and enzyme activities (Tabatabal, 1977; 
Drucker et al., 1979; Chang & Broadbent, 1981, 1982; 
Ross et al., 1981). In long-term tests, the addition of 
10 mg chromium(III)/kg dw affected the arylsulfatase 
activity, whereas soil respiration was affected at 
150 mg/kg and phosphatase activity at 280 mg/kg (IPCS, 
1988). Crommentuijn et al. (1997) reviewed the toxicity 
of chromium(III) to soil processes. The results of 51 
determinations were reported, covering arylsulfatase, 
nitrification, nitrogen mineralization, phosphatase, 
respiration, and urease. The test results (mainly 
expressed as lowest-observed-effect concentrations 
[LOECs]) ranged from 1 to 3332 mg/kg dw (both values 
being for arylsulfatase). All studies used soluble 
chromium(III) compounds, largely chromium(III) 
chloride. Data were selected from this survey, taking 
values where a NOEC was obtained directly or where 
the LOEC related to an effect level of 20% or less (and 
using LOEC/2 as the NOEC), in the European Union 
Risk Assessment Report (EU, 2005). A total of 37 
values were obtained, and a further selection was made, 
giving preference to longer exposure times in the same 
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Table 3: Toxicity of trivalent chromium to aquatic species.a 
 
Organism End-point 
Chromium 
salt 
Concentration (mg 
chromium/l) Reference 
Microorganisms     
    Freshwater 
Green alga (Selenastrum 
capricornutum) 
24-h EC50  – >1 Turbak et al. (1986) 
 96-h EC50 (growth) Chloride 0.4 USEPA (1985) 
 96-h EC50 (biomass) Chloride 0.3 Greene et al. (1988) 
 14- to 21-day EC50 
(biomass) 
– 0.6 Turbak et al. (1986) 
Protozoan (Tetrahymena 
pyriformis) 
9-h IC50 (growth) Chloride 50 Sauvant et al. (1995) 
    Marine 
Diatom (Ditylum brightwellii) 96-h EC Chloride 2 Canterford & Canterford (1980) 50
Invertebrates     
    Freshwater 
8.4 Snail (Amnicola sp.) 96-h LC – Rehwoldt et al. (1973) 50
9.3 Annelid worm (Nais sp.) 96-h LC – Rehwoldt et al. (1973) 50
bWater flea (Daphnia magna) 48-h LC Nitrate 17–59 USEPA (1985) 50
 24-h EC50 
(immobilization) 
Chloride 22 Kühn et al. (1989) 
 21-day NOEC 
(reproduction) 
Chloride 0.7 Kühn et al. (1989) 
 21-day LC Chloride 2 Biesinger & Christensen (1972) 50
 21-day EC50 
(reproductive 
impairment) 
Chloride 0.6 Biesinger & Christensen (1972) 
c Life cycle NOEC Nitrate 0.047 and 0.129 USEPA (1985) 
dWater flea (Daphnia pulex) 96-h LC Chloride 0.1–6 Stackhouse & Benson (1989) 50
Water hoglouse (Asellus aquaticus) 96-h LC Chloride 442 Martin & Holdich (1986) 50
3.2 Amphipod (Gammarus sp.) 96-h LC – Rehwoldt et al. (1973) 50
Amphipod (Crangonyx 
pseudogracilis) 
96-h LC Chloride 291 Martin & Holdich (1986) 50
Crayfish (Austropotamobius 
pallipes) 
96-h LC Chloride 3.4 Boutet & Chaisemartin (1973) 50
Crayfish (Orconectes limosus) 96-h LC Chloride 6.6 Boutet & Chaisemartin (1973) 50
Mayfly (Ephemerella subvaria) 96-h LC Chloride 2 Warnick & Bell (1969) 50
Caddis fly (Hydropsyche betteni) 96-h LC Chloride 64 Warnick & Bell (1969) 50
50 Caddisfly (unidentified) 96-h LC – Rehwoldt et al. (1973) 50
Stonefly (Acroneuria lycorias) 7-day LC Chloride 32 Warnick & Bell (1969) 50
43.1 Damsel fly (unidentified) 96-h LC – Rehwoldt et al. (1973) 50
11 Midge (Chironomus sp.) 96-h LC – Rehwoldt et al. (1973) 50
    Marine 
eAmerican oyster (Crassostrea 
virginica) 
48-h LC Chloride 10.3 Calabrese et al. (1973) 50
Polychaete (Ophryotrocha 
diadema) 
48-h LC – 100 Parker (1984) 50
Polychaete (Neanthes 
arenaceodentata) 
293-day NOEC 
(behaviour and 
reproduction) 
Chloride 50.4 Oshida et al. (1981) 
Brown mussel (Perna perna) 1-h EC50 (filtering 
rate) 
Chloride 2 Watling & Watling (1982) 
Crab (Sesarma haematocheir) zoea 96-h LC – 56 USEPA (1985) 50
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Table 3 (continued) 
Concentration (mg 
chromium/l) Organism End-point 
Chromium 
salt Reference 
Fish     
   Freshwater  
96-h LCRainbow trout (Oncorhynchus 
mykiss) 
Nitrate 24.1 Hale (1977) 50
– 11.2 Bills & Marking (1977) 96-h LC50
 96-h LC Nitrate 4.4 Stevens & Chapman (1984) 50
 72-day NOEC 
(survival)
Nitrate 0.05 Stevens & Chapman (1984) 
f
4.1 Goldfish (Carrasius auratus) 96-h LC Potassium 
sulfate 
Pickering & Henderson (1966) 50
 96-h LC – 98 Wong et al. (1982) 50
gCommon carp (Cyprinus carpio) 96-h LC – 14.3 Rehwoldt et al. (1972) 50
hFathead minnow (Pimephales 
promelas) 
96-h LC Potassium 
sulfate 
5.1–67.4 Pickering & Henderson (1966) 50
hBluegill (Lepomis macrochirus) 96-h LC Potassium 
sulfate 
7.5–71.9 Pickering & Henderson (1966) 50
gPumpkinseed (Lepomis gibbosus) 96-h LC – 17 Rehwoldt et al. (1972) 50
gBanded killifish (Fundulus 
diaphanous) 
96-h LC – 16.9 Rehwoldt et al. (1972) 50
gStriped bass (Roccus saxatilis) 96-h LC – 17.7 Rehwoldt et al. (1972) 50
gWhite perch (Roccus americanus) 96-h LC – 14.4 Rehwoldt et al. (1972) 50
Bighead (Aristichthys nobilis) 96-h LC – 151 Wong et al. (1982) 50
3.3 Guppy (Poecilia reticulata) 96-h LC Potassium 
sulfate 
Pickering & Henderson (1966) 50
gAmerican eel (Anguilla rostrata) 96-h LC – 13.9 Rehwoldt et al. (1972) 50
    Marine 
iMummichog (Fundulus heteroclitus) 96-h LC Chloride 31.5 Dorfman (1977) 50
Yellow eye mullet (Aldrichetta 
forsteri) 
96-h LC Nitrate 53 Negliski (1976) 50
EC , median effective concentration; IC , median inhibitory concentration; LC50 50 50, median lethal concentration; NOEC, no-observed-
effect concentration 
a  All freshwater tests conducted at a hardness of <100 mg calcium carbonate/l unless otherwise stated. 
b  Hardness ranging from 52 to 215 mg calcium carbonate/l. 
c  Hardness 52 and 100 mg calcium carbonate/l. 
d  Humic acid concentration ranging from 0 to 50 mg/l. 
e  Visible precipitate. 
f  Newly fertilized eggs to 30-day post-swim-up. 
g  Temperature = 28 °C (not significantly different from tests performed at 15 °C). 
h  Hardness ranging from 20 to 360 mg calcium carbonate/l. 
i  Salinity 6–24‰. 
 
 
studies, resulting in a final data set of 30 values. The 
statistical extrapolation method was then used to derive 
an HC5(50) value (the hazardous concentration for 5% of 
species, with a 50% confidence level) of 5.9 mg/kg dw. 
 
 Although chromium is present in all plants, it has 
not been proved to be an essential element for plants. 
Chromium can be absorbed through either the root or the 
leaf surface. Several factors affect the availability of 
chromium for the plant, including the pH of the soil, 
interactions with other minerals or organic chelating 
compounds, and carbon dioxide and oxygen concen-
trations (Black, 1968; IPCS, 1988). The main feature of 
chromium intoxication is chlorosis, which is also caused 
by iron deficiency. Although both chromium(III) and 
chromium(VI) are equally available to plants grown in 
nutrient solutions (NRCC, 1976), the results of most 
studies indicate that chromium(VI) is consistently more 
toxic than chromium(III) (IPCS, 1988). Whereas the 
toxic properties of hexavalent chromium originate from 
its action as an oxidizing agent, trivalent chromium 
causes toxic effects in plants as a result of its ability to 
coordinate various organic compounds, resulting in 
inhibition of some metalloenzyme systems. At high 
concentrations, chromium(III) can generate reactive 
oxygen species (Shanker et al., 2005). Levels of 200 mg 
chromium(III)/kg dw in soils resulted in a significant 
(23–36%) reduction in the yields of grass, lettuce, and 
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radish (Sykes et al., 1981). Janus & Krajnc (1990) 
reported that levels of 150 mg chromium(III)/kg dw or 
more in soil can inhibit the growth of sensitive plant 
species, depending on the nature of the soil. Wheat 
(variety Florence-Aurore) and tomatoes (variety John 
Moran) were grown in soil spiked with various con-
centrations of chromium(III) (10–500 mg chromium/kg 
soil for wheat; 20–1000 mg chromium/kg soil for 
tomatoes). Chromium(III), in the form of chromium 
sulfate, was shown to reduce the yields of wheat at 
concentrations of 200 mg chromium/kg and greater in
the acid soil and about 100 mg chromium/kg soil and 
greater in the alkaline soil. No effects were seen with 
chromium(III) in the form of the insoluble chromium 
oxide (Moulinier & Mazoyer, 1968). 
  
 
 In 8-week toxicity tests using activated sludge, no 
significant effect on the growth of earthworms (Eisenia 
foetida) was observed at the highest concentration tested 
(46 000 mg chromium(III)/kg, as chromium(III) oxide) 
(Hartenstein et al., 1981). Sivakumar & Subbhuraam 
(2005) reported 14-day LC50s for chromium(III) ranging 
from 1656 to 1902 mg/kg for E. foetida. Statistical 
analysis of the results predicted that the clay content of 
the soils accounted for 92% of the variation in toxicity. 
Van Gestel et al. (1993) found a significant reduction in 
reproduction of earthworms (Eisenia andrei) exposed to 
≥100 mg chromium(III)/kg dry artificial soil in 3-week 
tests; however, growth was significantly reduced only at 
the highest concentration tested (1000 mg/kg). The 
NOEC from the study was 32 mg/kg dry soil. 
 
 Tatara et al. (1998) reported the 24-h LC50 for total 
trivalent chromium at 967 mg/l (18.6 mmol/l) and for the 
free ion at 946 mg/l (18.2 mmol/l) for the free-living soil 
nematode Caenorhabditis elegans exposed to chromium 
nitrate. 
 
 Controlled studies on the toxicity of chromium to 
wild mammals and birds are very limited. Turkey hens 
fed 10 µg chromium(III)/g ww in their diet produced 
significantly fewer eggs than controls; however, egg 
fertility and hatchability were unaffected (Frobish, 
1980). Eisler (1986) and Outridge & Scheuhammer 
(1993) reviewed an unpublished study by Haseltine et al. 
(1985) in which juvenile American black ducks (Anas 
rubripes) fed 10 µg chromium(III)/g dw in the diet had 
increased concentrations of uric acid and reduced growth 
and survival. In adults administered 10 and 50 µg/g in 
the diet, there were no effects on survival, reproduction, 
or blood chemistry.  
 
 Significant adverse effects on growth and behaviour 
of herring gull (Larus argentatus) chicks were observed 
following a single intraperitoneal injection of chromium 
nitrate (25 mg/kg bw) (Burger & Gochfeld, 1995b). In 5-
day dietary tests with Japanese quail (Coturnix coturnix 
japonica), LC50s were >5000 mg chromium(III)/kg for 
chromium sulfate and chromium potassium sulfate and 
2476 mg chromium(III)/kg for chromium acetylaceto-
nate (Hill & Camardese, 1986). In further tests, a 5-day 
LC50 for mallard ducks (Anas platyrhynchos) of >5000 
mg chromium(III)/kg was reported for chromium acetyl-
acetonate (Hill et al., 1975). 
 
 
 
11. EFFECTS EVALUATION 
 
11.1 Evaluation of health effects 
 
11.1.1 Hazard identification and dose–response 
assessment 
 
 Human studies concerned with inorganic species of 
trivalent chromium are restricted to some experimental 
or occupational investigations dealing with toxico-
kinetics and clinical health outcomes. The latter do not 
provide sufficient data for dose–response assessments. 
The key toxicological end-point for chromium(III) oxide 
is respiratory toxicity associated with substance 
accumulation and overload in the lungs on repeated 
inhalation exposure. The key toxic end-points for basic 
chromium sulfate, presumably representing soluble 
inorganic chromium(III) salts as a group, are chronic 
respiratory toxicity on inhalation and contact sensitiza-
tion of the skin.  
 
 Absorbed chromium(III) is excreted mainly in the 
urine and to a lesser extent in the faeces.  
 
 In rats, the oral acute toxicity of chromium(III) 
oxide is low, with LD50 values above 5 g/kg bw. 
Similarly, acute oral toxicities of soluble chromium(III) 
salts are low. An oral LD50 for basic chromium sulfate of 
3530 mg/kg bw is reported (Bayer, 1978). In the case of 
chromium nitrate, values range from 1540 to 3250 
mg/kg bw (Smyth et al., 1969; Vernot et al., 1977). By 
parenteral routes (intraperitoneal or intravenous), 
chromium(III) salts have lethal effects in rats and mice 
at doses 2–3 orders of magnitude lower than those for 
the oral route. No acute toxicity data were available for 
inhalation or dermal exposure to any of the inorganic 
trivalent chromium compounds. 
 
 Based on animal studies, chromium oxide and basic 
chromium sulfate are not skin or eye irritants. Liquid 
aerosols of chromium chloride at a high concentration 
have caused slight irritancy in Syrian hamsters. On 
repeated exposure, inhaled dusts of basic chromium 
sulfate have caused irritation and inflammation in the 
respiratory system of rats, whereas the corresponding 
reaction to chromium oxide inhalation was mild.  
 
 46
Inorganic chromium(III) compounds 
 
 
 In a 90-day toxicity study with rats, no adverse 
effects were seen when the animals were fed with 
chromium(III) oxide baked in bread at dose levels as 
high as 1368 mg Cr
 Water-insoluble chromium(III) oxide, which 
normally covers the surface of metallic chromium, does 
not cause skin sensitization.  
3+ /kg bw per day (Ivankovic & 
Preussman, 1975). This lack of effects can be explained 
by the poor oral bioavailability of chromium(III) oxide. 
In a 20-week oral feeding study with water-soluble 
chromium chloride, no adverse effects were seen in 
Sprague-Dawley rats, even at the highest dose level, 
corresponding to a chromium intake of 7 mg/kg bw per 
day (Anderson et al., 1997). 
 Among trivalent chromium salts, chromium 
chloride and hydrated chromium sulfate have been 
sensitizing to guinea-pig skin in non-standard tests 
employing intradermal or subcutaneous injections, 
whereas chromium nitrate, chromium sulfate (hydrate), 
chromium acetate, and chromium oxalate have given 
negative responses (Van Neer, 1963; Gross et al., 1968; 
Jansen & Berrens, 1968; Polak et al., 1973; Siegenthaler 
et al., 1983). Chromium chloride has also given positive 
reactions after an epicutaneous challenge in guinea-pigs 
(Polak et al., 1973; Siegenthaler et al., 1983). Trivalent 
chromium acts as the ultimate haptenic determinant for 
chromium sensitization in the skin; however, especially 
because of their lower penetration into the skin, trivalent 
chromium compounds are less potent sensitizers than 
hexavalent chromium compounds.  
 
 In a 13-week inhalation toxicity study, no systemic 
adverse effects were seen in chromium(III) oxide–
exposed rats. However, in the lungs, the retention of 
chromium(III) oxide caused mild inflammatory changes, 
especially in mid- and high-dose animals (10 and 30 mg 
Cr3+/m3), but also at the lowest exposure level (3 mg 
Cr3+/m3; Derelanko et al., 1999). These small 
inflammatory changes may reflect a nonspecific lung 
response to accumulated insoluble particles rather than 
intrinsic toxicity of chromium(III), which is slowly 
liberated. The minimal severity of findings at the lowest 
exposure level suggests that the LOAEC of 3 mg 
Cr
 
 Clinical evidence pointing to the potential of soluble 
trivalent chromium to cause allergic skin reactions 
relates mainly to the wearing of leather articles tanned 
with chromium. Case-studies of more than 100 sensi-
tized patients, many of them having worn shoes in direct 
contact with the skin, such as sandals, and less fre-
quently having used wet gloves, have been reported over 
the last few decades. The issue is, however, clouded by 
the fact that, in addition to the higher levels of mobile 
trivalent chromium in the leather, even low levels of 
hexavalent chromium may have been present, or the 
reported cases of foot dermatitis may actually be 
elicitation reactions in previously chromium-sensitized 
people.  
3+/m3 is near a NOAEC for chromium(III) oxide in 
rats.  
 
 In a similar 13-week inhalation toxicity study with 
rats, dusts of basic chromium sulfate induced more 
severe and more widespread inflammatory effects in the 
respiratory tract and lungs than did chromium(III) oxide 
(Derelanko et al., 1999). Signs of systemic toxicity were 
also seen: body weights of mid- and high-dose (10 and 
30 mg Cr3+/m3) males and high-dose females were 
decreased. Histopathological findings were unremark-
able in organs other than the respiratory system. The 
lowest exposure level of 3 mg Cr
 
3+ Skin sensitization among workers handling trivalent 
chromium salts appears to be a rare event.  
/m3 (17 mg basic 
chromium sulfate/m3) was a NOAEC for systemic 
effects. However, since inflammatory changes in the 
lungs and the respiratory tract were seen even at the 
lowest level, it was a LOAEC for local effects. 
 
 There is currently no evidence to show that expo-
sure to trivalent chromium compounds (unlike exposure 
to hexavalent chromium) has induced occupational 
asthma. However, in a study of four persons with clin-
ical asthma from occupational exposure to hexavalent 
chromium, a bronchial provocation test with nebulized 
chromium sulfate elicited asthmatic responses.  
 
 Although chromium(III) may interact with DNA, 
the data on in vitro and in vivo genotoxicity studies are 
conflicting and give no clear evidence on the mutagen-
icity of trivalent chromium.  
  
 Only a few studies have addressed chronic 
respiratory effects of occupational exposure to 
chromium(III) compounds. Main findings have included 
an increased prevalence of respiratory symptoms 
indicative of sustained irritation. However, in view of 
the complexity of the dust exposures in occupational 
settings, the sustained respiratory irritation found in the 
workforce cannot be attributed exclusively to trivalent 
chromium. 
 Chromium(III) oxide did not cause local bronchial 
tumours (Levy & Venitt, 1986) in a well conducted 2-
year rat study using the intrabronchial pellet technique or 
any increased occurrence of any tumours when admin-
istered orally in feed (Ivankovic & Preussman, 1975).  
 
 Chromium sulfate did not induce tumours in a 30-
week strain A mouse lung tumour system, which 
involved administration of 24 intraperitoneal injections 
(Stoner et al., 1976). In a 2-year study with rats, intra-
bronchial administration of basic chromium sulfate 
 
 47
Concise International Chemical Assessment Document 76 
 
 
 No appropriate developmental toxicity studies were 
available for soluble trivalent chromium salts. 
(chrome tan) or chromium chloride hexahydrate from a 
cholesterol pellet in a stainless steel wire mesh did not 
cause any local tumours or an increased frequency of 
squamous metaplasia (Levy & Venitt, 1986). 
 
11.1.2 Criteria for setting tolerable intakes/ 
  concentrations  
 
 Among inorganic trivalent chromium compounds, 
insoluble species, typically chromium(III) oxide, must 
be distinguished from water-soluble salts. The key end-
point considered to be relevant for human exposure to 
chromium(III) oxide is sustained local irritation and 
inflammation associated with accumulation of respirable 
particles in the lungs to the extent that the clearance 
mechanisms are overloaded. The key end-points relevant 
for human exposure to basic chromium sulfate, pre-
sumed to represent soluble chromium(III) salts as a 
group, are local respiratory toxicity and sensitization of 
the skin. 
 Although conventional inhalation carcinogenicity 
studies are lacking, intrabronchial studies on chromi-
um(III) oxide, basic chromium sulfate, and chromium 
chloride hexahydrate are relevant for the evaluation of 
carcinogenicity. These studies did not provide any 
evidence of a local carcinogenic effect on the bronchial 
epithelium, whereas hexavalent chromium compounds 
caused local squamous metaplasia with or without local 
tumours. 
 
 For some occupations involving trivalent chromium 
exposure, increased risks for some cancers have been 
suggested, but the epidemiological data do not permit 
discrimination between effects due to trivalent chro-
mium and those due to hexavalent chromium or other 
carcinogenic agents in simultaneous exposures. A study 
on chromate production workers found that trivalent 
chromium showed no association with an increased risk 
of lung cancer when adjusted for hexavalent chromium 
exposure and smoking (Gibb et al., 2000). Studies of 
other occupations exposed to hexavalent and trivalent 
chromium found increased risks of lung cancer, but the 
studies did not discriminate between hexavalent and 
trivalent exposure. Chromium and trivalent chromium 
compounds have been evaluated by IARC (1990), with 
the conclusion that there is inadequate evidence in 
humans and animals for the carcinogenicity of metallic 
chromium and chromium(III) compounds (Group 3).  
 
 Data on the speciation of chromium in ambient air 
would be required for an accurate evaluation of respira-
tory effects in the general population by airborne tri-
valent chromium compounds. In reality, it is expected 
that the speciation is variable, depending on the sources 
of chromium emissions. Transport from soil to air, 
weathering of rocks, and many industrial point sources 
are expected to release mainly chromium(III) oxide to 
the environment, but combustion processes may also 
oxidize a proportion of the element to the hexavalent 
state. It is less likely that the general population is 
exposed via air to aerosols of soluble chromium(III) 
salts. However, in the following evaluation, both types 
of trivalent chromium species are considered. 
  
 Trivalent chromium is an essential element at very 
low dietary doses (some tens of micrograms per day), 
and human experience from the widespread use of 
mainly organic chromium(III) complexes (chromium 
picolinate, chromium nicotinate) as a food supplement at 
10-fold or even higher dose levels has not brought to 
light any consistent toxic effects. Animal studies also 
show that orally administered trivalent chromium has 
low toxicity.  
 
11.1.2.1 Chromium(III) oxide inhalation 
 In a 13-week inhalation toxicity study with rats, no 
compound-related effects on sperm parameters or 
testicular and ovarian weights were seen after inhalation 
exposure to chromium(III) (Derelanko et al., 1999). 
Also, a limited 90-day oral feeding study at two very 
high dose levels of chromium(III) oxide did not show 
any adverse effects on the reproductive performance of 
rats (Ivankovic & Preussman, 1975).  
 
 No compound-related effects on sperm parameters 
and testicular or ovarian weights were seen after a 13-
week inhalation exposure of rats to basic chromium 
sulfate for 6 h/day at concentrations up to 30 mg Cr
 
 In a 13-week rat inhalation toxicity study on 
chromium(III) oxide with a 13-week recovery period, 
mild, sustained inflammatory changes in the lungs were 
produced, with a dose–response at concentrations 
ranging from 3 to 30 mg Cr
3+/m3 
(Derelanko et al., 1999). Other studies on fertility effects 
of trivalent chromium salts suffer from several defi-
ciencies and cannot be used for the fertility assessment 
of chromium(III). 
3+/m3 (Derelanko et al., 
1999). The study identified a LOAEC of 3 mg Cr3+/m3. 
In Riihimäki & Luotamo (2006), a tolerable concentra-
tion for occupational exposure was set. Since the 
observed LOAEC was judged to be close to a NOAEC 
and because the effect was slight and probably non-
specific, no assessment factor was used for extrapolation 
from the LOAEC to a NOAEC. For extrapolation from 
 
 No malformations were seen in the offspring of 
female rats given chromium(III) oxide in a 90-day 
feeding study at two dose levels (about 560 or 1300 mg 
Cr3+/kg bw per day) (Ivankovic & Preussman, 1975). 
The study was limited to only a small number of animals 
and provided no quantitative data.  
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rats to humans, an assessment factor of 2 was used, as 
interspecies variation is not expected to be high because 
of the local type of effect and because the rat is a 
sensitive species for lung overload–related injury. An 
assessment factor of 3 was used to cover interindividual 
differences, resulting in an occupational exposure level 
of 0.5 mg Cr3+/m3. 
 
 In Riihimäki & Luotamo (2006), no tolerable con-
centration for continuous exposure was set. However, 
the LOAEC of 3 mg Cr3+/m3 is equivalent to 0.54 mg 
Cr3+/m3 for continuous exposure (3 mg × 6/24 h/day × 
5/7 days/week). Following the same principles as in the 
setting of the tolerable concentration for occupational 
exposure, no assessment factor is used for extrapolation 
from the LOAEC to a NOAEC, and an assessment factor 
of 2 is used to cover interspecies variation. However, for 
interindividual differences in the general population, an 
assessment factor of 10 is used. Application of the over-
all assessment factor of 20 to the LOAEC of 0.54 mg 
Cr3+/m3 generates a tolerable concentration of 27 µg 
Cr3+/m3.  
 
11.1.2.2 Basic chromium sulfate inhalation 
 
 In a 13-week rat inhalation study on basic chro-
mium sulfate with a 13-week recovery period, dose-
dependent chronic inflammation of the alveoli and 
chronic interstitial or granulomatous inflammation of the 
lungs and respiratory tract were produced at all three 
exposure concentrations: 3, 10, and 30 mg Cr3+/m3. 
These inflammatory changes found in the airways 
largely reverted during the 13-week recovery period. For 
local respiratory effects, the study identified a LOAEC 
of 3 mg Cr3+/m3. In Riihimäki & Luotamo (2006), a 
tolerable concentration for occupational exposure was 
set. For extrapolation from the LOAEC to a NOAEC, an 
assessment factor of 3 was used. An assessment factor of 
3 was also used for interspecies extrapolation, because 
interspecies variation was not expected to be large owing 
to the local type of effect. To cover interindividual varia-
tion in occupational exposure, an assessment factor of 2 
was used. This results in an occupational exposure level 
of 0.2 mg Cr3+/m3. 
 
 In Riihimäki & Luotamo (2006), no tolerable con-
centration for continuous exposure was set. However, 
the LOAEC of 3 mg Cr3+/m3 is equivalent to 0.54 mg 
Cr3+/m3 for continuous exposure (3 × 6/24 × 5/7). This 
concentration was a NOAEC for impaired weight gain as 
a systemic effect, which was presumably secondary to 
respiratory toxicity. Local respiratory system toxicity is 
the critical effect for basic chromium sulfate. For 
extrapolation from the LOAEC to a NOAEC, an assess-
ment factor of 3 is used. An assessment factor of 3 is 
also used for interspecies extrapolation, because inter-
species variation is not expected to be large owing to the 
local type of effect. An additional assessment factor of 
10 is used for interindividual differences. Application of 
the overall assessment factor of 90 to the LOAEC of 
0.54 mg Cr3+/m3 generates a tolerable concentration of 
6 µg Cr3+/m3 for continuous environmental exposure.  
 
 Concerning skin sensitization, it is rather unlikely 
that soluble trivalent chromium salts induce skin sensi-
tization in a person wearing shoes, gloves, or other 
articles made of chrome-tanned leather, whereas it is 
more likely that mobile trivalent chromium leached from 
the leather article can elicit chromium allergy in a 
previously sensitized person. Recently, the MET level 
for trivalent chromium has been determined in 
chromium(VI)-sensitive patients (Hansen et al., 2003). 
According to the study by Hansen et al. (2003), 10% of 
patients reacted to the skin application dose of 0.18 µg 
chromium(III)/cm2 per 48 h as chromium chloride. 
 
11.1.3 Sample risk characterization 
 
 The concentrations of total atmospheric chromium 
in the USA and Europe are very low in rural areas 
(<10 ng/m3), are about 10–30 ng/m3 in urban areas, and 
may reach 0.1–1 µg/m3 around polluting point sources. 
Thus, the concentrations in ambient air are generally 
several orders of magnitude lower than the tolerable 
concentrations; even in the vicinity of point sources, 
they fall below the tolerable concentrations. 
 
 There are no reliable data for the setting of tolerable 
daily intake for oral exposure; therefore, no sample risk 
characterization for oral exposure can be done. 
 
11.1.4 Uncertainties in the hazard characterization 
 
 Some uncertainty exists regarding the ability of 
trivalent chromium to induce contact allergy. Elicitation 
of skin allergy (induction of allergic reaction in a person 
previously sensitized to chromium(VI)) by trivalent 
chromium has been demonstrated. Developmental 
toxicity of trivalent chromium is not adequately studied. 
No reliable data exist for the setting of tolerable daily 
oral intake. 
 
11.2 Evaluation of environmental effects 
 
 Chromium(III) is required by only some micro-
organisms for specific metabolic processes, such as 
glucose metabolism and enzyme stimulation. Chromi-
um(III), in trace amounts, has been reported to be an 
essential component of animal nutrition and is most 
notably associated with glucose and fat metabolism. 
However, although chromium has been shown to be 
essential for glucose metabolism in rats under highly 
controlled experimental conditions in which body stores 
of chromium were depleted, studies on other animals are 
more equivocal.  
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Figure 1: Toxicity of trivalent chromium to aquatic organisms. 
 
 
 The available toxicity data for chromium(III) have 
been derived mainly using the water-soluble forms 
(chromium(III) chloride, chromium(III) nitrate, and 
chromium potassium sulfate). In the environment, 
chromium(III) is likely to be present in much less 
soluble forms and hence less bioavailable to aquatic 
organisms. 
 
 The toxicity data for aquatic organisms are sum-
marized in Figure 1. Ninety-six-hour EC50s for one 
freshwater alga, based on growth, ranged from 0.3 to 
0.4 mg chromium(III)/l. A 96-h EC50, based on growth, 
was reported for a marine diatom at 2 mg chromi-
um(III)/l. LC50s in freshwater invertebrates ranged from 
0.1 mg/l (Daphnia pulex) to 442 mg/l (Asellus 
aquaticus), with a life cycle NOEC of 0.047 mg/l for 
Daphnia magna. LC
 50
50s ranging from 10 to 100 mg/l 
have been reported for marine invertebrates. Ninety-six-
hour LC50s for freshwater fish ranged from 3.3 mg/l for 
the guppy (Poecilia reticulata) to 151 mg/l for the 
bighead (Aristichthys nobilis), whereas LC50s of 31.5 
and 53 mg/l were reported for marine fish. A 72-day 
NOEC (survival) of 0.05 mg/l was reported for rainbow 
trout (Oncorhynchus mykiss). 
 
 A guidance value for trivalent chromium toxicity in 
the freshwater environment can be derived using a 
probabilistic approach (ANZECC/ARMCANZ, 2000), 
since the data set is sufficiently large to warrant it. 
Appendix 5 details the methodology used as an example. 
For the freshwater environment, 28 toxicity values were 
chosen to derive a moderate-reliability guidance value. 
The criteria for choosing the toxicity values and the 
values are presented in Appendix 5. Acute and chronic 
toxicity values have been converted to estimates of 
NOEC using the factors described in Appendix 5 (see 
Table A5-1, Appendix 5). A moderate-reliability 
guidance value of 0.01 mg chromium(III)/l (10 µg 
chromium(III)/l) was derived for the protection of 99% 
of freshwater species with 50% confidence, based on 
tests performed at a hardness of <100 mg calcium 
carbonate/l (see Figure A5-1, Appendix 5). In 
comparison, if a deterministic approach is carried out 
using the toxicity data for freshwater organisms, this 
would be based on long-term NOEC values of 0.05 mg/l 
for fish, 0.047 mg/l for invertebrates, and a 96-h EC50 
(growth) of 0.4 mg/l for algae. The fish and invertebrate 
values relate to hardness levels of 26 and 52 mg/l, 
respectively. Applying an assessment factor of 10 to the 
lowest available NOEC gives a tentative predicted no-
effect concentration (PNEC) for chromium(III) of 5 µg/l 
for soft water, about half that obtained using the 
probabilistic method. 
 
 There were insufficient toxicity data on marine 
organisms to allow a guidance value to be calculated 
using a probabilistic method. A very limited data set was 
available based on a diatom, aquatic invertebrates, and 
fish. Therefore, a factor of 1000 was applied to the 
lowest reliable toxicity value (2 mg/l) to give a low-
reliability guidance value of 0.002 mg chromium(III)/l 
(2 µg chromium(III)/l). 
Inorganic chromium(III) compounds 
 
 
 The moderate-reliability guidance value of 10 µg 
chromium(III)/l for the freshwater environment suggests 
a low risk for surface waters in general. However, there 
is a potential risk to organisms when the guidance value 
is compared with the highest chromium(III) level of 
around 100 µg/l for surface waters in industrial areas, 
especially for softwater regions. The higher levels of 
trivalent chromium in effluent, especially from tanneries, 
suggest that there is a risk to freshwater organisms in the 
vicinity of such effluent releases. Comparing the low-
reliability guidance value of 2 µg chromium(III)/l for the 
marine environment with trivalent chromium concentra-
tions in seawater suggests a low risk of toxicity to 
marine organisms.  
 
 There are more limited data for terrestrial organ-
isms. The NOEC for chromium(III) to plants is of the 
order of 100 mg chromium/kg soil, with a NOEC of 
32 mg chromium/kg dry artificial soil being reported for 
earthworms and a NOEC/LOEC of ~100–330 mg 
chromium/kg soil also being reported. Applying an 
assessment factor of 10 to the lowest of these NOECs 
gives a PNEC for chromium(III) of approximately 
3.2 mg chromium/kg dry soil, which is equivalent to a 
PNEC of around 2.8 mg/kg on a wet weight of soil basis. 
Total chromium levels in soil vary greatly, with levels 
ranging from <1 to >6000 mg/kg, depending on the 
underlying geology and localized industrial contamina-
tion. However, both the PNEC for earthworms and most 
of the monitoring data for soils are reported as total 
chromium and do not give any indication of the bioavail-
ability of trivalent chromium. Therefore, in the absence 
of more data on the bioavailability of chromium in soils, 
it is difficult to assess the risk of chromium(III) to soil 
organisms. 
 
 
 
12. PREVIOUS EVALUATIONS BY INTER-
ORGANIZATION PROGRAMME FOR THE 
SOUND MANAGEMENT OF CHEMICALS 
(IOMC) BODIES 
 
 
 The International Agency for Research on Cancer 
(IARC) evaluated chromium and chromium compounds 
in 1990 and concluded that metallic chromium and 
chromium(III) compounds are not classifiable as to their 
carcinogenicity to humans (Group 3). 
 
 A World Health Organization (WHO) study group 
(WHO, 1996) evaluated the normative requirements for 
chromium. Their conclusion was that the available data 
were too limited to determine the basal and normative 
requirements for chromium. Their best guess at the time 
was that the minimum population mean intake likely to 
meet normative needs might be approximately 33 µg 
chromium/day.  
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sorbent. Analytica Chimica Acta, 505:25–35. 
  
 Yamamoto A, Wada O, Manabe S (1989) Evidence that 
chromium is an essential factor for biological activity of low-
molecular-weight, chromium binding substance. Biochemical 
and Biophysical Research Communications, 163:189–193. 
AAS atomic absorption spectrometry  
ATSDR Agency for Toxic Substances and Disease 
Registry  
Yeardley RB, Lazorchak JM, Paulsen SG (1998) Elemental fish 
tissue contamination in northeastern US lakes: Evaluation of an 
approach to regional assessment. Environmental Toxicology 
and Chemistry, 17:1875–1884. 
bw  body weight 
CAS Chemical Abstracts Service 
CICAD Concise International Chemical Assessment 
Document  
Yesilada E (2001) Genotoxicity testing of some metals in the 
Drosophila wing somatic mutation and recombination test. 
Bulletin of Environmental Contamination and Toxicology, 
66:464–469. 
DNA deoxyribonucleic acid  
dw dry weight 
EC median effective concentration  50 
EDTA ethylenediaminetetraacetic acid Young TC, Waltman MR, Theis TL, DePinto JV (1992) Studies 
of heavy metal sorption by Trenton Channel (Detroit River) 
sediments. Hydrobiologia, 235/236:649–660. 
FCA Freund’s complete adjuvant 
FEV forced expiratory volume in 1 s  1.0
Yu J, Wu X-J, Chen Z (2001) Separation and determination of 
Cr(III) by titanium dioxide–filled column and inductively coupled 
plasma mass spectrometry. Analytica Chimica Acta, 436:59–67. 
FIOH Finnish Institute of Occupational Health 
FVC forced vital capacity 
 GAAS graphite furnace atomic absorption 
spectrometry Yu W, Sipowicz MA, Haines DC, Birely L, Diwan BA, Riggs CW, 
Kasprzak KS, Anderson LM (1999) Preconception urethane or 
chromium(III) treatment of male mice: Multiple neoplastic and 
non-neoplastic changes in offspring. Toxicology and Applied 
Pharmacology, 158:161–176. 
GLP Good Laboratory Practice 
HC hazardous concentration for 5% of species 5
IARC International Agency for Research on Cancer 
 
IC median inhibitory concentration  Zachariae C, Agner T, Menne T (1996) Chromium allergy in 
consecutive patients in a country where ferrous sulfate has been 
added to cement since 1981. Contact Dermatitis, 35:83–85. 
50
ICDA International Chromium Development 
Association 
 
ICP-AES inductively coupled plasma atomic emission 
spectroscopy 
Zahid ZR, Al-Hakkak ZS, Kadhim AHH, Elias EA, Al-Jumaily IS 
(1990) Comparative effects of trivalent and hexavalent chro-
mium on spermatogenesis of the mouse. Toxicology and 
Environmental Chemistry, 25:131–136. 
ICP-MS inductively coupled plasma mass 
spectrometry 
 
Ig immunoglobulin Zhang L, Zhou K (1992) Background values of trace elements in 
the source area of the Yangtze River. Science of the Total 
Environment, 125:391–404. 
IPCS International Programme on Chemical Safety 
ISO International Organization for 
Standardization  
 LC median lethal concentration  50
LD median lethal dose  50
LMWCr low-molecular-weight chromium-binding 
substance 
LOAEC lowest-observed-adverse-effect 
concentration 
LOEC lowest-observed-effect concentration 
MET minimum elicitation threshold 
MMAD mass median aerodynamic diameter 
NAA neutron activation analysis 
NIOSH National Institute for Occupational Safety 
and Health (USA) 
NOAEC no-observed-adverse-effect concentration 
NOAEL no-observed-adverse-effect level 
NOEC  no-observed-effect concentration 
OECD Organisation for Economic Co-operation and 
Development 
OJ orange juice 
PNEC predicted no-effect concentration 
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APPENDIX 2 — SOURCE DOCUMENTS RNA ribonucleic acid 
 SCE sister chromatid exchange 
 USA United States of America Riihimäki V, Luotamo M, eds (2006) Health risk 
assessment report for metallic chromium and 
trivalent chromium. Paris, International 
Chromium Development Association 
(http://www.icdachromium.com/). 
USEPA United States Environmental Protection 
Agency 
WHO World Health Organization 
ww wet weight 
  
The Health Risk Assessment Report for Metallic Chromium 
and Trivalent Chromium (Riihimäki & Luotamo, 2006) was 
prepared by the Finnish Institute of Occupational Health (FIOH) 
for the Commission of the International Chromium Development 
Association (ICDA) and the International Stainless Steel Forum. 
The report was published by ICDA in 2006. Copies can be 
obtained from the ICDA Secretariat (see 
http://www.icdachromium.com/). 
 
The following scientists from FIOH contributed to the 
development of the Health Risk Assessment Report for Metallic 
Chromium and Trivalent Chromium: Dr Vesa Riihimäki (principal 
investigator), Dr Kerstin Engström, Dr Riitta Jolanki, Dr Mirja 
Kiilunen, Dr Kimmo Louekari, Dr Marita Luotamo, Dr Hannu 
Norppa, Dr Markku Nurminen, Ms Hanna Paananen, Dr Tiina 
Santonen, and Dr Antti Zitting. The document went through a 
peer review by the project steering group, which consisted of 
representatives of academia, FIOH scientists, and the chromium 
industry.  
 
 
ATSDR (2000) Toxicological profile for 
chromium. Atlanta, GA, United States 
Department of Health and Human Services, 
Public Health Service, Agency for Toxic 
Substances and Disease Registry. 
 
 The Toxicological Profile for Chromium was prepared by 
the Agency for Toxic Substances and Disease Registry 
(ATSDR) through a contract with the Syracuse Research 
Corporation. The profile was published in final form in 
September 2000. Copies of the profile can be obtained from: 
 
 Division of Toxicology 
Agency for Toxic Substances and Disease Registry 
Public Health Service 
United States Department of Health and Human Services 
1600 Clifton Road NE, Mailstop E-32 
Atlanta, Georgia 30333 
USA 
 
 Ms Sharon Wilbur, ATSDR, Division of Toxicology and 
Environmental Medicine, and Drs Lisa Ingerman, Mario Citra, 
Mark Osier, and David Wohlers, Syracuse Research 
Corporation, contributed to the development of the toxicological 
profile as chemical manager and authors. The profile has 
undergone three ATSDR internal reviews, including a Health 
Effects Review, a Minimal Risk Level Review, and a Data Needs 
Review. An external peer review panel was assembled for the 
update profile for chromium. The panel consisted of the 
following members: Dr William Berndt, University of Nebraska 
Medical Center; Dr Max Costa, The George Washington 
University Medical School and School of Public Health; and Dr 
Elizabeth Snow, New York University Medical Center. These 
experts collectively have knowledge of chromium’s physical and 
chemical properties, toxicokinetics, key health end-points, 
mechanisms of action, human and animal exposure, and 
quantification of risk to humans. All reviewers were selected in 
conformity with the conditions for peer review specified in 
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APPENDIX 3 — CICAD PEER REVIEW Section 104(i)(13) of the United States Comprehensive 
Environmental Response, Compensation, and Liability Act, as 
amended.  
  
 The draft CICAD on inorganic chromium(III) compounds 
was sent for review to institutions and organizations identified by 
IPCS after contact with IPCS national Contact Points and 
Participating Institutions, as well as to identified experts. An 
open invitation to participate in the peer review process was also 
published on the IPCS web site. Comments were received from:  
 Scientists from ATSDR reviewed the peer reviewers’ 
comments and determined which comments were to be included 
in the profile. A listing of the peer reviewers’ comments not 
incorporated in the profile, with a brief explanation of the 
rationale for their exclusion, exists as part of the administrative 
record for this compound. A list of databases reviewed and a list 
of unpublished documents cited are also included in the 
administrative record.  
 
M. Baril, Institut de recherche Robert Sauvé en santé et en 
securité du travail, Montreal, Quebec, Canada  
  The citation of the peer review panel should not be 
understood to imply its approval of the profile’s final content. R. Benson, United States Environmental Protection 
Agency, Denver, CO, USA  
  
S. Bull, Chemical Hazards and Poisons Division, Health 
Protection Agency, London, United Kingdom 
 
 
R. Chhabra, National Institute of Environmental Health 
Sciences, Research Triangle Park, NC, USA 
 
G. Darrie, International Chromium Development 
Association, Paris, France 
 
H. Gibb, Sciences International Inc., Alexandria, VA, USA 
 
R. Hertel, Federal Institute for Risk Assessment (BfR), 
Berlin, Germany 
 
J. Kielhorn, Fraunhofer Institute for Toxicology and 
Experimental Medicine, Hanover, Germany 
 
M. Nordberg, Institute of Environmental Medicine, 
Karolinska Institute, Stockholm, Sweden 
 
J. Stauber, CSIRO Centre for Environmental Contaminants 
Research, Sydney, New South Wales, Australia 
 
F. Sullivan, United Kingdom 
 
D. Willcocks, National Industrial Chemicals Notification and 
Assessment Scheme, Sydney, New South Wales, Australia 
 
K. Ziegler-Skylakakis, Secretariat of the Commission for 
the Investigation of Health Hazards of Chemical 
Compounds in the Workplace Area (MAK Commission), 
Freising-Weihenstephan, Germany 
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APPENDIX 4 — CICAD FINAL REVIEW 
BOARD 
Secretariat 
 
Dr J. Bartram, Assessing and Managing Environmental Risks to 
Health, World Health Organization, Geneva, Switzerland  Helsinki, Finland  
26–29 March 2007 Mrs S. Marples, International Programme on Chemical Safety, 
World Health Organization, Geneva, Switzerland  
  Ms L. Onyon, International Programme on Chemical Safety, 
World Health Organization, Geneva, Switzerland Members 
  
Mr M. Shibatsuji, International Programme on Chemical Safety, 
World Health Organization, Geneva, Switzerland 
Dr A. Aitio, Finnish Institute of Occupational Health, Helsinki, 
Finland 
 
Professor H. Bouwman, School of Environmental Sciences and 
Development, North-West University, Potchefstroom, South 
Africa 
 
Dr C. De Rosa, Agency for Toxic Substances and Disease 
Registry, Atlanta, GA, USA 
 
Dr S. Devotta, National Environmental Engineering Research 
Institute, Nagpur, India 
 
Dr S. Dobson, Centre for Ecology and Hydrology, Monks Wood, 
United Kingdom 
 
Dr L. Fructengarten, Centro de Controle de Intoxicacoes de Sao 
Paulo, Sao Paulo, Brazil 
 
Dr H. Gibb, Sciences International Inc., Alexandria, VA, USA 
 
Dr R. Hertel, Federal Institute for Risk Assessment (BfR), Berlin, 
Germany 
 
Mr P. Howe, Centre for Ecology and Hydrology, Monks Wood, 
United Kingdom 
 
Dr S. Keith, Agency for Toxic Substances and Disease Registry, 
Atlanta, GA, USA 
 
Dr J. Kielhorn, Fraunhofer Institute for Toxicology and 
Experimental Medicine, Hanover, Germany 
 
Ms M.E. Meek, Health Canada, Ottawa, Ontario, Canada 
  
Dr T. Santonen, Finnish Institute of Occupational Health, 
Helsinki, Finland 
  
Dr B. Sonawane, National Center for Environmental 
Assessment, Office of Research and Development, 
Environmental Protection Agency, Washington, DC, USA 
  
Dr J. Stauber, CSIRO Centre for Environmental Contaminants 
Research, Sydney, Australia 
 
Dr M. Sweeney, Division of Surveillance, Hazard Evaluations & 
Field Studies, National Institute for Occupational Safety and 
Health, Cincinnati, OH, USA 
 
Dr P. Watts, BIBRA Information Services Ltd, Sutton, United 
Kingdom 
 
Ms D. Willcocks, Australian Department of Health and Ageing, 
Sydney, Australia 
 
Dr K. Ziegler-Skylakakis, Secretariat of the Commission for the 
Investigation of Health Hazards of Chemical Compounds in the 
Work Area (MAK Commission), Munich, Germany 
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APPENDIX 5 — OUTLINE OF THE SPECIES 
SENSITIVITY DISTRIBUTION METHOD 
(DUTCH STATISTICAL EXTRAPOLATION 
METHOD) USED TO DERIVE GUIDANCE 
VALUES FOR TRIVALENT CHROMIUM FOR 
THE PROTECTION OF AQUATIC SPECIES 
 
 
Introduction 
 
 The traditional approach to using single-species toxicity 
data to protect field ecosystems has been to apply standardized 
assessment factors, safety factors, or application factors to the 
lowest toxicity figure for a particular chemical. The magnitude of 
these safety factors depends on whether acute or chronic 
toxicity figures are available and the degree of confidence that 
one has in whether the figures reflect the field situation. Most of 
the factors are multiples of 10, and larger factors are applied 
where there is less certainty in the data. For example, a factor of 
1000 is generally used for acute data. 
 
 Concerns have often been raised as to the arbitrary nature 
of assessment factors (Chapman et al., 1998) and the fact that 
they do not conform to risk assessment principles. OECD (1992) 
recommended that assessment factors be used only when there 
are inadequate data to allow statistical extrapolation methods to 
be used. 
 
 The following sections briefly outline the statistical 
extrapolation method used to derive the trivalent chromium 
guidance values for the protection of freshwater aquatic 
organisms for this CICAD. Much of the text is taken directly from 
the Australian and New Zealand Guidelines for Fresh and 
Marine Water Quality (ANZECC/ARMCANZ, 2000). 
 
Use of statistical extrapolation methods 
 
 New methods using statistical risk-based approaches have 
been developed over the last decade for deriving guideline 
(trigger) values. These are based on calculations of a statistical 
distribution of laboratory ecotoxicity data and attempt to offer a 
predetermined level of protection, usually 95%. The approach of 
Aldenberg & Slob (1993) has been adopted in the Netherlands, 
Australia, and New Zealand for guideline derivation and is 
recommended for use by the OECD. It was chosen because of 
its theoretical basis, its ease of use, and the fact that it has been 
extensively evaluated. Warne (1998) compared in detail the risk-
based and assessment factor approaches used in various 
countries.  
 
 The Aldenberg & Slob (1993) method uses a statistical 
approach to protect 95% of species with a predetermined level 
of confidence, provided there is an adequate data set. This 
approach uses available data from all tested species (not just 
the most sensitive species) and considers these data to be a 
subsample of the range of concentrations at which effects would 
occur in all species in the environment. The method may be 
applied if toxicity data, usually chronic NOEC values, are 
available for at least five different species from at least four 
taxonomic groups. Data are entered into a computer program 
and generally fitted to a log-logistic distribution. A hazardous 
concentration for p per cent of the species (HCp) is derived. HCp 
is a value such that the probability of selecting a species from 
the community with a NOEC lower than HCp is equal to p (e.g. 
5%, HC5). HC5 is the estimated concentration that should protect 
95% of species. A level of uncertainty is associated with this 
derived value, and so values with a given confidence level (e.g. 
50% or 95%) are computed in the program by attaching a 
distribution to the error in the tail. The ANZECC/ARMCANZ 
(2000) guidelines use the median of 50% confidence.  
 
 HC5 is estimated by dividing the geometric mean of the 
NOEC values for m species by an extrapolation factor T (OECD, 
1995), where: 
 
 T = exp(sm × k) 
 
and where sm is the sample standard deviation of the natural 
logarithm of the NOEC values for m species; and k is the one-
sided tolerance limit factor for a logistic or normal distribution 
(from computer simulations). 
 
 The Aldenberg & Slob (1993) extrapolation method is 
based on several critical assumptions, outlined below. Many of 
these are common to other statistical distribution methods: 
 
• The ecosystem is sufficiently protected if theoretically 95% 
of the species in the system are fully protected. 
• The distribution of the NOECs is symmetrical (not required 
in the ANZECC/ARMCANZ [2000] modification). 
• The available data are derived from independent random 
trials of the total distribution of sensitivities in the eco-
system. 
• Toxicity data are distributed log-logistically, i.e. a logistic 
distribution is the most appropriate to use.  
• There are no interactions between species in the eco-
system.  
• NOEC data are the most appropriate data to use to set 
ambient environmental guidelines.  
• NOEC data for five species are a sufficient data set. 
 
Modification of the Aldenberg & Slob (1993) 
approach 
 
 The Aldenberg & Slob (1993) approach assumes the data 
are best fitted to a log-logistic distribution. For some data sets, 
however, a better fit is obtained with other models. By using a 
program developed by CSIRO Biometrics, the data are com-
pared with a range of statistical distributions called the Burr 
family of distributions, of which the log-logistic distribution is one 
case. The program determines the distribution that best fits the 
available toxicity data and calculates the HC5 with 50% confi-
dence (ANZECC/ARMCANZ, 2000); this method has been used 
to calculate the HC5 for trivalent chromium. 
 
Application to the data set for trivalent 
chromium 
 
 For the freshwater risk assessment, acute LC50 values 
were converted to chronic NOEC values using an acute to 
chronic ratio of 10 following ANZECC/ARMCANZ (2000) 
guidelines. Chronic EC s and LC50 50s were converted to chronic 
NOECs by applying a factor of 5, according to ANZECC/ 
ARMCANZ (2000) guidelines. It would have been better to use 
experimentally derived acute to chronic conversion factors; 
however, these were not available for trivalent chromium. 
 
Freshwater guidance value 
 
 Twenty-nine freshwater data were used from Table 3 (see 
section 10.2), and from these data were calculated chronic 
NOECs (see Table A5-1). Non-standard test end-points or end-
points of uncertain significance were not included. 
 
 Using the calculated chronic NOECs, the HC5(50), i.e. the 
hazardous concentration to protect 95% of species with 50% 
confidence—a “safe” value to ensure protection against chronic 
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Table A5-1: Toxicity end-points and calculated chronic 
NOECs used in the derivation of a freshwater guidance 
value for trivalent chromium.
Table A5-1 (continued) 
Calculated 
chronic 
NOEC (mg 
Cr/l) 
a 
Chromium 
concentration 
(mg Cr/l) 
 End-
point Organism Calculated 
chronic 
NOEC (mg 
Cr/l) 
Chromium 
concentration 
(mg Cr/l) 
Fish     End-
point Organism 
Microalgae       
Green alga 
(Selenastrum 
capricornutum) 
96-h 
EC50
0.4 0.08 
Rainbow trout 
(Oncorhynchus 
mykiss) 
72-day 
NOEC 
0.05 0.05 
bGoldfish 
(Carrasius 
auratus) 
96-h LC 20 2 50
Protozoa      
Ciliated 
protozoan 
(Tetrahymena 
pyriformis) 
9-h IC50 50 5 
Common carp 
(Cyprinus 
carpio) 
96-h LC 14.3 1.4 50
5.1 0.5 
Invertebrates      
Snail (Amnicola 
sp.) 
96-h LC50 8.4 0.8 
Fathead 
minnow 
(Pimephales 
promelas) 
96-h LC50
7.5 0.75 
Annelid worm 
(Nais sp.) 
96-h LC50 9.3 0.9 
Bluegill 
(Lepomis 
macrochirus) 
96-h LC50
Pumpkinseed 
(Lepomis 
gibbosus) 
96-h LC 17 1.7 0.047 Water flea 
(Daphnia 
magna) 
Life cycle 
NOEC 
0.047 50
Water flea 
(Daphnia pulex) 
96-h LC50 0.6b 0.06 
Water hoglouse 
(Asellus 
aquaticus) 
96-h LC50 442 44.2 
Banded killifish 
(Fundulus 
diaphanous) 
96-h LC 16.9 1.7 50
17.7 1.8 
Amphipod 
(Gammarus 
sp.) 
96-h LC50 3.2 0.3 
Striped bass 
(Roccus 
saxatilis) 
96-h LC50
Amphipod 
(Crangonyx 
pseudogracilis) 
96-h LC50 291 29.1 
White perch 
(Roccus 
americanus) 
96-h LC 14.4 1.4 50
Crayfish 
(Austro-
potamobius 
pallipes) 
96-h LC50 3.4 0.3 
Bighead 
(Aristichthys 
nobilis) 
96-h LC 151 15.1 50
3.3 0.3 Guppy (Poecilia 
reticulata) 
96-h LC50
Crayfish 
(Orconectes 
limosus) 
96-h LC50 6.6 0.7 
American eel 
(Anguilla 
rostrata) 
96-h LC 13.9 1.4 50
EC , median effective concentration; IC50 50
Mayfly 
(Ephemerella 
subvaria) 
96-h LC50 2 0.2 
, median inhibitory 
concentration; LC50, median lethal concentration; NOEC, no-
observed-effect concentration 
a
Caddis fly 
(Hydropsyche 
betteni) 
96-h LC50 64 6.4 
  Tests conducted at a hardness of <100 mg calcium 
carbonate/l. 
b  Geometric mean of LC50 values for this species for the same 
time period. 
Caddisfly 
(unidentified) 
96-h LC50 50 5 
 
Stonefly 
(Acroneuria 
lycorias) 
7-day 
LC50
32 6.4 
Damsel fly 
(unidentified) 
96-h LC50 43.1 4.3 
toxicity for most freshwater species—was 0.06 mg chromi-
um(III)/l. However, the moderate-reliability guidance value of 
0.06 mg/l is not protective of chronic toxicity to D. magna 
(NOEC: 0.047 mg/l) and rainbow trout (NOEC: 0.05 mg/l), and 
so a protection level of 99% should be applied. Therefore, a 
moderate-reliability guidance value for the protection of 99% of 
freshwater species with 50% confidence was derived at 0.01 mg 
chromium(III)/l (Figure A5-1).  
 11 1.1 Midge 
(Chironomus 
sp.) 
96-h LC50  
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 Fig. A5-1: Probability curve for trivalent chromium in the  
freshwater environment using actual and derived data from 
Table A5-1. 
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CHROMIUM HYDROXIDE SULFATE ICSC: 1309
October 2004
CAS # 12336-95-7
RTECS # GB6240000
EC/EINECS # 235-595-8
Basic Chrome Sulphate
Monobasic chromium sulphate
CrOHSO4
Molecular mass: 165.1
TYPES OF HAZARD /
EXPOSURE
ACUTE HAZARDS /
SYMPTOMS
PREVENTION FIRST AID / FIRE
FIGHTING
FIRE Not combustible. In case of fire in the
surroundings: use appropriate
extinguishing media.
EXPLOSION
EXPOSURE STRICT HYGIENE!
Inhalation Cough. Sore throat. Local exhaust or breathing
protection.
Fresh air, rest.
Skin Protective gloves. Protective
clothing.
Rinse skin with plenty of water
or shower.
Eyes Safety goggles. First rinse with plenty of water
for several minutes (remove
contact lenses if easily
possible), then take to a doctor.
Ingestion Nausea. Abdominal pain.
Vomiting. Diarrhoea.
Do not eat, drink, or smoke
during work.
Rinse mouth. Do NOT induce
vomiting. Give one or two
glasses of water to drink. Refer
for medical attention.
SPILLAGE DISPOSAL PACKAGING & LABELLING
Vacuum spilled material. OR Sweep spilled substance into
covered containers; if appropriate, moisten first to prevent
dusting. Do NOT let this chemical enter the environment.
Personal protection: P2 filter respirator for harmful particles.
EMERGENCY RESPONSE STORAGE
Provision to contain effluent from fire extinguishing. Store in an area
without drain or sewer access.
IPCS
International
Programme on
Chemical Safety
Prepared in the context of cooperation between the International
Programme on Chemical Safety and the Commission of the
European Communities © IPCS, CEC 2005
SEE IMPORTANT INFORMATION ON BACK
CHROMIUM HYDROXIDE SULFATE ICSC: 1309
IMPORTANT DATA
PHYSICAL STATE; APPEARANCE
GREEN POWDER
CHEMICAL DANGERS
The substance decomposes on heating producing toxic fumes.
The solution in water is a weak acid.
OCCUPATIONAL EXPOSURE LIMITS
TLV: (as Cr metal & Cr(III) compounds) 0.5 mg/m³ as TWA; A4 (not
classifiable as a human carcinogen); (ACGIH 2008).
MAK: IIb (not established but data is available); sensitization of skin
(Sh); (DFG 2008).
INHALATION RISK
A harmful concentration of airborne particles can be reached quickly
when dispersed.
EFFECTS OF SHORT-TERM EXPOSURE
The substance is irritating to the respiratory tract.
EFFECTS OF LONG-TERM OR REPEATED EXPOSURE
Repeated or prolonged contact may cause skin sensitization.
PHYSICAL PROPERTIES
Melting point: >900°C
Density: 1.25 g/cm³
Solubility in water, g/100 ml at 20°C: 200
ENVIRONMENTAL DATA
The substance is toxic to aquatic organisms.
NOTES
Chrometan, Tanolin, Neochrome, Chromedol and Chromosal are trade names. Do NOT take working clothes home. Card has been partially
updated in February 2009: see Occupational Exposure Limits, Storage, Ingestion First Aid.
ADDITIONAL INFORMATION
LEGAL NOTICE Neither the CEC nor the IPCS nor any person acting on behalf of the CEC or the IPCS is responsible for the use
which might be made of this information
© IPCS, CEC 2005
CHROMIUM(III) CHLORIDE (ANHYDROUS) ICSC: 1316
October 2004
CAS # 10025-73-7
RTECS # GB5425000
EC/EINECS # 233-038-3
Chromic chloride
Chromium trichloride
Trichlorochromium
CrCl3
Molecular mass: 158.4
TYPES OF HAZARD /
EXPOSURE
ACUTE HAZARDS /
SYMPTOMS
PREVENTION FIRST AID / FIRE
FIGHTING
FIRE Not combustible. In case of fire in the
surroundings: use appropriate
extinguishing media.
EXPLOSION
EXPOSURE
Inhalation Cough. Local exhaust or breathing
protection.
Fresh air, rest.
Skin Protective gloves. Remove contaminated clothes.
Rinse skin with plenty of water
or shower.
Eyes Redness. Safety goggles. First rinse with plenty of water
for several minutes (remove
contact lenses if easily
possible), then take to a doctor.
Ingestion Do not eat, drink, or smoke
during work.
Rinse mouth.
SPILLAGE DISPOSAL PACKAGING & LABELLING
Sweep spilled substance into containers; if appropriate,
moisten first to prevent dusting. Personal protection: P2 filter
respirator for harmful particles.
EMERGENCY RESPONSE STORAGE
IPCS
International
Programme on
Chemical Safety
Prepared in the context of cooperation between the International
Programme on Chemical Safety and the Commission of the
European Communities © IPCS, CEC 2005
SEE IMPORTANT INFORMATION ON BACK
CHROMIUM(III) CHLORIDE (ANHYDROUS) ICSC: 1316
IMPORTANT DATA
PHYSICAL STATE; APPEARANCE
VIOLET CRYSTALS.
OCCUPATIONAL EXPOSURE LIMITS
TLV: (as Cr metal & Cr(III) compounds) 0.5 mg/m³ as TWA; A4 (not
classifiable as a human carcinogen); (ACGIH 2008).
MAK: IIb (not established but data is available); (DFG 2008).
INHALATION RISK
A harmful concentration of airborne particles can be reached quickly
when dispersed.
EFFECTS OF SHORT-TERM EXPOSURE
May cause mechanical irritation to
the eyes
and
the respiratory tract.
PHYSICAL PROPERTIES
Boiling point (decomposes): 1300°C
Melting point: 1152°C
Density: 2.87 g/cm³
Solubility in water: none
ENVIRONMENTAL DATA
NOTES
The recommendations on this card do not apply to water soluble forms of chromium chloride. See ICSC 1532 Chromium(III) chloride
hexahydrate.
ADDITIONAL INFORMATION
LEGAL NOTICE Neither the CEC nor the IPCS nor any person acting on behalf of the CEC or the IPCS is responsible for the use
which might be made of this information
© IPCS, CEC 2005
CHROMIUM (III) HYDROXIDE HYDRATE ICSC: 1455
July 2003
CAS # 1308-14-1
RTECS # GB2670000
EC/EINECS # 215-158-8
Chromic (III) hydroxide hydrate
Cr(HO)3.nH2O
Molecular mass: See Notes
TYPES OF HAZARD /
EXPOSURE
ACUTE HAZARDS /
SYMPTOMS
PREVENTION FIRST AID / FIRE
FIGHTING
FIRE Not combustible. In case of fire in the
surroundings: use appropriate
extinguishing media.
EXPLOSION
EXPOSURE
Inhalation
Skin Protective gloves. Remove contaminated clothes.
Rinse skin with plenty of water
or shower.
Eyes Redness. Pain. Safety spectacles. First rinse with plenty of water
for several minutes (remove
contact lenses if easily
possible), then take to a doctor.
Ingestion Do not eat, drink, or smoke
during work.
Rest. Refer for medical
attention.
SPILLAGE DISPOSAL PACKAGING & LABELLING
Sweep spilled substance into containers; if appropriate,
moisten first to prevent dusting. Carefully collect remainder,
then remove to safe place. (Extra personal protection: P2
filter respirator for harmful particles.)
EMERGENCY RESPONSE STORAGE
IPCS
International
Programme on
Chemical Safety
Prepared in the context of cooperation between the International
Programme on Chemical Safety and the Commission of the
European Communities © IPCS, CEC 2005
SEE IMPORTANT INFORMATION ON BACK
CHROMIUM (III) HYDROXIDE HYDRATE ICSC: 1455
IMPORTANT DATA
PHYSICAL STATE; APPEARANCE
BLUE TO GREEN POWDER OR BLACK PARTICLES.
CHEMICAL DANGERS
The substance decomposes on heating to chromic oxide.
OCCUPATIONAL EXPOSURE LIMITS
TLV: (as Cr metal & Cr(III) compounds) 0.5 mg/m³ as TWA; A4 (not
classifiable as a human carcinogen); (ACGIH 2008).
MAK: IIb (not established but data is available) (DFG 2008).
ROUTES OF EXPOSURE
The substance can be absorbed into the body by inhalation and by
ingestion.
INHALATION RISK
Evaporation at 20°C is negligible; a nuisance-causing concentration of
airborne particles can, however, be reached quickly especially if
powdered.
EFFECTS OF SHORT-TERM EXPOSURE
May cause mechanical irritation to the eyes
PHYSICAL PROPERTIES
Solubility in water: none
ENVIRONMENTAL DATA
NOTES
The name Chromic acid is used for this product, as well as for Chromic (VI) acid (CAS 7738-94-5) and for Chromium (VI) oxide (CAS 1333-82-0,
see ICSC 1194).The molecular weight may vary depending on the degree of hydration. Card has been partially updated in February 2009: see
Occupational Exposure Limits.
ADDITIONAL INFORMATION
LEGAL NOTICE Neither the CEC nor the IPCS nor any person acting on behalf of the CEC or the IPCS is responsible for the use
which might be made of this information
© IPCS, CEC 2005
CHROMIUM(III) NITRATE NONAHYDRATE ICSC: 1530
October 2004
CAS # 7789-02-8
RTECS # GB6300000
UN # 2720
EC/EINECS # 236-921-1
Chromic nitrate
Chromium trinitrate
Nitric acid, chromium(III) salt
Cr(NO3)3•9H2O
Molecular mass: 400.2
TYPES OF HAZARD /
EXPOSURE
ACUTE HAZARDS /
SYMPTOMS
PREVENTION FIRST AID / FIRE
FIGHTING
FIRE Not combustible but enhances
combustion of other
substances. Gives off irritating
or toxic fumes (or gases) in a
fire.
NO open flames. In case of fire in the
surroundings: use appropriate
extinguishing media.
EXPLOSION Risk of fire and explosion.
EXPOSURE STRICT HYGIENE!
Inhalation Cough. Sore throat. Local exhaust or breathing
protection.
Fresh air, rest.
Skin Protective gloves. Protective
clothing.
Remove contaminated clothes.
Rinse skin with plenty of water
or shower.
Eyes Safety goggles. First rinse with plenty of water
for several minutes (remove
contact lenses if easily
possible), then take to a doctor.
Ingestion Abdominal pain. Diarrhoea.
Nausea. Vomiting.
Do not eat, drink, or smoke
during work.
Rinse mouth. Do NOT induce
vomiting. Refer for medical
attention.
SPILLAGE DISPOSAL PACKAGING & LABELLING
Sweep spilled substance into sealable containers; if
appropriate, moisten first to prevent dusting. Personal
protection: P2 filter respirator for harmful particles. Do NOT
let this chemical enter the environment.
UN Classification
UN Hazard Class: 5.1
UN Pack Group: III
EMERGENCY RESPONSE STORAGE
Transport Emergency Card: TEC (R)-51G02-I+II+III Separated from combustible and reducing substances. Provision to
contain effluent from fire extinguishing. Store in an area without drain or
sewer access.
IPCS
International
Programme on
Chemical Safety
Prepared in the context of cooperation between the International
Programme on Chemical Safety and the Commission of the
European Communities © IPCS, CEC 2005
SEE IMPORTANT INFORMATION ON BACK
CHROMIUM(III) NITRATE NONAHYDRATE ICSC: 1530
IMPORTANT DATA
PHYSICAL STATE; APPEARANCE
DEEP VIOLET CRYSTALS
CHEMICAL DANGERS
The substance is a strong oxidant and reacts with combustible and
reducing materials. The solution in water is a weak acid.
OCCUPATIONAL EXPOSURE LIMITS
TLV: (as Cr metal, Cr(III) compounds) 0.5 mg/m³ as TWA; A4 (not
classifiable as a human carcinogen); (ACGIH 2008).
MAK: IIb (not established but data is available); sensitization of skin
(Sh); (DFG 2008).
INHALATION RISK
A harmful concentration of airborne particles can be reached quickly
when dispersed.
EFFECTS OF SHORT-TERM EXPOSURE
The substance is irritating to the respiratory tract.
EFFECTS OF LONG-TERM OR REPEATED EXPOSURE
Repeated or prolonged contact may cause skin sensitization.
PHYSICAL PROPERTIES
Decomposes below boiling point
Melting point: 66°C
Density: 1.8 g/cm³
Solubility in water: very good
ENVIRONMENTAL DATA
The substance is toxic to aquatic organisms.
NOTES
Do NOT take working clothes home. The recommendations on this Card also apply to Chromium(III) nitrate anhydrous. Card has been partially
updated in February 2009: see Occupational Exposure Limits, Storage.
ADDITIONAL INFORMATION
LEGAL NOTICE Neither the CEC nor the IPCS nor any person acting on behalf of the CEC or the IPCS is responsible for the use
which might be made of this information
© IPCS, CEC 2005
CHROMIUM(III) OXIDE ICSC: 1531
October 2004
CAS # 1308-38-9
RTECS # GB6475000
EC/EINECS # 215-160-9
Chromic oxide
Dichromium trioxide
Cr2O3
Molecular mass: 152
TYPES OF HAZARD /
EXPOSURE
ACUTE HAZARDS /
SYMPTOMS
PREVENTION FIRST AID / FIRE
FIGHTING
FIRE Not combustible. In case of fire in the
surroundings: use appropriate
extinguishing media.
EXPLOSION
EXPOSURE PREVENT DISPERSION OF
DUST!
Inhalation Cough. Local exhaust or breathing
protection.
Fresh air, rest.
Skin Protective gloves. Rinse skin with plenty of water
or shower.
Eyes Redness. Safety goggles. First rinse with plenty of water
for several minutes (remove
contact lenses if easily
possible), then take to a doctor.
Ingestion Do not eat, drink, or smoke
during work.
Rinse mouth.
SPILLAGE DISPOSAL PACKAGING & LABELLING
Sweep spilled substance into containers; if appropriate,
moisten first to prevent dusting. Personal protection: P2 filter
respirator for harmful particles.
EMERGENCY RESPONSE STORAGE
IPCS
International
Programme on
Chemical Safety
Prepared in the context of cooperation between the International
Programme on Chemical Safety and the Commission of the
European Communities © IPCS, CEC 2005
SEE IMPORTANT INFORMATION ON BACK
CHROMIUM(III) OXIDE ICSC: 1531
IMPORTANT DATA
PHYSICAL STATE; APPEARANCE
LIGHT TO DARK GREEN POWDER
OCCUPATIONAL EXPOSURE LIMITS
TLV: (as Cr metal, Cr(III) compounds) 0.5 mg/m³ as TWA; A4 (not
classifiable as a human carcinogen); (ACGIH 2008).
MAK: IIb (not established but data is available) (DFG 2008).
INHALATION RISK
A harmful concentration of airborne particles can be reached quickly
when dispersed.
EFFECTS OF SHORT-TERM EXPOSURE
May cause mechanical irritation to
the eyes
and
the respiratory tract.
PHYSICAL PROPERTIES
Boiling point: 4000°C
Melting point: 2435°C
Density: 5.22 g/cm³
Solubility in water: none
ENVIRONMENTAL DATA
NOTES
Chromium oxide green and Chrome oxide are trade names. Card has been partially updated in February 2009: see Occupational Exposure
Limits.
ADDITIONAL INFORMATION
LEGAL NOTICE Neither the CEC nor the IPCS nor any person acting on behalf of the CEC or the IPCS is responsible for the use
which might be made of this information
© IPCS, CEC 2005
CHROMIUM(III) CHLORIDE HEXAHYDRATE ICSC: 1532
October 2004
CAS # 10060-12-5
RTECS # GB5450000
Chromic chloride hexahydrate
Chromium trichloride hexahydrate
CrCl3•6H2O
Molecular mass: 266.5
TYPES OF HAZARD /
EXPOSURE
ACUTE HAZARDS /
SYMPTOMS
PREVENTION FIRST AID / FIRE
FIGHTING
FIRE Not combustible. In case of fire in the
surroundings: use appropriate
extinguishing media.
EXPLOSION
EXPOSURE STRICT HYGIENE!
Inhalation Cough. Sore throat. Local exhaust or breathing
protection.
Fresh air, rest.
Skin Protective gloves. Protective
clothing.
Remove contaminated clothes.
Rinse skin with plenty of water
or shower.
Eyes Safety goggles. First rinse with plenty of water
for several minutes (remove
contact lenses if easily
possible), then take to a doctor.
Ingestion Abdominal pain. Diarrhoea.
Nausea. Vomiting.
Do not eat, drink, or smoke
during work.
Rinse mouth. Do NOT induce
vomiting. Give one or two
glasses of water to drink. Refer
for medical attention.
SPILLAGE DISPOSAL PACKAGING & LABELLING
Sweep spilled substance into sealable containers; if
appropriate, moisten first to prevent dusting. Personal
protection: P2 filter respirator for harmful particles. Do NOT
let this chemical enter the environment.
EMERGENCY RESPONSE STORAGE
Provision to contain effluent from fire extinguishing. Store in an area
without drain or sewer access.
IPCS
International
Programme on
Chemical Safety
Prepared in the context of cooperation between the International
Programme on Chemical Safety and the Commission of the
European Communities © IPCS, CEC 2005
SEE IMPORTANT INFORMATION ON BACK
CHROMIUM(III) CHLORIDE HEXAHYDRATE ICSC: 1532
IMPORTANT DATA
PHYSICAL STATE; APPEARANCE
GREEN CRYSTALLINE POWDER
CHEMICAL DANGERS
The solution in water is a weak acid.
OCCUPATIONAL EXPOSURE LIMITS
TLV: (as Cr metal, Cr(III) compounds) 0.5 mg/m³ as TWA; A4 (not
classifiable as a human carcinogen); (ACGIH 2008).
MAK: IIb (not established but data is available); sensitization of skin
(Sh); (DFG 2008).
INHALATION RISK
A harmful concentration of airborne particles can be reached quickly
when dispersed.
EFFECTS OF SHORT-TERM EXPOSURE
The substance is irritating to the respiratory tract.
EFFECTS OF LONG-TERM OR REPEATED EXPOSURE
Repeated or prolonged contact may cause skin sensitization.
PHYSICAL PROPERTIES
Melting point: (see Notes) 83 - 95°C
Density: 2.76 g/cm³
Solubility in water, g/100 ml at 20°C: 59
ENVIRONMENTAL DATA
The substance is toxic to aquatic organisms.
NOTES
Do NOT take working clothes home. Melting points vary depending on crystal structure. Card has been partially updated in February 2009: see
Occupational Exposure Limits, Ingestion First Aid, Storage.
ADDITIONAL INFORMATION
LEGAL NOTICE Neither the CEC nor the IPCS nor any person acting on behalf of the CEC or the IPCS is responsible for the use
which might be made of this information
© IPCS, CEC 2005
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alimentaires contenant du chrome, l’air ambiant, les 
articles en cuir qui ont subi un tannage au chrome, les 
produits cosmétiques contenant des pigments à base de 
chrome, certains articles en inox, les implants 
prothétiques et les appareils orthodontiques. Les 
nombreuses activités industrielles liées à la production, à 
la préparation et à l’utilisation du chrome et de ses 
dérivés entraînent également une exposition profession-
nelle à ces substances. 
RÉSUMÉ D’ORIENTATION 
 
 
1 Le présent CICAD  (Concise International 
Chemical Assessment Document/Document concis 
d’évaluation chimique internationale) relatif aux 
composés minéraux du chrome (III) a été préparé 
conjointement par l’Institut finlandais de la santé 
publique dont le siège se trouve à Helsinki (Finlande) 
pour les sections portant sur la santé humaine, et par le 
Centre d’écologie et d’hydrologie de Monks Wood 
(Royaume Uni) pour les sections traitant de 
l’environnement. Il s’inspire d’un rapport intitulé Health 
Risk Assessment Report for Metallic Chromium and 
Trivalent Chromium (Rapport d’évaluation des risques 
pour la santé imputables au chrome métallique et aux 
dérivés du chrome trivalent) rédigé par l’Institut 
finlandais de la santé publique (Riihimäki & Luotamo, 
2006) et d’un document de l’Agency for Toxic 
Substances and Disease Registry intitulé Profil 
toxicologique du chrome (ATSDR, 2000). Les dernières 
recherches bibliographiques remontent à décembre 2004 
pour la partie du présent CICAD relative aux effets 
sanitaires et à décembre 2005 pour la partie relative à 
l’environnement. L’appendice 2 donne des 
renseignements sur les sources bibliographiques. Des 
informations sur l’examen par des pairs du présent 
CICAD figurent à l’appendice 3. Ce CICAD relatif aux 
dérivés minéraux du chrome a été approuvé en tant 
qu’évaluation internationale lors la réunion du Comité 
d’évaluation finale qui s’est tenue à Helsinki (Finlande) 
du 26 au 29 mars 2007. La liste des participants à cette 
réunion figure à l’appendice 4. Les fiches internationales 
sur la sécurité chimique des composés courants du 
chrome trivalent sont également reproduites dans ce 
document (IPCS, 2002,b, 2004a,b,c,d, 2006). Ce CICAD 
ne concerne que les composés minéraux du chrome 
trivalent, mais chaque fois qu’il a été possible d’en 
étendre la portée, des données relatives aux dérivés 
organiques du chrome y ont été également ajoutées. Le 
CICAD No 78 consacré au chrome hexavalent est en 
cours de préparation. 
 
 Le chrome accomplit un cycle complet qui part des 
roches ou du sol, se poursuit chez les végétaux, les 
animaux et l’Homme pour revenir ensuite dans le sol. 
Du chrome est libéré dans l’atmosphère, non seulement 
à partir de sources anthropogéniques mais aussi chaque 
fois qu’une combustion se produit, par exemple lors de 
feux de forêt. Dans l’atmosphère, le chrome est 
principalement présent sous la forme de particules. 
 
 Certaines industries déchargent dans les eaux de 
surface des effluents contenant du chrome, dont une 
partie se trouve à l’état hexavalent. Quant à savoir dans 
quelle mesure le chrome demeure sous forme 
hexavalente jusqu’à ce qu’il parvienne à l’océan, cela 
dépend de la quantité de matières organiques présentes 
dans l’eau. Si ces matières sont présentes en grande 
quantité, il est possible qu’elles réduisent le chrome (VI) 
en chrome (III) qui sera ensuite adsorbé à la surface des 
particules. S’il n’est pas adsorbé, le chrome (III) va 
former de gros complexes polynucléaires qui ne sont 
plus solubles. En anaérobiose, la réduction du chrome  
(VI) en chrome (III) est un processus rapide et des 
conditions réductrices existent généralement dans les 
eaux souterraines profondes. La majeure partie du 
chrome déchargé dans l’eau va finir par se déposer sur 
les sédiments. A l’état dissous, le chrome (III) est 
principalement présent sous les formes suivantes : Cr3+, 
CrOH2+
 
 C’est à l’état trivalent que le chrome est le plus 
stable du point de vue thermodynamique. Dans 
l’environnement, le chrome est presque toujours présent 
à l’état naturel sous cette forme. Il existe dans le 
commerce toute une gamme de dérivés du chrome (III), 
dont les plus importants sont l’oxyde de chrome (III) et 
le sulfate de chrome basique. 
 
 L’exposition de la population générale au chrome 
trivalent trouve principalement son origine dans le 
régime alimentaire de tous les jours. Parmi les autres 
sources d’exposition on peut citer certains suppléments 
 
1 La liste complète des acronymes et abréviations utilisés dans 
le présent rapport se trouve à l’appendice 1. 
, Cr(OH)30 et Cr (OH)4− . 
 
 Dans le sol, le chrome est essentiellement présent 
sous forme d’oxyde insoluble et sa mobilité est réduite. 
On estime que le chrome (III) est rapidement et 
fortement adsorbé par le sol, notamment par les oxydes 
de fer et de manganèse, les minéraux argileux et le sable. 
La mobilité des espèces solubles présentes dans le sol va 
dépendre des propriétés sorbantes du sol. Les végétaux 
et les animaux absorbent la forme hexavalente de 
préférence à la forme trivalente mais une fois résorbé, le 
chrome (VI) est réduit à l’état de chrome (III), qui est 
plus stable. 
 
 Dans le cas du chrome (VI), le facteur de biocon-
centration pour les poissons est à peu près égal à 1; 
toutefois, une fois présent dans leur organisme, le 
chrome (VI) est apparemment réduit en chrome (III) 
avec, pour résultat, une accumulation de chrome total 
quelque 100 fois supérieure à la concentration dans 
l’eau. 
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 Dans les zones reculées, la concentration 
atmosphérique du chrome total va de 0,005 à 2,6 ng/m3, 
avec une valeur habituellement égale à moins de 10 
ng/m3 en milieu rural et comprise entre 10 et 30 ng/m3 
en milieu urbain. On a fait état de concentrations plus 
élevées (>500 ng/m3) au voisinage de sources 
anthropogéniques de chrome. Aux Etats-Unis 
d’Amérique, la concentration en chrome total dans les 
cours d’eau est généralement comprise entre moins de 
1 et 30 µg/l, avec une valeur médiane de 10 µg/l. En 
Europe, on indique une concentration médiane en 
chrome total de 0,38 µg /l (<0,01-43,3 µg/l) dans les 
eaux de surface. Dans l’eau des lacs, la concentration en 
chrome total ne dépasse généralement pas 5 µg/l. Des 
concentrations moyennes en chrome (III) allant jusqu’à 
2 µg/l ont été relevées dans des eaux superficielles. La 
présence de teneurs élevées en chrome peut être 
attribuée à une pollution par des sources anthropogén-
iques, les valeurs les plus élevées – pouvant atteindre 
40 mg de chrome (III) par litre – étant observées à 
proximité des points de décharge des tanneries. 
 
 La concentration du chrome dans les eaux 
océaniques est généralement beaucoup plus faible que 
dans les lacs ou les cours d’eau. En effet, la 
concentration moyenne en chrome total dans les eaux 
océaniques est de 0,3 µg/l (avec une fourchette de 0,2 à 
50 µg/l). Une concentration moyenne en chrome (III) de 
2 à 3 µg/l a été relevée dans les eaux littorales. Dans les 
étendues d’eau, on a constaté que les matières en 
suspension et les sédiments présentaient des teneurs en 
chrome total allant de 1 à 500 mg/kg. Dans le sol, la 
concentration en chrome total est très variable et dépend 
de la composition des roches à partir desquelles tel ou tel 
sol s’est formé. Au Canada et aux Etats-Unis, la 
fourchette de concentration du chrome total dans les 
différents sols et autres matériaux de surface est de 1 à 
2000 mg/kg avec une moyenne géométrique d’environ 
40 mg/kg. En Europe, la concentration médiane du 
chrome dans la couche superficielle du sol s’est révélée 
égale à 60 mg/kg (<3-6230 mg/kg) après extraction à 
l’acide fluorhydrique et à 22 mg/kg (<1-2340 mg/kg) 
après extraction à l’acide nitrique. On a fait état de 
valeurs plus élevées sur des sites contaminés. 
 
 Le chrome (III) est considéré comme un 
oligoélément essentiel pour les mammifères, car il 
intervient dans le métabolisme des lipides et des 
glucides. Une proportion limitée de chrome (III) est 
absorbée à partir d’une ration alimentaire normale (<0,5 
à 2 %) – davantage si la teneur en chrome de la ration est 
anormalement faible et moins si l’apport de chrome est 
plus important. Les aérosols hydrosolubles de chrome 
(III) que leur granulométrie rend respirables sont plus 
efficacement absorbés par l’appareil respiratoire que par 
les voies digestives : ils peuvent être rapidement 
résorbés dans une proportion d’environ 5 % en l’espace 
de quelques heures, mais il leur faut ensuite des 
semaines ou des mois pour passer dans le courant 
sanguin. Dans le cas de l’oxyde de chrome (III) qui est 
insoluble, la résorption des particules déposées et 
retenues est un très long processus. Les sels hydro-
solubles de chrome (III) peuvent pénétrer dans le 
revêtement cutané mais on ne les retrouve pas dans la 
circulation générale. 
 
 Dans le plasma sanguin, le chrome (III) est lié à 
95 % à des protéines de masse moléculaire élevée (par 
ex. la transferrine), mais on le trouve également associé 
à la chromoduline, un oligopeptide appelé également 
substance de liaison au chrome de faible masse 
moléculaire (LMWCr). Le chrome se répartit 
principalement dans le foie, le rein, la rate et les os. 
Après administration, une partie du chrome peut 
atteindre le tissu interstitiel testiculaire et il peut 
également s’accumuler dans le placenta, mais il ne peut 
traverser la barrière placentaire qu’en petite quantité. 
Une fois absorbé, le chrome (III) est principalement 
excrété par la voie urinaire et dans une moindre mesure 
par la voie fécale. 
 
 Chez le rat, la toxicité aiguë de l’oxyde de chrome 
(III) est très faible par voie orale, la dose létale médiane 
(DL50) étant supérieure à 5 g par kg de poids corporel 
(p.c.). En ce qui concerne le sulfate de chrome basique, 
on indique une DL50 par voie orale de 3530 mg/kg de 
poids corporel pour le rat. Pour le nitrate de chrome, la 
valeurs vont de 1540 à 3250 mg/kg de p.c. 
 
 D’après les résultats de l’expérimentation animale, 
l’oxyde chrome (III) et le sulfate de chrome basique ne 
sont irritants ni pour la peau ni pour les yeux. 
 
 L’oxyde chrome (III), insoluble, ne provoque pas de 
sensibilisation cutanée. Le chrome trivalent pourrait se 
comporter comme un déterminant hapténique extrême de 
la sensibilisation cutanée par le chrome, mais la faible 
pénétration tégumentaire des dérivés du chrome (III) 
limite leur pouvoir sensibilisateur. Des tests non 
classiques comportant des injections intradermiques ou 
sous-cutanées de sels hydrosolubles de chrome trivalent 
comme le chlorure de chrome ou le sulfate de chrome 
hydraté ont mis en évidence les effets sensibilisateurs de 
ces sels. Deux études sur le chlorure de chrome ont 
également permis d’observer une réaction positive lors 
d’une épreuve de sensibilisation épicutanée. Les données 
cliniques relatives à la sensibilisation cutanée mettent 
principalement en cause le port d’articles en cuir. Il est 
malaisé de définir le rôle exact du chrome trivalent dans 
la sensibilisation cutanée due au port d’articles de 
maroquinerie du fait que du chrome hexavalent peut être 
présent à faible concentration dans le cuir tanné et que 
les cas de dermatite du pied dont on a connaissance 
peuvent correspondre en fait à des réactions d’élicitation 
chez des sujets déjà sensibilisés au chrome. Chez les 
travailleurs qui manipulent des sels de chrome trivalent, 
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il semble que les cas de sensibilisation cutanée soient 
rares. Actuellement, rien ne prouve de façon indubitable 
que l’exposition professionnelle à des composés du 
chrome (III) puisse provoquer de l’asthme. 
 
 L’inhalation de chrome (III) sous forme d’oxyde à 
des concentrations moyennes de 3, 10 ou 30 mg/m3 a 
provoqué de très légères modifications de nature 
inflammatoire au niveau des poumons chez des rats 
exposés à toutes ces concentrations dans l’air, mais à des 
concentrations identiques de Cr3+ dans l’air, des 
poussières de sulfate de chrome basique ont provoqué 
des effets inflammatoires et fait apparaître des signes de 
toxicité générale plus sévères et plus disséminés chez les 
animaux des groupes soumis aux doses intermédiaire et 
élevée. Les légères modifications de nature 
inflammatoire observées après inhalation d’oxyde de 
chrome (III) pourraient être imputables à une réaction 
non spécifique du tissu pulmonaire à l’accumulation de 
particules insolubles (surcharge) plutôt qu’à la toxicité 
intrinsèque du chrome (III). La concentration sans effet 
nocif observé (NOAEC) a été trouvée égale à 3 mg de 
Cr3+/m3 en ce qui concerne les effets généraux du sulfate 
de chrome basique; toutefois, comme des modifications 
de nature inflammatoire ont été observées au niveau des 
voies respiratoires et du poumon en particulier, même à 
la concentration la plus faible, on a considéré que cette 
valeur représentait la concentration la plus faible 
provoquant un effet nocif observable localement 
(LOAEC). La gravité minime des anomalies observées 
après exposition à la concentration la plus faible incite à 
penser que, chez le rat, cette LOAEC de 3 mg de Cr3+/m3 
est proche de la NOAEC de l’oxyde de chrome (III). 
 
 L’administration à des rats de rations alimentaires 
contenant de l’oxyde de chrome (III), même à forte dose, 
n’a provoqué aucune effet nocif. Cette absence d’effets 
peut s’expliquer par la faible biodisponibilité de cette 
substance par voie orale. Lors d’une étude de 20 
semaines comportant l’administration de chlorure de 
chrome hydrosoluble par voie orale à des rats Sprague-
Dawley, on n’a pas observé d’effet nocif imputable à ce 
traitement, même à la dose la plus élevée, qui 
correspondait à l’ingestion journalière de 7 mg de 
chrome par kg de poids corporel. 
 
 Des interactions sont possibles entre le chrome (III) 
et l’acide désoxyribonucléique (ADN), mais les résultats 
des études de génotoxicité in vitro et in vivo sont 
contradictoires et ne fournissent aucune preuve 
manifeste d’une mutagénicité du chrome trivalent. 
 
 Les études sur des animaux de laboratoire qui 
seraient susceptibles de permettre une évaluation de la 
cancérogénicité du chrome (III) ne mettent en évidence 
aucune augmentation de l’incidence des cancers après 
exposition à ses composés. On a avancé qu’il existerait 
un risque accru de certains cancers chez les sujets 
exerçant des professions qui les exposent à des 
composés du chrome (III), mais les données 
épidémiologiques ne permettent pas de faire la 
distinction entre les effets respectifs du chrome trivalent, 
du chrome hexavalent ou d’autres substances 
cancérogènes en cas d’exposition simultanée à ces 
diverses substances. 
 
 A la lumière des données disponibles, il semble que 
le chrome trivalent n’ait aucun effet sur la fécondité. Si 
l’on se base sur sa faible biodisponibilité et sur les 
résultats d’une étude limitée de ses effets toxiques à 
forte dose, il apparaît que l’oxyde de chrome (III) n’a 
pas d’effets nocifs sur le développement. Il n’existe pas 
d’étude convenable relative aux effets nocifs des sels 
solubles de chrome (III) sur le développement. 
 
 En ce qui concerne l’exposition de sujets humains à 
l’oxyde de chrome (III), on considère que son effet 
essentiel consiste en une irritation et une inflammation 
locales durables liées à l’accumulation intrapulmonaire 
de particules respirables dans une proportion qui 
provoque la saturation de l’ascenseur mucociliaire. Dans 
le cas de l’exposition humaine au sulfate de chrome 
basique, qui est censé représenter l’ensemble de sels 
solubles de chrome (III), les effets considérés comme 
essentiels sont une toxicité respiratoire locale et la 
sensibilisation cutanée. Les concentrations tolérables 
(27 µg de Cr3+/m3 pour les composés insolubles du 
chrome (III) et 6 µg de Cr3+/m3 pour ses composés 
solubles) établies sur la base de ces effets compte tenu 
des facteurs d’évaluation appropriés, sont en général 
largement supérieures aux concentrations de chrome 
(III) présentes dans l’air; même à proximité de sources 
ponctuelles, la concentrations atmosphérique est 
inférieure aux concentrations tolérables. Pour ce qui est 
de la sensibilisation cutanée par des sels solubles de 
chrome trivalent, s’il est assez peu probable que les 
personnes portant des chaussures, des gants et autres 
articles en cuir tanné au chrome puissent en souffrir, il 
est possible, en revanche, que les petites quantités de 
chrome libérées par des articles en cuir déclenchent une 
réaction allergique chez des sujets déjà sensibilisés. 
 
 Il y a des microorganismes qui ont besoin de 
chrome (III) pour assurer certains de leurs processus 
métaboliques et stimuler leurs enzymes. A l’état de 
traces, le chrome (III) est un oligoélément essentiel pour 
la nutrition animale et il intervient tout particulièrement 
dans le métabolisme du glucose et des lipides. A noter 
toutefois que si le chrome se révèle essentiel pour le 
métabolisme du glucose chez certains mammifères de 
laboratoire, les études portant sur d’autres animaux 
donnent des résultats ambigus. 
 
 Les données toxicologiques relatives au chrome 
(III) sont principalement tirées d’études portant sur des 
dérivés hydrosolubles (chlorure et nitrate de chrome (III) 
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et sulfate double de chrome et de potassium). Dans 
l’environnement, il est probable que le chrome (III) est 
présent sous des formes beaucoup moins solubles et par 
conséquent moins biodisponibles pour les organismes 
aquatiques. 
 
 Dans le cas d’une algue d’eau douce, on a trouvé, 
pour la concentration effective médiane à quatre-vingt 
seize heures (CE50), des valeurs allant de 0,3 à 0,4 mg de 
chrome (III) par litre. Pour une diatomée marine, on a 
déterminé, sur la base de la croissance, une CE50 à 96 h 
de 2 mg de chrome (III) par litre. Chez les invertébrés 
aquatiques, les valeurs de la concentration létale 
médiane (CL50) vont de 0,1 mg/l (Daphnia pulex) à 
442 mg/l (Asellus aquaticus), la concentration sans effet 
observé (NOEC) sur l’ensemble du cycle évolutif étant 
égale à 0,047 mg/l pour Daphnia magna. En ce qui 
concerne les invertébrés marins, les valeurs de la CL50 
qui ont été relevées vont de 10 à 100 mg/l. Dans le cas 
des poissons d’eau douce, les valeurs de la CL50 à 96 h 
qui sont rapportées vont de 3,3 mg/l pour le guppy 
(Poecilia reticulata) à 151 mg/l pour la carpe marbrée 
(Aristichthys nobilis), les valeurs de cette même CL50 à 
96 h oscillant entre 31,5 et 53 mg/l pour les poissons de 
mer. Pour la truite arc-en-ciel (Oncorhynchus mykiss), 
on fait état d’une concentration sans effet observé à 72 
jours (NOEC) égale à 0,05 mg/l.  
 
 Il est possible de calculer une valeur-guide pour la 
toxicité du chrome trivalent en utilisant une méthode 
probabiliste, étant donné que la somme de données est 
suffisamment importante pour justifier cette démarche. 
C’est ainsi que pour une protection de 99 % des espèces 
d’eau douce, on a obtenu une valeur-guide modérément 
fiable égale à 10 µg de chrome trivalent par litre avec un 
taux de confiance de 50 %. Les données toxicologiques 
relatives aux organismes marins sont insuffisantes pour 
que l’on puisse déterminer une valeur-guide selon une 
méthode probabiliste. On ne dispose que d’un ensemble 
très limité de données concernant une diatomée, des 
invertébrés aquatiques et des poissons. On a donc 
appliqué un facteur de sécurité de 1000 à la donnée 
toxicologique fiable ayant la valeur la plus basse (2 
mg/l), ce qui donne une valeur-guide de faible fiabilité 
égale à 2 µg de chrome trivalent par litre. 
 
 Avec une valeur-guide modérément fiable égale à 
10 µg de chrome (III) par litre, on peut estimer que le 
risque est faible pour les eaux de surface en général. 
Toutefois, si l’on compare la valeur-guide à la 
concentration la plus élevée de chrome (III) relevée dans 
les eaux de surface des zones industrielles (environ 100 
µg/l), on voit qu’il existe un risque potentiel pour les 
êtres vivants présents dans ces zones. Les valeurs 
élevées de la concentration en chrome trivalent mesurées 
dans les effluents industriels, notamment ceux qui 
proviennent de tanneries, indiquent qu’il peut y avoir un 
risque pour les organismes d’eau douce qui vivent à 
proximité des points de décharge de ces effluents. Si l’on 
compare maintenant la valeur-guide de faible fiabilité 
qui a été fixée, pour le milieu marin, à 2 µg de chrome 
(III) par litre, aux concentrations de chrome trivalent 
relevées dans l’eau de mer, on peut penser que le risque 
reste faible pour les organismes marins. 
 
 Chez les végétaux, une intoxication par le chrome se 
traduit principalement par une chlorose. Le chrome (VI) 
se révèle plus toxique que le chrome (III) pour les 
plantes terrestres. 
 
 Faute de données plus abondantes au sujet de la 
biodisponibilité du chrome dans les sols, il est difficile 
d’évaluer le risque que le chrome (III) représente pour 
les organismes terricoles.  
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 Hay un ciclo completo del cromo, desde las rocas o 
el suelo a las plantas, los animales y las personas y su 
vuelta al suelo. Se libera en el aire, no sólo a partir de 
fuentes antropogénicas, sino también por los procesos de 
combustión, incluidos los incendios forestales. El cromo 
está presente en la atmósfera sobre todo en forma de 
partículas. 
RESUMEN DE ORIENTACIÓN 
 
 
 Este Documento abreviado de evaluación 
internacional de productos químicos (CICAD)1 sobre 
compuestos inorgánicos de cromo (III), preparado 
conjuntamente por el Instituto Finlandés de Salud 
Ocupacional de Helsinki (Finlandia) (secciones relativas 
a la salud humana) y el Centro de Ecología e Hidrología 
de Monks Wood (Reino Unido) (secciones relativas al 
medio ambiente), se basó en el Informe de evaluación 
del riesgo para la salud del cromo metálico y el cromo 
trivalente, preparado por el Instituto Finlandés de Salud 
Ocupacional (Riihimäki & Luotamo, 2006), y el Perfil 
toxicológico del cromo, de la Agencia para el Registro 
de Sustancias Tóxicas y Enfermedades (ATSDR, 2000). 
La última búsqueda bibliográfica sobre los efectos en la 
salud se hizo en diciembre de 2004 y sobre el medio 
ambiente en diciembre de 2005. La información sobre 
los documentos originales se presenta en el apéndice 2. 
La información sobre el examen colegiado de este 
CICAD figura en el apéndice 3. Este CICAD sobre 
compuestos inorgánicos de cromo se aprobó como 
evaluación internacional en una reunión de la Junta de 
Evaluación Final, celebrada en Helsinki (Finlandia) del 
26 al 29 de marzo de 2007. La lista de participantes en 
esta reunión aparece en el apéndice 4. También se 
reproducen en este documento las Fichas internacionales 
de seguridad química para los compuestos inorgánicos 
comunes de cromo trivalente (IPCS, 2002b, 2004a,b,c,d, 
2006). Aunque este CICAD se limita a los compuestos 
inorgánicos de cromo trivalente, también contiene datos 
sobre compuestos orgánicos de cromo cuando pueden 
aportar algún valor adicional. En este momento se está 
preparando el CICAD Nº 78 sobre el cromo hexavalente. 
 
 En las aguas superficiales se vierten efluentes 
industriales que contienen cromo, parte del cual está en 
forma hexavalente. La posibilidad de que se mantenga 
hexavalente hasta llegar al mar depende de la cantidad 
de materia orgánica presente en el agua. En presencia de 
una cantidad grande de materia orgánica, la materia 
particulada puede reducir el cromo (VI) y adsorber el 
cromo (III). Si no se produce la adsorción del cromo 
(III), éste formará grandes complejos polinucleados que 
dejan de ser solubles. La reducción del cromo (VI) a 
cromo (III) es rápida en condiciones anaerobias, y suelen 
ser éstas las condiciones que existen en las aguas 
freáticas más profundas. La mayor parte del cromo que 
se libera en el agua con el tiempo se acaba depositando 
en el sedimento. Las principales especies de cromo (III) 
disueltas son Cr3+
 
 El estado trivalente es la forma más estable del 
cromo desde el punto de vista termodinámico. Casi todo 
el cromo presente en el medio ambiente se encuentra en 
ese estado. Hay una gran variedad de compuestos de 
cromo trivalente disponibles en el comercio, siendo los 
más importantes el óxido de cromo (III) y el sulfato 
básico de cromo. 
 
 La población general está expuesta al cromo 
trivalente fundamentalmente a partir de la alimentación 
diaria. Otras fuentes son los complementos alimenticios 
que contienen cromo, el aire ambiente, los artículos de 
piel curtida con cromo, los cosméticos fabricados con 
pigmentos de cromo, los artículos de acero inoxidable, 
los implantes protésicos y los aparatos de ortodoncia. Se 
puede producir exposición profesional al cromo tri-
valente en una gran variedad de actividades industriales 
relacionadas con la producción, formulación y uso del 
cromo.  
 
1 La lista completa de las siglas y abreviaturas utilizadas en 
este informe figura en el apéndice 1. 
, CrOH2+, Cr(OH)30 y Cr(OH)4−. 
 
 El cromo está presente en el suelo fundamental-
mente como óxido insoluble y su movilidad es baja. Para 
el cromo (III) se prevé una adsorción rápida e intensa en 
el suelo, en particular por los óxidos de hierro y 
manganeso, los minerales de arcilla y la arena. La 
movilidad en el suelo del cromo soluble depende de las 
características de sorción de dicho suelo. Las plantas y 
los animales vivos absorben mejor la forma hexavalente 
que la trivalente, pero, una vez absorbida, la forma 
hexavalente se reduce al estado trivalente, que es más 
estable.  
 
 Los factores de bioconcentración del cromo (VI) en 
los peces son bajos, de alrededor de 1; sin embargo, una 
vez en el organismo parece que el cromo (VI) se reduce 
a cromo (III), dando lugar a una acumulación de cromo 
total hasta alcanzar un factor de unas 100 veces la 
concentración en el agua.  
 
 Las concentraciones de cromo total en la atmósfera 
de zonas remotas oscilan entre 0,005 y 2,6 ng/m3, siendo 
normalmente <10 ng/m3 en las zonas rurales y de 10 a 
30 ng/m3 en las urbanas. Se han notificado concentraci-
ones más elevadas (>500 ng/m3) cerca de fuentes 
antropogénicas. Las concentraciones totales de cromo en 
las aguas fluviales de los Estados Unidos de América 
suelen ser de <1 a 30 µg/l, con un valor mediano de 
10 µg/l. En Europa se ha notificado para aguas super-
ficiales una concentración mediana de cromo total de 
0,38 µg/l (<0,01–43,3 µg/l). Las concentraciones totales 
de cromo en las aguas lacustres no suelen rebasar los 5 
µg/l. Se han notificado para aguas superficiales concen-
traciones medias de cromo (III) de hasta 2 µg/l. Los 
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niveles más elevados de cromo pueden estar relacion-
ados con fuentes de contaminación antropogénicas, 
alcanzando los niveles máximos, de hasta 40 mg de 
cromo (III)/l, cerca de los efluentes de curtidurías. 
 
 La concentración de cromo en el agua marina suele 
ser mucho más baja que en la de lagos y ríos. La concen-
tración total media de cromo en el agua marina es de 
0,3 µg/l, con un intervalo de 0,2 a 50 µg/l. Se han 
notificado en aguas costeras concentraciones medias de 
cromo (III) de 2 a 3 µg/l. En los materiales en suspen-
sión y los sedimentos de las masas de agua, los niveles 
totales de cromo oscilaron entre 1 y 500 mg/kg. Los 
niveles totales de cromo en el suelo varían considerable-
mente y dependen de la composición de la roca que dio 
origen al suelo. La gama de concentraciones de cromo 
total en el suelo y en otros materiales superficiales del 
Canadá y los Estados Unidos era de 1 a 2000 mg/kg, con 
una media geométrica de unos 40 mg/kg. En Europa, las 
concentraciones medianas de cromo en la superficie del 
suelo tras la extracción con ácido fluorhídrico eran de 
60 mg/kg (<3–6230 mg/kg) y de 22 mg/kg (<1–2340 
mg/kg) con ácido nítrico. En lugares contaminados se 
han notificado niveles más altos. 
 
 Se considera que el cromo trivalente es un 
oligoelemento esencial en los mamíferos, puesto que 
interviene en el metabolismo de los lípidos y la glucosa. 
Se absorben cantidades limitadas (<0,5–2%) de cromo 
(III) de la alimentación normal, más si el contenido de 
cromo en los alimentos es anormalmente bajo y menos si 
la ingesta es más elevada. La absorción de aerosoles 
hidrosolubles de cromo (III) de tamaño respirable es más 
eficaz a partir del sistema respiratorio que del aparato 
digestivo: alrededor del 5% se puede absorber con 
rapidez en unas horas, y sigue una liberación más lenta 
en la circulación durante semanas y meses. Para el óxido 
de cromo (III) insoluble, la absorción de las partículas 
depositadas y retenidas es un proceso muy lento. Si bien 
las sales de cromo trivalente hidrosolubles pueden 
penetrar en la piel, no se ha observado que lleguen a la 
circulación sistémica. 
 
 El 95% del cromo (III) presente en el plasma 
sanguíneo está unido a proteínas de peso molecular 
elevado (por ejemplo, la transferrina), pero también se 
asocia con un oligopéptido denominado sustancia 
fijadora de cromo de bajo peso molecular. El cromo se 
distribuye fundamentalmente en el hígado, los riñones, 
el bazo y los huesos. Parte del cromo administrado 
puede alcanzar el intersticio testicular; también se puede 
acumular en la placenta, pero sólo la atraviesan 
cantidades pequeñas. El cromo (III) se excreta sobre 
todo en la orina y en menor grado en las heces.  
 
 En las ratas, la toxicidad aguda por vía oral del 
óxido de cromo (III) es muy baja, con dosis letales 
medianas (valores de la DL50) superiores a 5 g/kg de 
peso corporal. Se ha notificado una DL50 del sulfato 
básico de cromo por vía oral de 3530 mg/kg de peso 
corporal. Los valores obtenidos para el nitrato de cromo 
varían entre 1540 y 3250 mg/kg de peso corporal.  
 
 En los estudios realizados en animales se ha 
observado que el óxido de cromo (III) y el sulfato básico 
de cromo no son irritantes cutáneos ni oculares.  
 
 El óxido de cromo (III) insoluble no provoca 
sensibilización cutánea. El cromo trivalente puede actuar 
como un auténtico determinante hapténico de la 
sensibilización cutánea, pero su escasa penetración 
limita la capacidad de sensibilización de sus sales. Se ha 
demostrado el efecto sensibilizador de las sales de cromo 
trivalente, el cloruro de cromo y el sulfato de cromo 
hidratado, que son hidrosolubles, en pruebas no 
normalizadas utilizando inyecciones intradérmicas o 
subcutáneas. En dos estudios sobre el cloruro de cromo 
también se observaron reacciones positivas tras una 
aplicación epicutánea. Las pruebas clínicas relativas a la 
sensibilización cutánea se refieren en particular al uso de 
artículos de cuero. La relación entre el cromo trivalente 
y la sensibilización inducida por los artículos de cuero se 
ve empañada por el hecho de que el cuero curtido puede 
contener niveles bajos de cromo hexavalente y de que 
los casos notificados de dermatitis de los pies pueden 
deberse en realidad a que se producen reacciones en 
personas previamente sensibilizadas al cromo. La 
sensibilización cutánea en los trabajadores que 
manipulan sales de cromo trivalente parece ser un 
fenómeno raro. No hay en este momento ninguna prueba 
inequívoca que demuestre que la exposición a los 
compuestos de cromo trivalente ha inducido asma 
profesional.  
 
 La inhalación de concentraciones medias de cromo 
de 3, 10 y 30 mg/m3 en forma de óxido de cromo (III) 
provocó cambios inflamatorios muy leves en los 
pulmones de ratas expuestas a todos los niveles en el 
aire, mientras que el polvo de sulfato básico de cromo 
con las mismas concentraciones de Cr3+ en el aire dio 
lugar a efectos inflamatorios más graves y generalizados 
y a signos de toxicidad sistémica en los grupos 
expuestos a dosis medias y altas. Los cambios 
inflamatorios leves observados tras la inhalación de 
óxido de cromo (III) pueden reflejar una respuesta 
pulmonar no específica a la acumulación de partículas 
insolubles (sobrecarga) más que a la toxicidad intrínseca 
del cromo (III). Para los efectos sistémicos del sulfato 
básico de cromo se identificó una concentración sin 
efectos adversos observados (NOAEC) de 3 mg Cr3+/m3; 
sin embargo, dado que se observaron cambios 
inflamatorios en los pulmones y el sistema respiratorio 
incluso con el nivel más bajo, se la consideró como la 
concentración más baja con efectos adversos observados 
(LOAEC) para los efectos locales. La gravedad mínima 
observada en las ratas con el nivel de exposición más 
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bajo parece indicar que para el óxido de cromo (III) la 
LOAEC de 3 mg Cr3+/m3 se acerca a la NOAEC. 
 
 La administración a ratas de óxido de cromo (III) 
con los alimentos incluso en dosis muy elevadas no 
produjo ningún efecto adverso. Esta falta de efectos se 
puede explicar por la escasa biodisponibilidad oral del 
óxido de cromo (III). En un estudio de administración 
oral de cloruro de cromo hidrosoluble a ratas Sprague-
Dawley durante 20 semanas, no se observaron efectos 
adversos relacionados con el tratamiento incluso con las 
dosis más elevadas, correspondientes a una ingesta de 
cromo de 7 mg/kg de peso corporal al día. 
 
 Aunque puede haber una interacción del cromo (III) 
con el ácido desoxirribonucleico (ADN), los datos de los 
estudios de genotoxicidad in vitro e in vivo son 
contradictorios y no demuestran de manera clara la 
mutagenicidad del cromo trivalente.  
 
 En los estudios en animales considerados 
pertinentes para la evaluación de la carcinogenidad del 
cromo (III) no se observó una incidencia mayor de 
cáncer con los compuestos de cromo trivalente. Para 
algunas ocupaciones relacionadas con la exposición al 
cromo trivalente se ha indicado que es posible un mayor 
riesgo de algunos tipos de cáncer, pero los datos 
epidemiológicos no permiten distinguir entre la 
exposición simultánea al cromo trivalente y hexavalente 
y a otros agentes carcinogénicos.  
 
 Los datos disponibles parecen indicar una falta de 
efectos del cromo trivalente en la fecundidad. Teniendo 
en cuenta la escasa biodisponibilidad y los resultados de 
un estudio limitado de la toxicidad en el desarrollo por 
vía oral a dosis elevadas, el óxido de cromo (III) no es 
tóxico en el desarrollo. No se dispone de estudios 
apropiados de toxicidad en el desarrollo para las sales de 
cromo trivalente solubles.  
 
 Los efectos finales fundamentales que se considera 
que son pertinentes para la exposición humana al óxido 
de cromo (III) se basan en la irritación y la inflamación 
locales asociadas con la acumulación de partículas 
respirables en los pulmones, en la medida en que los 
mecanismos de limpieza están sobrecargados. Los 
efectos finales fundamentales para la exposición humana 
al sulfato básico de cromo, como supuesto representante 
de las sales de cromo (III) solubles como grupo, son la 
toxicidad respiratoria local y la sensibilización cutánea. 
Las concentraciones tolerables (27 µg de Cr3+/m3 para el 
cromo (III) insoluble y 6 µg de Cr3+/m3 para los 
compuestos de cromo (III) solubles) basadas en estos 
efectos y los factores de evaluación aplicables suelen 
estar muy por encima de los niveles de cromo (III) en el 
aire; incluso en la proximidad de fuentes puntuales, los 
niveles en el aire están por debajo de las concentraciones 
tolerables. Con respecto a la sensibilización cutánea, es 
bastante poco probable que las sales de cromo trivalente 
solubles la induzcan en personas que utilizan zapatos, 
guantes u otros artículos de cuero curtido con cromo, 
mientras que es posible la aparición de alergia al cromo 
en una persona previamente sensibilizada debido a la 
filtración de pequeñas cantidades de cromo de los 
artículos de cuero. 
 
 Algunos microorganismos necesitan cromo (III) 
para procesos metabólicos específicos, como el 
metabolismo de la glucosa y la estimulación enzimática. 
Se ha informado de que el cromo (III), en cantidades 
minúsculas, es un componente esencial de la nutrición 
animal y está fuertemente asociado con el metabolismo 
de la glucosa y las grasas. No obstante, si bien se ha 
demostrado que el cromo es esencial para el 
metabolismo de la glucosa en algunos mamíferos de 
laboratorio, hay estudios en otros animales que son 
ambiguos.  
 
 Los datos disponibles de la toxicidad del cromo (III) 
se han obtenido en particular utilizando formas hidro-
solubles (cloruro de cromo (III), nitrato de cromo (III) y 
sulfato de cromo y potasio). Es probable que el cromo 
(III) se encuentre en el medio ambiente en formas 
mucho menos solubles, y por consiguiente con menor 
biodisponibilidad para los organismos acuáticos. 
 
 Las concentraciones efectivas medianas a las 96 
horas (CE50) para un alga de agua dulce, basándose en el 
crecimiento, fueron de 0,3 a 0,4 mg de cromo (III)/l. Se 
notificó una CE50 a las 96 horas para una diatomea 
marina, basándose en el crecimiento, de 2 mg de cromo 
(III)/l. Las concentraciones letales medianas (CL50) en 
los invertebrados de agua dulce iban de 0.1 mg/l 
(Daphnia pulex) a 442 mg/l (Asellus aquaticus), con una 
concentración sin efectos observados (NOEC) en el ciclo 
biológico de 0,047 mg/l para Daphnia magna. Para los 
invertebrados marinos se han notificado valores de las 
CL50 que oscilan entre 10 y 100 mg/l. Las CL50 a las 96 
horas para los peces de agua dulce estaban entre 3,3 mg/l 
para el “guppy” (Poecilia reticulata) y 151 mg/l para la 
carpa cabezona (Aristichthys nobilis), mientras que en 
los peces marinos se notificaron CL50 a las 96 horas de 
31,5 y 53 mg/l. Se informó de una NOEC a las 72 horas 
(supervivencia) de 0,05 mg/l para la trucha arco iris 
(Oncorhynchus mykiss). 
 
 Se puede obtener un valor guía para la toxicidad del 
cromo trivalente en un entorno de agua dulce utilizando 
un método probabilístico, puesto que el conjunto de 
datos disponibles es suficientemente amplio para 
justificarlo. Se derivó un valor guía de fiabilidad 
moderada de 10 µg de cromo (III)/l para la protección 
del 99% de las especies de agua dulce con una confianza 
del 50%. Los datos de la toxicidad no fueron suficientes 
para poder calcular un valor guía utilizando un método 
probabilístico. 
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 El valor guía de fiabilidad moderada de 10 µg de 
cromo (III)/l asignado al entorno de agua dulce parece 
indicar un riesgo bajo para las aguas superficiales en 
general. Sin embargo, hay un riesgo potencial para los 
organismos cuando dicho valor guía se compara con el 
nivel más elevado de cromo (III), de unos 100 µg/l, en 
las aguas superficiales de zonas industriales. Los niveles 
más altos de cromo trivalente en los efluentes, sobre 
todo de las curtidurías, parecen indicar que hay un riesgo 
para los organismos de agua dulce en las proximidades 
de las descargas de dichos efluentes. La comparación del 
valor guía de fiabilidad baja de 2 µg de cromo (III)/l del 
entorno marino con las concentraciones de cromo 
trivalente en el agua del mar parece indicar un riesgo 
bajo de toxicidad para los organismos marinos.  
 
 La característica principal de la intoxicación de las 
plantas por cromo es la clorosis. El cromo hexavalente 
parece ser más tóxico para las plantas terrestres que el 
trivalente.  
 
 En ausencia de más datos sobre la biodisponibilidad 
del cromo en el suelo, es difícil evaluar el riesgo del 
cromo (III) para los organismos presentes en él. 
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